Diagnostic accuracy of multi-parametric MRI and TRUS: a paired validating confirmatory study

Citation Report

#	Article	IF	Citations
1	Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. Lancet, The, 2017, 389, 767-768.	6.3	4
2	Is a negative prostate biopsy a risk factor for a prostate cancer related death?. Lancet Oncology, The, 2017, 18, 162-163.	5.1	7
3	The drama of prostate cancer diagnostics. Lancet Oncology, The, 2017, 18, e132.	5.1	2
4	Improving diagnosis â€" can MP-MRI fulfil its PROMIS?. Nature Reviews Clinical Oncology, 2017, 14, 137-137.	12.5	0
5	Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European Urology, 2017, 72, 189-191.	0.9	12
6	Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer â€" Authors' reply. Lancet Oncology, The, 2017, 18, e188.	5.1	10
8	Re: Diagnostic Accuracy of Multi-parametric Magnetic Resonance Imaging and Transrectal Ultrasound Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study. European Urology, 2017, 72, 315-316.	0.9	0
9	The need for active surveillance for low risk prostate cancer. Expert Review of Anticancer Therapy, 2017, 17, 487-489.	1.1	3
10	Contrast Agentâ€"Induced High Signal Intensity in Dentate Nucleus on Unenhanced T1-Weighted Images. Investigative Radiology, 2017, 52, 389-395.	3.5	26
11	Additional benefit of using a riskâ€based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU International, 2017, 120, 394-400.	1.3	12
12	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. Journal of Urology, 2017, 198, 1046-1053.	0.2	6
13	Intraindividual Comparison of ^{18}F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. Journal of Nuclear Medicine, 2017, 58, 1805-1810.	2.8	91
14	Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer and Prostatic Diseases, 2017, 20, 311-317.	2.0	55
15	Rapid Diffusion-Weighted Magnetic Resonance Imaging of the Brain Without Susceptibility Artifacts. Investigative Radiology, 2017, 52, 428-433.	3.5	15
17	Atypical Small Acinar Proliferation and High-grade Prostatic Intraepithelial Neoplasia in the Era of Multiparametric Magnetic Resonance Imaging: A Contemporary Review. Urology, 2017, 107, 5-10.	0.5	7
18	Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. Journal of Urology, 2017, 198, 708-709.	0.2	0
19	^{68}Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. Journal of Nuclear Medicine, 2017, 58, 1943-1948.	2.8	81
20	Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes. International Urology and Nephrology, 2017, 49, 1335-1342.	0.6	12

#	ARTICLE	IF	CITATIONS
21	Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure. Journal of Urology, 2017, 198, 493-495.	0.2	0
22	The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer. Current Urology Reports, 2017, 18, 52.	1.0	15
23	Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer. Urology, 2017, 107, 196-201.	0.5	21
24	The Next Generation of Prostate Cancer Risk Calculators. European Urology, 2017, 72, 897-898.	0.9	0
25	Robust 2-Dâ€"3-D Registration Optimization for Motion Compensation During 3-D TRUS-Guided Biopsy Using Learned Prostate Motion Data. IEEE Transactions on Medical Imaging, 2017, 36, 2010-2020.	5.4	9
26	Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance. Clinical Genitourinary Cancer, 2017, 15, e907-e913.	0.9	11
27	When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers. Cancer Treatment Reviews, 2017, 58, 14-21.	3.4	12
28	Updates on the diagnosis and treatment of prostate cancer. British Journal of Radiology, 2017, 90, 20170180.	1.0	14
29	The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naÃ¯ve men. Current Opinion in Urology, 2017, 27, 488-494.	0.9	15
30	The PROMIS of a New Diagnostic Pathway for Men with Suspected Prostate Cancer. Clinical Oncology, 2017, 29, 397-400.	0.6	1
31	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. European Urology, 2017, 72, 250-266.	0.9	305
32	The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. British Journal of Cancer, 2017, 116, 1159-1165.	2.9	90
33	The Value of PSA Density in Combination with PI-RADSâ„¢ for the Accuracy of Prostate Cancer Prediction. Journal of Urology, 2017, 198, 575-582.	0.2	179
34	A prospective study investigating the impact of multiparametric MRI in biopsy-naÃ¯ve patients with clinically suspected prostate cancer: The PROKOMB study. Contemporary Clinical Trials, 2017, 56, 46-51.	0.8	3
35	Detection of prostate cancer on multiparametric MRI. Proceedings of SPIE, 2017, , .	0.8	12
36	How to Biopsy. Urologic Clinics of North America, 2017, 44, 525-534.	0.8	21
37	Contemporary Active Surveillance. Urologic Clinics of North America, 2017, 44, 565-574.	0.8	20
38	Focal Ablation of Early-Stage Prostate Cancer. Urologic Clinics of North America, 2017, 44, 575-585.	0.8	15

#	ARTICLE	IF	CITATIONS
39	Prediagnostic Risk Assessment with Prostate MRI and MRI-Targeted Biopsy. Urologic Clinics of North America, 2017, 44, 535-546.	0.8	9
41	Use of cylindrical coordinates to localize prostate cancers on MRI and prostatectomy pathology. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 673.e15-673.e20.	0.8	2
42	HistoScanningTM to Detect and Characterize Prostate Cancer—a Review of Existing Literature. Current Urology Reports, 2017, 18, 97.	1.0	8
43	Developments in urologic oncology "OncoForum" The best of 2016. Actas Urológicas Españolas (English Edition), 2017, 41, 543-551.	0.2	0
45	Clinical News. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 188-191.	0.2	0
46	Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal Biopsies. Urologia Internationalis, 2017, 99, 168-176.	0.6	17
48	TOP: Prospective Evaluation of a Volume Based, Computer Assisted Method for Transperineal Optimized Prostate Biopsy. Urologia Internationalis, 2017, 99, 149-155.	0.6	4
49	Current Role of Magnetic Resonance Imaging in Prostate Cancer. Current Radiology Reports, 2017, 5, 1.	0.4	1
50	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. BMJ Open, 2017, 7, e017863.	0.8	14
51	Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Current Urology Reports, 2017, 18, 93.	1.0	2
52	Diffusion Kurtosis Imaging Helps to Predict Upgrading in Biopsy-Proven Prostate Cancer With a Gleason Score of 6. American Journal of Roentgenology, 2017, 209, 1081-1087.	1.0	10
53	Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy. Acta Oncológica, 2017, 56, 1647-1651.	0.8	3
54	Where Do Transrectal Ultrasound- and Magnetic Resonance Imaging-guided Biopsies Miss Significant Prostate Cancer?. Urology, 2017, 110, 154-160.	0.5	16
55	Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml. Future Oncology, 2017, 13, 1793-1800.	1.1	9
56	Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways. Expert Review of Anticancer Therapy, 2017, 17, 1159-1168.	1.1	4
57	Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy. Urology, 2017, 110, 148-153.	0.5	22
58	Advances in Imaging in Prostate and Bladder Cancer. Current Urology Reports, 2017, 18, 69.	1.0	6
59	Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy. Journal of Urology, 2017, 198, 1301-1308.	0.2	22

#	ARTICLE	IF	CITATIONS
60	Avances en uroncologÃa Â«OncoForumÂ»: lo mejor de 2016. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 543-551.	0.3	0
61	Diagnostic accuracy of the PROMIS study â€" Authorsâ€™ reply. Lancet, The, 2017, 390, 362.	6.3	5
62	Comparison between target magnetic resonance imaging (<scp>MRI</scp>) inâ€gantry and cognitively directed transperineal or transrectalâ€guided prostate biopsies for Prostate Imagingâ€"Reporting and Data System (<scp>PI</scp>â€<scp>RADS</scp>) 3â€"5 <scp>MRI</scp> lesions. BJU International, 2017, 120, 43-50.	1.3	42
63	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology, 2017, 28, 2472-2480.	0.6	45
64	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. European Journal of Epidemiology, 2017, 32, 521-527.	2.5	36
65	Diagnostic accuracy of the PROMIS study. Lancet, The, 2017, 390, 362.	6.3	1
66	Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience. World Journal of Urology, 2017, 35, 1857-1862.	1.2	3
67	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 604.e17-604.e24.	0.8	2
68	Clinical PET Imaging in Prostate Cancer. Radiographics, 2017, 37, 1512-1536.	1.4	100
69	MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men. Journal of Endourology, 2017, 31, 1111-1116.	1.1	14
70	Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. British Journal of Radiology, 2018, 91, 20170645.	1.0	23
74	Contemporary and past challenges of prostate cancer diagnostics. Scandinavian Journal of Urology, 2017, 51, 193-201.	0.6	1
78	Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions. EJNMMI Research, 2017, 7, 85.	1.1	5
79	Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Canadian Urological Association Journal, 2017, 11, 298-309.	0.3	55
80	Update on Screening for Urological Malignancies. Rambam Maimonides Medical Journal, 2017, 8, e0041.	0.4	7
81	Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. Frontiers in Oncology, 2017, 7, 290.	1.3	7
82	Focal therapy for prostate cancer: the technical challenges. Journal of Contemporary Brachytherapy, 2017, 4, 383-389.	0.4	10
83	A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer. BMC Urology, 2017, 17, 117.	0.6	23

#	ARTICLE	IF	CITATIONS
84	A multidisciplinary group for prostate cancer management: A single institution experience. Oncology Letters, 2017, 15, 1823-1828.	0.8	4
85	Transrectal ultrasound-guided biopsy for prostate cancer detection: Systematic and/or magnetic-resonance imaging-targeted. Canadian Urological Association Journal, 2017, 11, E330-7.	0.3	10
86	Multi-parametric MRI imaging of the prostate—implications for focal therapy. Translational Andrology and Urology, 2017, 6, 453-463.	0.6	19
87	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 883.	3.8	296
88	Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4–10Âng/ml?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 987-995.	1.2	22
89	A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification. JAMA Oncology, 2018, 4, 678.	3.4	141
90	Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31–2. European Urology, 2018, 73, e151-e152.	0.9	0
91	Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA. World Journal of Urology, 2018, 36, 687-691.	1.2	23
92	Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer. Abdominal Radiology, 2018, 43, 1237-1244.	1.0	6
93	MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. American Journal of Roentgenology, 2018, 210, W218-W225.	1.0	22
94	Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. Diagnostic and Interventional Imaging, 2018, 99, 403-411.	1.8	6
95	Cost and cost-effectiveness studies in urologic oncology using large administrative databases. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 213-219.	0.8	6
96	Utility of MR Angiography in the Identification of Prostatic Artery Origin Prior to Prostatic Artery Embolization. Journal of Vascular and Interventional Radiology, 2018, 29, 307-310.e1.	0.2	20
97	Can Negative Prostate Magnetic Resonance Imaging Give Us the Reassurance We Need To Avoid Standard Biopsy? An Evidence-based Practical Approach. European Urology, 2018, 74, 55-56.	0.9	4
98	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology, 2018, 117, 57-63.	0.5	43
99	Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. Journal of Urology, 2018, 200, 774-778.	0.2	68
100	Re: Predictors of Infectious Complications After Targeted Prophylaxis for Prostate Needle Biopsy. European Urology, 2018, 74, 523-524.	0.9	5
101	Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. Urology, 2018, 116, 137-143.	0.5	10

#	ARTICLE	IF	CITATIONS
102	Virusâ€Inspired Nanogenes Free from Manâ€Made Materials for Hostâ€Specific Transfection and Bioâ€Aided MR Imaging. Advanced Materials, 2018, 30, e1707459.	11.1	28
103	Primary magnetic resonance imaging/ultrasonography fusionâ€guided biopsy of the prostate. BJU International, 2018, 122, 211-218.	1.3	37
104	Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies. Clinical Genitourinary Cancer, 2018, 16, e953-e960.	0.9	9
105	In-bore 3.0-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy in a Repeat Biopsy Population: Diagnostic Performance, Complications, and Learning Curve. Urology, 2018, 114, 139-146.	0.5	11
106	Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population. Journal of Urology, 2018, 200, 89-94.	0.2	44
107	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. Journal of Urology, 2018, 200, 104-113.	0.2	41
108	Accuracy of standardized 12â€core template biopsies versus nonâ€standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen. Prostate, 2018, 78, 365-369.	1.2	3
109	Costâ€effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU International, 2018, 122, 50-58.	1.3	49
110	Targeted biopsy. Current Opinion in Urology, 2018, 28, 219-226.	0.9	6
111	3-D Quantitative Dynamic Contrast Ultrasound for Prostate Cancer Localization. Ultrasound in Medicine and Biology, 2018, 44, 807-814.	0.7	11
112	The new frontier of prostate biopsy: determining the role of imageâ€guidance in moving the needle. BJU International, 2018, 121, 4-5.	1.3	0
113	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. Urologia Internationalis, 2018, 100, 155-163.	0.6	12
114	Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?. European Radiology, 2018, 28, 2236-2245.	2.3	16
115	The CADMUS trial â€" Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. Contemporary Clinical Trials, 2018, 66, 86-92.	0.8	9
116	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	2.4	16
117	Editorial Comment. Journal of Urology, 2018, 199, 712-712.	0.2	0
118	Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. Journal of Urology, 2018, 199, 1475-1481.	0.2	26
119	Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?. Progres En Urologie, 2018, 28, 18-24.	0.3	10

#	Article	IF	Citations
120	MR Imaging for Prostate Cancer Screening and Active Surveillance. Radiologic Clinics of North America, 2018, 56, 251-261.	0.9	6
121	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Radiologic Clinics of North America, 2018, 56, 239-250.	0.9	13
122	Future Perspectives and Challenges of Prostate MR Imaging. Radiologic Clinics of North America, 2018, 56, 327-337.	0.9	11
123	Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate. European Urology, 2018, 73, 637.	0.9	4
124	Assessment of Needle Tip Deflection During Transrectal Guided Prostate Biopsy: Implications for Targeted Biopsies. Journal of Endourology, 2018, 32, 252-256.	1.1	21
125	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 57-63.	2.0	134
126	MR-guided biopsy and focal therapy. Current Opinion in Urology, 2018, 28, 93-101.	0.9	7
127	Role of Prostate MR Imaging in Radiation Oncology. Radiologic Clinics of North America, 2018, 56, 319-325.	0.9	15
128	A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness. European Radiology, 2018, 28, 1949-1960.	2.3	16
129	Imaging of the Large Prostate. , 2018, , 23-40.		0
130	Management of an Elevated PSA and Biopsy Strategies in the Large Prostate. , 2018, , 41-51.		0
131	Utility of early transperineal template‐guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer. BJU International, 2018, 121, 863-870.	1.3	11
132	Sobrediagnóstico por imagen. Radiologia, 2018, 60, 362-367.	0.3	3
133	National implementation of multi‐parametric magnetic resonance imaging for prostate cancer detection â€" recommendations from a <scp>UK</scp> consensus meeting. BJU International, 2018, 122, 13-25.	1.3	106
134	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocrine-Related Cancer, 2018, 25, 569-581.	1.6	19
135	Performance Characteristics of Transrectal Shear Wave Elastography Imaging in the Evaluation of Clinically Localized Prostate Cancer: A Prospective Study. Journal of Urology, 2018, 200, 549-558.	0.2	32
136	A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy. Journal of Urology, 2018, 200, 302-308.	0.2	9
137	Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy. Journal of Urology, 2018, 200, 559-563.	0.2	4

#	Article	IF	Citations
138	Toward a real-time system for temporal enhanced ultrasound-guided prostate biopsy. International Journal of Computer Assisted Radiology and Surgery, 2018, 13, 1201-1209.	1.7	8
139	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. Journal of Urology, 2018, 200, 309-318.	0.2	43
140	Role and Indications of Organ-Sparing "Radical" Cystectomy. Urologic Clinics of North America, 2018, 45, 199-214.	0.8	9
141	Diseases of the Abdomen and Pelvis 2018-2021. IDKD Springer Series, 2018, , .	0.8	22
142	Role of PROPELLER-DWI of the prostate in reducing distortion and artefact from total hip replacement metalwork. European Journal of Radiology, 2018, 102, 213-219.	1.2	31
143	Performance characteristics of multiparametric-MRI at a non-academic hospital using transperineal template mapping biopsy as a reference standard. International Journal of Surgery Open, 2018, 10, 66-71.	0.2	2
144	Editorial Comment. Journal of Urology, 2018, 199, 989-989.	0.2	1
145	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	13.9	2,036
146	Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?. European Urology, 2018, 74, 48-54.	0.9	141
147	Opening Our Eyes to Multiparametric Magnetic Resonance Imaging Before Prostate Biopsy. European Urology, 2018, 73, 361-362.	0.9	0
148	Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. Urology Practice, 2018, 5, 165-171.	0.2	3
149	Diagnostic accuracy of a five‐point Likert scoring system for magnetic resonance imaging (MRI) evaluated according to results of MRI/ultrasonography image‐fusion targeted biopsy of the prostate. BJU International, 2018, 121, 77-83.	1.3	22
150	Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. Acta Radiologica, 2018, 59, 619-626.	0.5	11
151	Abbreviated breast MRI for screening women with dense breast: the EA1141 trial. British Journal of Radiology, 2018, 91, 20170441.	1.0	66
152	New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?. Abdominal Radiology, 2018, 43, 702-712.	1.0	15
153	Transrectal Ultrasound-Guided Transrectal and Transperineal Prostate Biopsy. , 2018, , 79-85.		0
154	Surgical Procedures for Core Urology Trainees. , 2018, , .		0
155	Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy. Investigative Radiology, 2018, 53, 186-190.	3.5	44

#	ARTICLE	IF	CITATIONS
156	An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. Insights Into Imaging, 2018, 9, 87-101.	1.6	69
157	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). European Urology, 2018, 73, 23-30.	0.9	133
158	Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. Journal of Urology, 2018, 199, 699-705.	0.2	16
159	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. Journal of Urology, 2018, 199, 438-444.	0.2	11
160	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e1-13.e10.	0.8	11
161	The â€œPROMISâ€•of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis?. European Urology, 2018, 73, 31-32.	0.9	17
162	Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsyâ€naÃ¯ve men with suspicion of prostate cancer. BJU International, 2018, 122, 40-49.	1.3	108
163	Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. Current Opinion in Urology, 2018, 28, 46-54.	0.9	6
164	Magnetic resonance imaging of the prostate and targeted biopsy, Comparison of PIRADS and Gleason grading. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 183-187.	0.9	22
165	Combined 18F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 762-768.	2.8	27
166	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsyâ€naÃ¯ve patients. BJU International, 2018, 121, 53-60.	1.3	47
167	Current Utilization and Acceptance of Multiparametric MRI in the Diagnosis of Prostate Cancer. A Regional Survey. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 419-426.	0.7	6
168	Editorial Comment. Journal of Urology, 2018, 199, 87-88.	0.2	0
169	Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy. Journal of Urology, 2018, 199, 969-975.	0.2	5
170	Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance. Journal of Urology, 2018, 199, 954-960.	0.2	11
171	Suspicious findings on micro-ultrasound imaging and early detection of prostate cancer. Urology Case Reports, 2018, 16, 98-100.	0.1	12
172	Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population. European Radiology, 2018, 28, 3141-3150.	2.3	31
173	MRI improves cost and accuracy of prostate cancer biopsy. Nature Reviews Urology, 2018, 15, 6-8.	1.9	3

#	Article	IF	Citations
174	Advances in imaging. Nature Reviews Urology, 2018, 15, 81-82.	1.9	0
175	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
176	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU International, 2018, 121, 619-626.	1.3	70
177	Molecular imaging of prostate cancer. British Journal of Radiology, 2018, 91, 20170736.	1.0	16
178	Characteristics of PI-RADS 4 lesions within the prostatic peripheral zone: a retrospective diagnostic accuracy study evaluating 170 lesions. Abdominal Radiology, 2018, 43, 2176-2182.	1.0	6
179	Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens. European Urology, 2018, 73, 351-352.	0.9	0
180	Targeted vs systematic robotâ€assisted transperineal magnetic resonance imagingâ€transrectal ultrasonography fusion prostate biopsy. BJU International, 2018, 121, 791-798.	1.3	22
181	Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI. American Journal of Roentgenology, 2018, 210, 347-357.	1.0	56
182	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. International Urology and Nephrology, 2018, 50, 7-12.	0.6	19
183	3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. European Radiology, 2018, 28, 1634-1641.	2.3	29
184	Epidural Abscess Following Prostate Biopsy. Urology, 2018, 113, 1-5.	0.5	0
185	Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Compositionâ€"A Hypothesis-generating Study. Radiology, 2018, 286, 918-928.	3.6	54
186	Re: Rita Faria, Marta O. Soares, Eldon Spackman, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol 2018;73:23â€"30. European Urology, 2018, 73, e108-e109.	0.9	5
187	Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate. European Radiology, 2018, 28, 17-23.	2.3	34
188	Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?. European Radiology, 2018, 28, 869-876.	2.3	20
189	Interpreting Prostate Multiparametric Magnetic Resonance Imaging: Urologists' Guide Including Prostate Imaging Reporting and Data System. Urology, 2018, 111, 136-138.	0.5	4
190	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. Journal of Clinical Oncology, 2018, 36, 937-941.	0.8	7
191	Focal therapy of prostate cancer. Current Opinion in Urology, 2018, 28, 550-554.	0.9	7

#	ARTICLE	IF	CITATIONS
192	Optimizing patient selection for focal therapy—mapping and ablating the index lesion. Translational Andrology and Urology, 2018, 7, S519-S525.	0.6	3
193	The prostate cancer focal therapy. Gland Surgery, 2018, 7, 89-102.	0.5	15
194	Imaging for the selection and monitoring of men on active surveillance for prostate cancer. Translational Andrology and Urology, 2018, 7, 228-235.	0.6	4
195	Magnetic resonance imaging in active surveillance—a modern approach. Translational Andrology and Urology, 2018, 7, 116-131.	0.6	11
196	Prostate imaging features that indicate benign or malignant pathology on biopsy. Translational Andrology and Urology, 2018, 7, S420-S435.	0.6	30
197	Prostate cancer screening—when to start and how to screen?. Translational Andrology and Urology, 2018, 7, 34-45.	0.6	13
198	Stopping screening, when and how?. Translational Andrology and Urology, 2018, 7, 46-53.	0.6	6
199	Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer. Translational Andrology and Urology, 2018, 7, 236-242.	0.6	0
200	Entering an era of radiogenomics in prostate cancer risk stratification. Translational Andrology and Urology, 2018, 7, S443-S452.	0.6	7
201	PI-RADS v2: Current standing and future outlook. Turkish Journal of Urology, 2018, 44, 189-194.	1.3	13
202	Detection of extraprostatic disease and seminal vesicle invasion in patients undergoing magnetic resonance imaging-targeted prostate biopsies. Translational Andrology and Urology, 2018, 7, S392-S396.	0.6	9
204	Advances in prostate cancer imaging. F1000Research, 2018, 7, 1337.	0.8	11
205	The value of routinely combining the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators with multiparametric magnetic resonance imaging to predict clinically significant prostate cancer remains uncertain. AME Medical Journal, 2018, 3, 106-106.	0.4	0
206	Advances in Medical Imaging Technology for Accurate Detection of Prostate Cancer. , 0, , .		0
207	The transrectal ultrasound/MRI fusion biopsy for prostate cancer diagnosis after previous negative biopsy: a case report. , 2018, 97, 348-352.	0.0	0
211	Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. European Urology Oncology, 2018, 1, 109-117.	2.6	37
212	Multiparametric Magnetic Resonance Imaging Cost-effectiveness in Active Surveillance: More a Belief than Evidence. European Urology Oncology, 2018, 1, 484-485.	2.6	0
213	Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation. Current Opinion in Urology, 2018, 28, 506-511.	0.9	4

#	Article	IF	Citations
214	Diagnostic accuracy of magnetic resonance-guided prostate biopsy and template-guided transperineal saturation biopsy. Medicine (United States), 2018, 97, e12495.	0.4	2
216	Aptamer-conjugated multi-walled carbon nanotubes as a new targeted ultrasound contrast agent for the diagnosis of prostate cancer. Journal of Nanoparticle Research, 2018, 20, 303.	0.8	43
217	Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. British Journal of Cancer, 2018, 119, 1445-1450.	2.9	0
218	Prostate focal therapy. Current Opinion in Urology, 2018, 28, 512-521.	0.9	6
219	Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. Current Opinion in Urology, 2018, 28, 493-498.	0.9	8
220	A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clinical Epigenetics, 2018, 10, 147.	1.8	26
222	Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 528.e15-528.e20.	0.8	32
223	Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports, 2018, 8, 16708.	1.6	27
224	MRI to guide biopsies or avoid biopsies?. Current Opinion in Urology, 2018, 28, 522-528.	0.9	3
225	Effect on prostatic specific antigen by a short time treatment with a Curcuma extract: A real life experience and implications for prostate biopsy. Archivio Italiano Di Urologia Andrologia, 2018, 90, 107.	0.4	7
226	Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy. Research and Reports in Urology, 2018, Volume 10, 233-235.	0.6	5
227	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers, 2018, 10, 480.	1.7	24
228	Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. Investigative Radiology, 2018, 53, 736-741.	3.5	20
229	Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5688-5697.	1.6	17
230	Prostate Cancer Classification on VERDICT DW-MRI Using Convolutional Neural Networks. Lecture Notes in Computer Science, 2018, , 319-327.	1.0	7
231	Learning from Noisy Label Statistics: Detecting High Grade Prostate Cancer in Ultrasound Guided Biopsy. Lecture Notes in Computer Science, 2018, , 21-29.	1.0	7
232	Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB. Korean Journal of Radiology, 2018, 19, 733.	1.5	6
233	68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients. Nuclear Medicine Communications, 2018, 39, 871-880.	0.5	5

#	Article	IF	Citations
234	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. BMJ Open, 2018, 8, e024941.	0.8	14
235	Objective value on Apparent diffusion coefficient (ADC) map to categorize the intensity of diffusion-weighted imaging (DWI) restriction for prostate cancer detection on multiparametric prostate MRI. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 882-891.	0.7	5
237	Multiparametric <scp>MRI</scp>: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU International, 2018, 122, 721-722.	1.3	1
238	Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?. Journal of Cancer, 2018, 9, 3634-3639.	1.2	22
239	Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50. Research and Reports in Urology, 2018, Volume 10, 145-150.	0.6	4
240	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	1.2	16
241	MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?. Translational Andrology and Urology, 2018, 7, 70-82.	0.6	112
242	Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 362, k3519.	2.4	319
243	Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ: British Medical Journal, 2018, 362, k3581.	2.4	110
244	A negative multiparametric magnetic resonance imaging finding does not guarantee the absence of significant cancer among biopsy-proven prostate cancer patients: a real-life clinical experience. International Urology and Nephrology, 2018, 50, 1989-1997.	0.6	8
245	Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. Diagnostic and Interventional Radiology, 2018, 24, 316-320.	0.7	12
246	MR imaging-guided prostate interventional imaging: Ready for a clinical use?. Diagnostic and Interventional Imaging, 2018, 99, 743-753.	1.8	12
247	Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. Journal of Urology, 2018, 200, 1215-1220.	0.2	36
248	Pitfalls in interpreting positive and negative predictive values: Application to prostate multiparametric magnetic resonance imaging. Diagnostic and Interventional Imaging, 2018, 99, 515-518.	1.8	12
249	Diagnostic Accuracy of a Rapid Biparametric MRI Protocol for Detection of Histologically Proven Prostate Cancer. Urology, 2018, 122, 133-138.	0.5	34
250	Reproducibility of Index Lesion Size and Mean Apparent Diffusion Coefficient Values Measured by Prostate Multiparametric MRI: Correlation With Whole-Mount Sectioning of Specimens. American Journal of Roentgenology, 2018, 211, 783-788.	1.0	7
251	Comparison of conventional transrectal ultrasound, magnetic resonance imaging, and micro-ultrasound for visualizing prostate cancer in an active surveillance population: A feasibility study. Canadian Urological Association Journal, 2018, 13, E70-E77.	0.3	26
252	The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?. World Journal of Men?s Health, 2018, 36, 223.	1.7	6

#	ARTICLE	IF	CITATIONS
254	Variability in the multicenter National Registry in Active Surveillance: a questionnaire for urologists. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 442-449.	0.2	0
255	Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study. Journal of Urology, 2018, 200, 1235-1240.	0.2	55
256	Current status and progress of focal therapy in Asia. Current Opinion in Urology, 2018, 28, 529-535.	0.9	1
258	New Imaging Techniques in Prostate Cancer. Cancer Treatment and Research, 2018, 175, 1-13.	0.2	2
259	Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience. PLoS ONE, 2018, 13, e0202872.	1.1	1
260	High-Intensity Focused Ultrasound (HIFU) Options for High-Risk Prostate Cancer. , 2018, , 157-168.		0
261	Diagnostic Pathway of Patients with a Clinical Suspicion of Prostate Cancer: Does One Size Fit All?. European Urology, 2018, 74, 400-401.	0.9	7
262	Label-driven weakly-supervised learning for multimodal deformarle image registration. , 2018, , .		67
263	Computerâ€aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm. BJU International, 2018, 122, 411-417.	1.3	84
264	Organized Chaos: Does PI-RADS Version 2 Work in the Transition Zone?. Radiology, 2018, 288, 492-494.	3.6	13
265	Prostate cancer diagnostics: A review of practice across the northwest of England. Journal of Clinical Urology, 2018, 11, 220-225.	0.1	0
266	Moving toward a more rational, evidenceâ€based approach to PSA screening, diagnosis, and treatment of prostate cancer. Cancer, 2018, 124, 2684-2686.	2.0	1
267	The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy. World Journal of Urology, 2018, 36, 2021-2025.	1.2	21
268	Prostate biopsy. Current Opinion in Urology, 2018, 28, 354-359.	0.9	16
269	Editorial Comment: Advances in MRI and PET of the prostate: concurrence or complementarity?. European Radiology, 2018, 28, 3138-3140.	2.3	0
270	PSA-density does not improve bi-parametric prostate MR detection of prostate cancer in a biopsy naÃ¯ve patient population. European Journal of Radiology, 2018, 104, 64-70.	1.2	36
272	Variabilidad dentro del Registro Nacional multicÃ©ntrico en Vigilancia Activa; cuestionario a urÃ³logos. Actas UrolÃ³gicas EspaÃ±olas, 2018, 42, 442-449.	0.3	6
273	Not All Multiparametric Magnetic Resonance Imagingâ€"targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 120-128.	2.6	55

#	Article	IF	Citations
274	Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. European Urology Oncology, 2018, 1, 208-214.	2.6	24
275	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	2.6	5
276	Editorial Comment. Journal of Urology, 2018, 200, 368-368.	0.2	0
277	Longâ€term outcomes of partial prostate treatment with magnetic resonance imagingâ€guided brachytherapy for patients with favorableâ€risk prostate cancer. Cancer, 2018, 124, 3528-3535.	2.0	15
278	â€œDonâ€™t Let the Perfect Be the Enemy of the Goodâ€ Time to Embrace Magnetic Resonance Imaging Before First Prostate Biopsy. European Urology, 2018, 74, 411-412.	0.9	2
279	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	1.0	25
280	Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Scientific Reports, 2018, 8, 9189.	1.6	56
281	MRI Robots for Needle-Based Interventions: Systems and Technology. Annals of Biomedical Engineering, 2018, 46, 1479-1497.	1.3	64
282	Focal Therapy Versus Surveillance in Intermediate-Risk Cancer. , 2018, , 59-74.		0
283	Magnetic Resonance Imaging Prior to First Prostate Biopsyâ€"Are we there yet?. European Urology, 2018, 74, 409-410.	0.9	11
284	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, .	0.3	15
285	Imaging biomarkers in oncology: Basics and application to MRI. Journal of Magnetic Resonance Imaging, 2018, 48, 13-26.	1.9	39
286	Deep Recurrent Neural Networks for Prostate Cancer Detection: Analysis of Temporal Enhanced Ultrasound. IEEE Transactions on Medical Imaging, 2018, 37, 2695-2703.	5.4	57
287	Quantitative evaluation of the relative apparent diffusion coefficient values on multiparametric magnetic resonance imaging to predict higher Gleason score prostate cancer. Scandinavian Journal of Urology, 2018, 52, 180-185.	0.6	5
288	Editorial Comment. Journal of Urology, 2018, 200, 572-572.	0.2	0
289	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	1.9	78
290	Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values. Radiology, 2018, 289, 128-137.	3.6	162
291	Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urology, 2018, 18, 55.	0.6	3

#	ARTICLE	IF	CITATIONS
292	Current state of multiparameter magnetic resonance imaging of the prostate. Einstein (Sao Paulo,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.3	0
293	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRIâ€characterized prostates. Prostate, 2018, 78, 1229-1237.	1.2	9
294	Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications. Prostate Cancer and Prostatic Diseases, 2018, 21, 573-578.	2.0	27
295	The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging. British Journal of Radiology, 2018, 91, 20170960.	1.0	1
296	Tradeoffs in Refining the Diagnosis of Prostate Cancer. European Urology, 2018, 74, 729-730.	0.9	0
297	Evaluation of Exponential ADC (eADC) and Computed DWI (cDWI) for the Detection of Prostate Cancer. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 758-766.	0.7	5
298	Editorial Comment. Urology, 2018, 118, 125-126.	0.5	0
299	Computer-aided diagnosis of clinically significant prostate cancer from MRI images using sparse autoencoder and random forest classifier. Biocybernetics and Biomedical Engineering, 2018, 38, 733-744.	3.3	33
300	Getting the Balance Rightâ€"The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer. European Urology, 2018, 74, 430-431.	0.9	1
301	Magnetic Resonance Imagingâ€"Based Prostate Cancer Screening. JAMA Network Open, 2018, 1, e180220.	2.8	0
302	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	0.9	70
303	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Urologic Clinics of North America, 2018, 45, 455-466.	0.8	9
305	Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models. BMC Cancer, 2018, 18, 84.	1.1	30
306	A Review of Prostate Biopsy Techniques. Seminars in Roentgenology, 2018, 53, 213-218.	0.2	2
307	Update on Multiparametric Prostate Magnetic Resonance Imaging. Seminars in Roentgenology, 2018, 53, 206-212.	0.2	0
308	Focal Therapy for Prostate Cancer: A More Vehement View of the Approach Could Translate into Real Benefits for Our Patients. European Urology, 2018, 74, 537-539.	0.9	7
309	Aportes actuales de la resonancia magnÃ©tica para el manejo del cÃ¡ncer de prÃ³stata. Revista MÃ©dica ClÃnica Las Condes, 2018, 29, 136-141.	0.2	0
310	Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Research, 2018, 8, 23.	1.1	22

#	Article	IF	Citations
311	MRI-Targeted versus Ultrasonography-Guided Biopsy for Suspected Prostate Cancer. New England Journal of Medicine, 2018, 378, 1835-1836.	13.9	6
312	68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. Radiologia Medica, 2018, 123, 952-965.	4.7	16
313	Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 401.e1-401.e9.	0.8	32
314	State of the art of prostatic arterial embolization for benign prostatic hyperplasia. Gland Surgery, 2018, 7, 188-199.	0.5	20
315	Prostate Cancer in Primary Care. Advances in Therapy, 2018, 35, 1285-1294.	1.3	103
316	MRI improves active surveillance of prostate cancer however biopsy is still crucial. BJU International, 2018, 122, E1-E2.	1.3	2
317	A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. Therapeutic Advances in Urology, 2018, 10, 357-358.	0.9	2
318	Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 347-360.	3.9	17
319	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology, 2018, 122, 152-157.	0.5	36
320	Computer-aided classification of prostate cancer grade groups from MRI images using texture features and stacked sparse autoencoder. Computerized Medical Imaging and Graphics, 2018, 69, 60-68.	3.5	62
321	Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial. Journal of Urology, 2018, 200, 1227-1234.	0.2	38
322	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	3.2	112
324	Engaging the primary care community to encourage appropriate prostate cancer screening. Therapeutic Advances in Urology, 2018, 10, 11-16.	0.9	3
326	Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. Journal of Urology, 2018, 200, 1041-1047.	0.2	66
327	MRI-Targeted Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 379, 589-590.	13.9	59
328	Evaluation of stacked resonators to enhance the performance of a surface receive-only array for prostate MRI at 3 Tesla. Magnetic Resonance Imaging, 2018, 53, 164-172.	1.0	1
329	Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer. European Urology Oncology, 2018, 1, 129-133.	2.6	21
330	Outcomes of Magnetic Resonance Imaging–Ultrasound Fusion Prostate Biopsy of PI-RADS 3, 4, and 5 Lesions. Canadian Association of Radiologists Journal, 2018, 69, 303-310.	1.1	2

#	Article	IF	Citations
331	Advances in Urologic Imaging. Urologic Clinics of North America, 2018, 45, 503-524.	0.8	27
332	Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men. JAMA Network Open, 2018, 1, e180219.	2.8	135
333	Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels. Clinical Radiology, 2018, 73, 810-817.	0.5	8
334	The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study. European Urology Oncology, 2018, 1, 476-483.	2.6	12
335	Re: MRI-targeted or Standard Biopsy for Prostate-cancer Diagnosis. European Urology, 2018, 74, 524-525.	0.9	3
336	Systematic transperineal and magnetic resonance imaging–targeted biopsies: the resolution of uncertainty. BJU International, 2018, 122, 6-7.	1.3	0
337	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) with targeted fusion biopsy: is the time now?. BJU International, 2018, 122, 1-2.	1.3	0
338	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. European Urology, 2018, 74, 357-368.	0.9	105
339	PRECISION delivers on the PROMIS of mpMRI in early detection. Nature Reviews Urology, 2018, 15, 529-530.	1.9	9
340	Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. European Urology Oncology, 2018, 1, 29-36.	2.6	43
341	Radiomics and radiogenomics of prostate cancer. Abdominal Radiology, 2019, 44, 2021-2029.	1.0	43
342	Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. World Journal of Urology, 2019, 37, 221-234.	1.2	25
343	Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram. European Urology Focus, 2019, 5, 815-822.	1.6	18
344	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	0.9	200
345	Temporal changes in MRI appearance of the prostate after focal ablation. Abdominal Radiology, 2019, 44, 272-278.	1.0	12
346	Correlation of 3T multiparametric prostate MRI using prostate imaging reporting and data system (PIRADS) version 2 with biopsy as reference standard. Abdominal Radiology, 2019, 44, 252-258.	1.0	6
347	Improvement of prostate cancer detection combining a computer-aided diagnostic system with TRUS-MRI targeted biopsy. Abdominal Radiology, 2019, 44, 264-271.	1.0	15
348	Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?. World Journal of Urology, 2019, 37, 235-241.	1.2	31

#	Article	IF	Citations
349	The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer. BJU International, 2019, 123, 82-90.	1.3	25
350	Performance of T2 Maps in the Detection of Prostate Cancer. Academic Radiology, 2019, 26, 15-21.	1.3	29
351	Comparison of the accuracy of multiparametric magnetic resonance imaging (mpMRI) results with the final pathology findings for radical prostatectomy specimens in the detection of prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, e20-e27.	0.7	7
352	Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. European Radiology, 2019, 29, 299-308.	2.3	27
353	Factors influencing urinary retention after transperineal template biopsy of the prostate: outcomes from a regional cancer centre. World Journal of Urology, 2019, 37, 337-342.	1.2	17
354	Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection. World Journal of Urology, 2019, 37, 327-335.	1.2	12
355	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. World Journal of Urology, 2019, 37, 243-251.	1.2	37
356	Implementation of multiparametric magnetic resonance imaging technology for evaluation of patients with suspicion for prostate cancer in the clinical practice setting. BJU International, 2019, 123, 239-245.	1.3	5
357	Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. European Urology, 2019, 75, 310-318.	0.9	129
358	The reporting quality of studies of diagnostic accuracy in the urologic literature. World Journal of Urology, 2019, 37, 969-974.	1.2	5
359	Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. Urologia Internationalis, 2019, 102, 20-26.	0.6	6
360	Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology, 2019, 124, 98-106.	0.5	9
361	Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2019, 22, 39-48.	2.0	21
362	Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 84-90.	2.0	17
363	MRI in active surveillance: a critical review. Prostate Cancer and Prostatic Diseases, 2019, 22, 5-15.	2.0	36
364	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology, 2019, 75, 300-309.	0.9	99
365	Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clinical Epigenetics, 2019, 11, 115.	1.8	24
366	Developing an effective strategy to improve the detection of significant prostate cancer by combining the 4Kscore and multiparametric MRI. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 672-677.	0.8	11

#	ARTICLE	IF	CITATIONS
367	Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance. Acta Radiologica Open, 2019, 8, 205846011986635.	0.3	6
368	Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer. JAMA Network Open, 2019, 2, e198427.	2.8	47
369	The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations. Medical Sciences (Basel, Switzerland), 2019, 7, 85.	1.3	6
372	Association Between Tumor Multifocality on Multi-parametric MRI and Detection of Clinically-Significant Prostate Cancer in Lesions with Prostate Imaging Reporting and Data System (PI-RADS) Score 4. Urology, 2019, 134, 173-180.	0.5	3
373	Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 448-456.	0.4	41
374	Impact of PI-RADS v2 on indication of prostate biopsy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 486-494.	0.7	9
375	Screening of Prostate Cancer. , 2019, , 97-108.		0
376	Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 678-687.	0.8	7
377	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. Human Pathology, 2019, 93, 6-15.	1.1	3
378	Prostate imaging reporting and data system correlation with Gleason score: Pathological aspects of magnetic resonance imaging findings. Urologia, 2019, 86, 189-196.	0.3	1
379	Preventing Erectile Dysfunction after Radical Prostatectomy: Nerve-Sparing Techniques, Penile Rehabilitation, and Novel Regenerative Therapies. , 0, , .		2
380	Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization. European Journal of Radiology, 2019, 118, 51-57.	1.2	15
381	Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. Clinical Radiology, 2019, 74, 894.e1-894.e9.	0.5	38
382	A comparison of magnetic resonance imaging techniques used to secure biopsies in prostate cancer patients. Expert Review of Anticancer Therapy, 2019, 19, 705-716.	1.1	9
383	A randomised trial comparing two protocols for transrectal prostate repeat biopsy: six lateral posterior plus six anterior cores versus a standard posterior 12-core biopsy. Scandinavian Journal of Urology, 2019, 53, 217-221.	0.6	2
384	Can prostate cancer be NICE?. Clinical Radiology, 2019, 74, 823-830.	0.5	3
385	Diagnostic performance of multiparametric MRI parameters for Gleason score and cellularity metrics of prostate cancer in different zones: a quantitative comparison. Clinical Radiology, 2019, 74, 895.e17-895.e26.	0.5	5
386	Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging. Frontiers in Oncology, 2019, 9, 572.	1.3	11

#	ARTICLE	IF	CITATIONS
387	Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer. Cancers, 2019, 11, 1064.	1.7	9
388	^{18}F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. Journal of Nuclear Medicine, 2019, 60, 1705-1712.	2.8	12
389	Biomarkers for Diagnosis and Prognosis of Prostate Cancer. , 2019, , .		8
390	Increasing the use of active surveillance for prostate cancer in younger men. Cancer, 2019, 125, 3292-3295.	2.0	6
391	Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer. American Journal of Roentgenology, 2019, 213, 831-835.	1.0	8
392	Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urology, 2019, 19, 94.	0.6	25
393	PSA screeningâ€"aÂmatter of debate?. Memo - Magazine of European Medical Oncology, 2019, 12, 244-248.	0.3	9
394	Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort. European Urology Oncology, 2019, 2, 716-722.	2.6	11
395	Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer. Urologia Internationalis, 2019, 103, 270-278.	0.6	16
396	MRI-Fusion Targeted vs. Systematic Prostate Biopsyâ€"How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?. Frontiers in Surgery, 2019, 6, 55.	0.6	19
397	Automated grading of prostate cancer using convolutional neural network and ordinal class classifier. Informatics in Medicine Unlocked, 2019, 17, 100256.	1.9	36
400	The use of multiparametric MRI for prostate cancer diagnosis in contemporary practice. European Urology Supplements, 2019, 18, e2532.	0.1	0
401	PSA persistence after radical prostatectomy needs more than standard therapeutic options to improve outcomes. BJU International, 2019, 124, 716-718.	1.3	0
402	Prostate mpMRI in the UK: the state of the nation. Clinical Radiology, 2019, 74, 894.e11-894.e18.	0.5	23
403	Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. European Journal of Radiology, 2019, 121, 108704.	1.2	70
404	In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2019, 43, 337-347.	0.2	1
405	DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clinical Epigenetics, 2019, 11, 152.	1.8	7
406	Special issue on prostate imaging. Clinical Radiology, 2019, 74, 821-822.	0.5	2

#	ARTICLE	IF	CITATIONS
407	A multicentre assessment of prostate MRIÂquality and compliance with UK and international standards. Clinical Radiology, 2019, 74, 894.e19-894.e25.	0.5	42
408	Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?. European Urology Oncology, 2019, 2, 664-669.	2.6	23
409	Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European Urology Oncology, 2019, 2, 605-616.	2.6	30
410	Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. European Urology Oncology, 2021, 4, 594-600.	2.6	12
412	Does clinical validation and the implementation of new models of outpatient service delivery have the potential to reduce waiting lists? A pilot study in Letterkenny University Hospital. European Urology Supplements, 2019, 18, e2530-e2531.	0.1	0
413	Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases. Clinical Radiology, 2019, 74, 895.e1-895.e15.	0.5	25
414	Is PSA being over utilized in the acute hospital inpatient setting: A single centre review. European Urology Supplements, 2019, 18, e2532.	0.1	0
415	The Effect of Pre-Biopsy MRI on Potential Grade Migration in Prostate Cancer. European Urology Supplements, 2019, 18, e2532.	0.1	0
416	Assessment of the influence of transrectal and transperineal prostate biopsies on erectile function: A prospective observational singleâ€center study. International Journal of Urology, 2019, 26, 1054-1058.	0.5	11
417	Avoiding biopsy in men with <scp>PIâ€RADS</scp> scores 1 and 2 on multiparametric <scp>MRI</scp> of the prostate, ready for prime time?. BJU International, 2019, 124, 715-716.	1.3	2
418	Trans-Perineal Template-Guided Mapping Biopsy vs. Freehand Trans-Perineal Biopsy in Chinese Patients With PSA < 20 ng/ml: Similar Cancer Detection Rate but Different Lesion Detection Rate. Frontiers in Oncology, 2019, 9, 758.	1.3	15
419	Prediction of significant prostate cancer in biopsy-naÃ¯ve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. PLoS ONE, 2019, 14, e0221350.	1.1	13
421	Multiparametric MRI Approach to Prostate Cancer with a Pictorial Essay on PI-RADS. Journal of Gastrointestinal and Abdominal Radiology, 2019, 02, 004-017.	0.2	1
422	The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa). Current Urology Reports, 2019, 20, 60.	1.0	18
423	Multimodality Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1350-1358.	2.8	51
424	A review of optimal prostate biopsy: indications and techniques. Therapeutic Advances in Urology, 2019, 11, 175628721987007.	0.9	36
425	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. International Journal of Hyperthermia, 2019, 36, 914-924.	1.1	6
426	Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT). Radiotherapy and Oncology, 2019, 141, 181-187.	0.3	9

#	Article	IF	Citations
427	Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration. Medical Image Analysis, 2019, 58, 101558.	7.0	45
428	18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1348.	1.7	34
429	Elastic fusion biopsy versus systematic biopsy for prostate cancer detection: Results of a multicentric study on 1119 patients. Actas Urológicas Españolas (English Edition), 2019, 43, 431-438.	0.2	2
430	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scandinavian Journal of Urology, 2019, 53, 295-302.	0.6	23
431	Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging. Clinical Hemorheology and Microcirculation, 2019, 73, 105-111.	0.9	5
432	Prostate MRI technical parameters standardization: A systematic review on adherence to PI-RADSv2 acquisition protocol. European Journal of Radiology, 2019, 120, 108662.	1.2	38
433	Obstacles in prostate cancer screening: Current issues and future solutions. Journal of Clinical Urology, 2019, 12, 111-116.	0.1	0
434	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology. BJU International, 2019, 124, 221-241.	1.3	4
435	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect real‐world practice?. BJU International, 2019, 123, 197-198.	1.3	2
436	^{68}Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. Journal of Nuclear Medicine, 2019, 60, 1118-1123.	2.8	30
437	Prostate Magnetic Resonance Imaging: Lesion Detection and Local Staging. Annual Review of Medicine, 2019, 70, 451-459.	5.0	3
438	Update on Strategies to Reduce Infectious Complications After Prostate Biopsy. European Urology Focus, 2019, 5, 20-28.	1.6	33
439	The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy. European Urology Oncology, 2019, 2, 135-140.	2.6	53
440	The current role of prostate multiparametric magnetic resonance imaging. Asian Journal of Urology, 2019, 6, 137-145.	0.5	11
441	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. Radiology, 2019, 291, 83-89.	3.6	43
442	Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review. World Journal of Urology, 2019, 37, 1517-1534.	1.2	20
443	Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility. European Urology, 2019, 76, 24-26.	0.9	3
444	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. journal of applied laboratory medicine, The, 2019, 3, 1014-1021.	0.6	0

#	ARTICLE	IF	CITATIONS
445	MRI-targeted biopsies: What's next?. World Journal of Urology, 2019, 37, 219-220.	1.2	0
446	The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI. American Journal of Roentgenology, 2019, 212, 823-829.	1.0	16
447	Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2019, 76, 284-303.	0.9	153
448	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. BMJ Open, 2019, 9, e027816.	0.8	11
449	Is Magnetic Resonance Imaging-targeted Biopsy Now the Standard of Care?. European Urology, 2019, 76, 304-305.	0.9	2
450	MRI for Radiotherapy. , 2019, , .		4
451	Prostate cancer "super-active surveillance"era opened by vascular targeted photodynamic therapy . Research and Reports in Urology, 2019, Volume 11, 157-163.	0.6	2
452	PI-RADS version 2.1: one small step for prostate MRI. Clinical Radiology, 2019, 74, 841-852.	0.5	108
453	Tumor-Activatable Clinical Nanoprobe for Cancer Imaging. Nanotheranostics, 2019, 3, 196-211.	2.7	12
454	Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men. BJU International, 2019, 124, 775-784.	1.3	31
455	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine, 2019, 16, e1002813.	3.9	43
456	The primacy of multiparametric MRI in men with suspected prostate cancer. European Radiology, 2019, 29, 6940-6952.	2.3	51
457	Multiparametric MRI <i>Versus</i> Multiparametric US in the Detection of Prostate Cancer. Anticancer Research, 2019, 39, 3101-3110.	0.5	16
458	Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. Modern Pathology, 2019, 32, 1536-1543.	2.9	21
459	Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard. European Journal of Radiology, 2019, 116, 180-185.	1.2	10
460	Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. Cancer Medicine, 2019, 8, 3659-3665.	1.3	16
461	Teaching Urologists "How to Read Multi-Parametric Prostate MRIs Using PIRADSv2" Results of an iBook Pilot Study. Urology, 2019, 131, 40-45.	0.5	8
462	Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data. Cancer Imaging, 2019, 19, 26.	1.2	6

#	Article	IF	Citations
463	Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer. European Urology, 2019, 76, 535-536.	0.9	1
464	Prostate cancer aggressive prediction: preponderant diagnostic performances of intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) beyond ADC at 3.0 T scanner with gleason score at final pathology. Abdominal Radiology, 2019, 44, 3441-3452.	1.0	20
465	Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. European Urology, 2019, 76, 704-705.	0.9	1
466	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. European Urology, 2019, 76, 574-581.	0.9	114
467	The use of European Randomized study of Screening for Prostate Cancer calculator as a diagnostic tool for prostate biopsy indication. Bratislava Medical Journal, 2019, 120, 331-335.	0.4	0
468	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
469	Regional Standardization of Prostate Multiparametric MRI Performance and Reporting: Is There a Role for a Director of Prostate Imaging?. American Journal of Roentgenology, 2019, 213, 844-850.	1.0	14
470	Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive. JAMA Surgery, 2019, 154, 811.	2.2	119
471	Closing the Loop on the Role of Multiparametric Magnetic Resonance Imaging–Targeted Prostate Biopsy. JAMA Surgery, 2019, 154, 818.	2.2	1
473	Contemporary approach to active surveillance for favorable risk prostate cancer. Asian Journal of Urology, 2019, 6, 146-152.	0.5	32
474	Clinically significant prostate cancer detection on MRI: A radiomic shape features study. European Journal of Radiology, 2019, 116, 144-149.	1.2	71
475	Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy. Urologia Internationalis, 2019, 103, 33-40.	0.6	7
476	Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-naive Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study. European Urology, 2019, 76, 534-535.	0.9	3
477	Utility of an Automated Radiology-Pathology Feedback Tool. Journal of the American College of Radiology, 2019, 16, 1211-1217.	0.9	13
478	Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer. BJU International, 2019, 124, 992-998.	1.3	25
479	Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. Clinical Genitourinary Cancer, 2019, 17, e745-e750.	0.9	7
480	A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU International, 2019, 124, 609-620.	1.3	30
481	Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. American Journal of Roentgenology, 2019, 213, W66-W75.	1.0	14

#	ARTICLE	IF	CITATIONS
482	Evaluation of prostate MRI: can machine learning provide support where radiologists need it?. European Radiology, 2019, 29, 4751-4753.	2.3	0
483	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 142-150.	0.9	80
484	Targeted biopsy of the prostate: does this result in improvement in detection of highâ€grade cancer or the occurrence of the Will Rogers phenomenon?. BJU International, 2019, 124, 643-648.	1.3	13
485	Prostate biopsy: when and how to perform. Clinical Radiology, 2019, 74, 853-864.	0.5	31
486	CEâ€"MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. British Journal of Cancer, 2019, 120, 1120-1128.	2.9	25
487	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. Urology, 2019, 130, 106-112.	0.5	3
488	Role of novel imaging in the management of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 611-618.	0.8	14
489	Magnetic resonance imagingâ€"transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives. Scandinavian Journal of Urology, 2019, 53, 89-96.	0.6	6
490	Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. International Journal of Molecular Sciences, 2019, 20, 1637.	1.8	80
491	Automated segmentation of prostate zonal anatomy on T2â€weighted (T2W) and apparent diffusion coefficient (<scp>ADC</scp>) map <scp>MR</scp> images using Uâ€Nets. Medical Physics, 2019, 46, 3078-3090.	1.6	36
492	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 490-496.	2.6	13
493	Comparison of multiparametric <scp>MRI</scp>â€based and transrectal ultrasoundâ€based preplans with intraoperative ultrasoundâ€based planning for low dose rate interstitial prostate seed implantation. Journal of Applied Clinical Medical Physics, 2019, 20, 31-38.	0.8	6
494	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. American Journal of Roentgenology, 2019, 213, 384-396.	1.0	39
495	Early Second Round Targeted Biopsy of PI-RADS Score 3 or 4 in 256 Men With Persistent Suspicion of Prostate Cancer. In Vivo, 2019, 33, 897-901.	0.6	4
496	Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy. European Urology, 2019, 76, 14-17.	0.9	64
498	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer, 2019, 125, 2955-2964.	2.0	21
499	Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy. Journal of Visualized Experiments, 2019, , .	0.2	3
501	Role of MRI in planning radical prostatectomy: what is the added value?. World Journal of Urology, 2019, 37, 1289-1292.	1.2	26

#	Article	IF	Citations
502	A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies. Prostate Cancer and Prostatic Diseases, 2019, 22, 609-616.	2.0	20
503	Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low‐Risk Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 542.	1.0	3
504	Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?. Clinical Genitourinary Cancer, 2019, 17, e664-e671.	0.9	8
505	Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1531-1541.	3.3	25
506	Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies . Research and Reports in Urology, 2019, Volume 11, 29-42.	0.6	8
508	To see or not to see â€" what renders prostate cancer visible?. Nature Reviews Urology, 2019, 16, 274-275.	1.9	0
509	Cartography-based quality control of prostate cancer care. Current Opinion in Urology, 2019, 29, 65-69.	0.9	1
510	Triaging patients to primary biopsy or prostate MRI based on digital rectal examination improves the detection rate of TRUS biopsy and avoids unnecessary biopsies. Journal of Clinical Urology, 2019, 12, 117-121.	0.1	1
511	Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?. American Journal of Roentgenology, 2019, 212, 1244-1252.	1.0	7
512	Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan. International Journal of Urology, 2019, 26, 544-549.	0.5	7
513	Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer and Prostatic Diseases, 2019, 22, 546-551.	2.0	37
515	Epidemiology, aetiology and screening of bladder cancer. Translational Andrology and Urology, 2019, 8, 5-11.	0.6	97
516	Prostate cancer detection rate according to lesion visibility using ultrasound and MRI. Clinical Radiology, 2019, 74, 474-479.	0.5	4
517	Structured reporting of prostate magnetic resonance imaging has the potential to improve interdisciplinary communication. PLoS ONE, 2019, 14, e0212444.	1.1	26
518	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928.	1.2	9
520	Characterization and PI-RADS version 2 assessment of prostate cancers missed by prebiopsy 3-T multiparametric MRI: Correlation with whole-mount thin-section histopathology. Clinical Imaging, 2019, 55, 174-180.	0.8	9
521	The role of multiparametric MRI in biopsy-naive prostate cancer. Nature Reviews Urology, 2019, 16, 276-277.	1.9	10
522	Establishing MRI-guided prostate intervention at a UK Centre. British Journal of Radiology, 2019, 92, 20180918.	1.0	0

#	ARTICLE	IF	CITATIONS
523	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. European Radiology, 2019, 29, 4861-4870.	2.3	23
524	Smarter screening for prostate cancer. World Journal of Urology, 2019, 37, 991-999.	1.2	44
525	Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nature Reviews Urology, 2019, 16, 302-317.	1.9	86
526	Deep neural maps for unsupervised visualization of high-grade cancer in prostate biopsies. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1009-1016.	1.7	17
527	Biparametric vs multiparametric prostate magnetic resonance imaging for the detection of prostate cancer in treatmentâ€naÃ¯ve patients: a diagnostic test accuracy systematic review and metaâ€analysis. BJU International, 2019, 124, 209-220.	1.3	78
528	Resonancia magnÃ©tica funcional de la prÃ³stata. EMC - UrologÃa, 2019, 51, 1-11.	0.0	0
529	Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. Urology, 2019, 130, 99-105.	0.5	29
530	Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdominal Radiology, 2019, 44, 1883-1893.	1.0	80
531	The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors. Urology, 2019, 127, 68-73.	0.5	15
532	Artificial intelligence in cancer imaging: Clinical challenges and applications. Ca-A Cancer Journal for Clinicians, 2019, 69, 127-157.	157.7	965
534	False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdominal Radiology, 2019, 44, 1044-1051.	1.0	25
535	Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients. European Journal of Radiology, 2019, 113, 1-6.	1.2	11
536	Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry. American Journal of Surgical Pathology, 2019, 43, 361-368.	2.1	13
537	Optimization and repeatability of multipool chemical exchange saturation transfer MRI of the prostate at 3.0â€‰T. Journal of Magnetic Resonance Imaging, 2019, 50, 1238-1250.	1.9	14
538	MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer?. Clinical Radiology, 2019, 74, 259-267.	0.5	7
539	Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU International, 2019, 124, 730-737.	1.3	14
540	Best practice in active surveillance for men with prostate cancer: a Prostate Cancer <scp>UK</scp> consensus statement. BJU International, 2019, 124, 47-54.	1.3	23
541	Difference in MRI-guided biopsy cancer detection rates between individual clinicians. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 299.e1-299.e6.	0.8	5

#	Article	IF	Citations
542	PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens. Prostate, 2019, 79, 768-777.	1.2	4
543	Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study. American Journal of Roentgenology, 2019, 212, 839-846.	1.0	40
544	Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. Molecular Cancer Research, 2019, 17, 1155-1165.	1.5	50
545	Diagnosis of prostate cancer. Asian Journal of Urology, 2019, 6, 129-136.	0.5	80
546	Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. BMJ Open, 2019, 9, e031032.	0.8	6
547	Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surgery, Interventions, and Health Technologies, 2019, 1, e000010.	0.6	1
549	PCASTt/SPCG-17â€"a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	0.8	19
550	Las biopsias de prÃ³stata dirigidas Â¿estÃ¡n listas para reemplazar las biopsias de prÃ³stata sistemÃ¡ticas?. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 573-578.	0.3	3
551	The use of prostate MR for targeting prostate biopsies. BJR|Open, 2019, 1, 20180044.	0.4	0
552	A novel biparametric magnetic resonance imaging sequence provides a more efficient and similarly efficacious method of risk stratifying men clinically suspected of having prostate cancer. Translational Andrology and Urology, 2019, 8, S484-S485.	0.6	0
553	Magnetic resonance imaging sequences for prostate cancer triage: two is a couple, three is a crowd?. Translational Andrology and Urology, 2019, 8, S476-S479.	0.6	2
554	A NICE change? The evidence for mpMRI triage in prostate cancer. Trends in Urology & Men's Health, 2019, 10, 7-10.	0.2	0
555	Using Multiparametric Magnetic Resonance Imaging to Shift Prostate Cancer Diagnosis Toward Clinically Significant Disease and Minimize Overdiagnosis (and Overtreatment). International Journal of Radiation Oncology Biology Physics, 2019, 105, 915-917.	0.4	0
556	Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. The Cochrane Library, 2019, 2019, CD012663.	1.5	234
557	Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 257-264.	2.6	5
558	Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7â€"10 Prostate Cancer in Biopsy-naÃ¯ve Men. European Urology Oncology, 2019, 2, 311-319.	2.6	74
559	Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer. European Urology Oncology, 2019, 2, 329-332.	2.6	62
560	68Ga PSMA PET-CT: New Hope in Prostate Cancer Imaging and Therapy. Bangladesh Journal of Nuclear Medicine, 2019, 22, 53-57.	0.0	0

#	Article	IF	Citations
562	The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. Scientific Reports, 2019, 9, 17862.	1.6	6
564	Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. Scandinavian Journal of Urology, 2019, 53, 304-311.	0.6	31
565	Risk stratification and avoiding overtreatment in localized prostate cancer. Current Opinion in Urology, 2019, 29, 612-619.	0.9	9
566	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. Radiology Imaging Cancer, 2019, 1, e190016.	0.7	1
567	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. Therapeutic Advances in Urology, 2019, 11, 175628721988280.	0.9	1
568	Comparing significant prostate cancer detection rates after the introduction of pre-biopsy MRI: turning PROMIS into action. Journal of Clinical Urology, 2019, 12, 341-346.	0.1	1
569	MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: AÂfeasibility follow-up study. PLoS ONE, 2019, 14, e0226764.	1.1	3
571	Optimizing prostate biopsy techniques. Current Opinion in Urology, 2019, 29, 578-586.	0.9	23
572	A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. Investigative Radiology, 2019, 54, 437-447.	3.5	24
573	Are targeted prostate biopsies ready to replace systematic prostate biopsies?. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2019, 43, 573-578.	0.2	1
574	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	9
575	MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 145-152.	1.0	10
576	Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions â€œinvisibleâ€•on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 20-30.	3.3	79
577	Histologic findings associated with false-positive multiparametric magnetic resonance imaging performed for prostate cancer detection. Human Pathology, 2019, 83, 159-165.	1.1	24
578	Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy. Urology, 2019, 126, 152-157.	0.5	27
579	Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T_2 MR Images. Journal of Magnetic Resonance Imaging, 2019, 50, 910-917.	1.9	16
580	The value of MR textural analysis in prostate cancer. Clinical Radiology, 2019, 74, 876-885.	0.5	27
581	Partial gland therapy for prostate cancer. Cancer, 2019, 125, 818-819.	2.0	1

#	ARTICLE	IF	CITATIONS
582	Association of training level and outcome of software-based image fusion-guided targeted prostate biopsies. World Journal of Urology, 2019, 37, 2119-2127.	1.2	10
583	Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men. Japanese Journal of Radiology, 2019, 37, 154-164.	1.0	7
584	Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis. European Journal of Radiology, 2019, 110, 22-29.	1.2	37
585	In-bore Multiparametric Magnetic Resonance Imaging Targeted Biopsy: As Good as it Gets?. European Urology, 2019, 75, 579-581.	0.9	4
586	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologistsâ€™ Training Program?. Clinical Genitourinary Cancer, 2019, 17, 88-96.	0.9	22
587	A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. European Urology, 2019, 75, 558-561.	0.9	64
588	Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdominal Radiology, 2019, 44, 1052-1061.	1.0	16
589	Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 551-559.	1.2	25
590	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naÃ¯ve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology, 2019, 75, 570-578.	0.9	521
591	Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate. American Journal of Roentgenology, 2019, 212, 124-129.	1.0	15
592	Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 331-336.	2.0	43
593	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 57-62.	0.8	24
594	Clinical association of metabolic syndrome, Câ€reactive protein and testosterone levels with clinically significant prostate cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 934-942.	1.6	19
595	A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imagingâ€guided biopsy. BJU International, 2019, 123, 612-617.	1.3	12
596	Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology, 2019, 75, 910-917.	0.9	34
597	Future Perspectives in Multiparametric Prostate MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2019, 27, 117-130.	0.6	6
598	MR Imagingâ€"Guided Focal Therapies of Prostate Cancer. Magnetic Resonance Imaging Clinics of North America, 2019, 27, 131-138.	0.6	7
599	Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer. European Radiology, 2019, 29, 4150-4159.	2.3	8

#	ARTICLE	IF	CITATIONS
600	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology, The, 2019, 20, 100-109.	5.1	701
601	Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonographyâ€fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system versionÂ2 score of 3â€"5. International Journal of Urology, 2019, 26, 217-222.	0.5	7
602	A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World Journal of Urology, 2019, 37, 2109-2117.	1.2	56
603	The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e1-298.e9.	0.8	26
604	Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?. World Journal of Urology, 2019, 37, 277-287.	1.2	51
605	Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting. Clinical Hemorheology and Microcirculation, 2019, 71, 165-170.	0.9	14
606	Optimising prostate mpMRI: prepare for success. Clinical Radiology, 2019, 74, 831-840.	0.5	37
607	The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?. Scandinavian Journal of Urology, 2019, 53, 21-25.	0.6	4
608	Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy, 2019, 18, 198-203.	0.2	1
609	Quantitative T2-mapping using MRI for detection of prostate malignancy: a systematic review of the literature. Acta Radiologica, 2019, 60, 1181-1189.	0.5	21
610	Automatic Needle Segmentation and Localization in MRI With 3-D Convolutional Neural Networks: Application to MRI-Targeted Prostate Biopsy. IEEE Transactions on Medical Imaging, 2019, 38, 1026-1036.	5.4	42
611	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. European Urology, 2019, 75, 506-514.	0.9	188
612	MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting. Clinical Hemorheology and Microcirculation, 2019, 70, 433-440.	0.9	13
613	The Role of Transrectal Ultrasound for Finding Focal Lesions in Prostate Cancer Detection Compared to Systematic Sextant Biopsy. Academic Radiology, 2019, 26, 1023-1029.	1.3	0
614	MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis. BMJ Evidence-Based Medicine, 2019, 24, 116-117.	1.7	2
615	Prostate MRI using an external phased array wearable pelvic coil at 3T: comparison with an endorectal coil. Abdominal Radiology, 2019, 44, 1062-1069.	1.0	17
616	What Needs To Be Done Before Prostate Magnetic Resonance Imaging Can Safely Be Applied in the General Population. European Urology, 2019, 75, 397-398.	0.9	1
617	Tumor cell heterogeneity and resistance; report from the 2018 Coffeyâ€Holden Prostate Cancer Academy Meeting. Prostate, 2019, 79, 244-258.	1.2	13

#	ARTICLE	IF	CITATIONS
618	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
619	Prospective Inclusion of Apparent Diffusion Coefficients in Multiparametric Prostate MRI Structured Reports: Discrimination of Clinically Insignificant and Significant Cancers. American Journal of Roentgenology, 2019, 212, 109-116.	1.0	24
620	A novel fourth order chaotic system and its algorithm for medical image encryption. Multidimensional Systems and Signal Processing, 2019, 30, 1637-1657.	1.7	33
621	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World Journal of Urology, 2019, 37, 1255-1261.	1.2	37
622	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. BJU International, 2019, 124, 76-86.	1.3	18
623	Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. European Radiology, 2019, 29, 1820-1830.	2.3	24
624	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	2.6	27
625	Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery. Prostate Cancer and Prostatic Diseases, 2019, 22, 391-398.	2.0	28
626	Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes. Journal of Endourology, 2019, 33, 100-106.	1.1	8
627	Practice changing for prostate cancer: a vision of the future. Nature Reviews Urology, 2019, 16, 71-72.	1.9	6
628	Voxelâ€wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International, 2019, 123, 1020-1030.	1.3	9
629	Combination of ^{68}Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis. Journal of Nuclear Medicine, 2019, 60, 944-949.	2.8	88
630	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 181.e15-181.e21.	0.8	6
631	The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. European Urology, 2019, 75, 733-740.	0.9	67
632	Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2019, 22, 206-220.	2.0	19
633	Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. European Urology, 2019, 75, 712-720.	0.9	187
634	Prospective comparison of a fast 1.5â€T biparametric with the 3.0â€T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer. BJU International, 2019, 123, 411-420.	1.3	16
635	Comparison of complications rates between multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion and systematic TRUS prostatic biopsies. Abdominal Radiology, 2019, 44, 732-738.	1.0	2

#	ARTICLE	IF	CITATIONS
636	MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World Journal of Urology, 2019, 37, 1263-1279.	1.2	25
637	Value of MR-US fusion in guidance of repeated prostate biopsy in men with PSAâ€<â€10â€ng/mL. Clinical Imaging, 2019, 53, 1-5.	0.8	14
638	National Private Payer Coverage of Prostate MRI. Journal of the American College of Radiology, 2019, 16, 24-29.	0.9	10
640	Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer. European Urology Focus, 2019, 5, 62-68.	1.6	9
641	Prostate Indeterminate Lesions on Magnetic Resonance Imagingâ€"Biopsy Versus Surveillance: A Literature Review. European Urology Focus, 2019, 5, 799-806.	1.6	27
642	Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). European Urology Focus, 2019, 5, 1022-1028.	1.6	48
643	Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. European Urology Focus, 2019, 5, 592-599.	1.6	179
644	Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting. BJU International, 2020, 125, 244-252.	1.3	60
645	Exhaled-breath Testing for Prostate Cancer Based on Volatile Organic Compound Profiling Using an Electronic Nose Device (Aeonoseâ„¢): A Preliminary Report. European Urology Focus, 2020, 6, 1220-1225.	1.6	36
646	Evidence-based approach to active surveillance of prostate cancer. World Journal of Urology, 2020, 38, 555-562.	1.2	9
647	A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach. Journal of Robotic Surgery, 2020, 14, 69-74.	1.0	21
648	Declining use of radical prostatectomy and pelvic lymphadenectomy despite more robotics: National population data over 15 years. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e118-e124.	0.7	10
649	Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. World Journal of Urology, 2020, 38, 371-379.	1.2	23
650	Molecular imaging of the prostate: Comparing total sodium concentration quantification in prostate cancer and normal tissue using dedicated ^{13}C and ^{23}Na endorectal coils. Journal of Magnetic Resonance Imaging, 2020, 51, 90-97.	1.9	9
651	Less, not More, Antibiotics Please. European Urology Focus, 2020, 6, 102-103.	1.6	0
652	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. World Journal of Urology, 2020, 38, 663-671.	1.2	10
653	One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis. World Journal of Urology, 2020, 38, 949-956.	1.2	14
654	Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer. World Journal of Urology, 2020, 38, 981-991.	1.2	10

#	ARTICLE	IF	CITATIONS
655	Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score. Magnetic Resonance in Medical Sciences, 2020, 19, 40-47.	1.1	4
656	Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection. World Journal of Urology, 2020, 38, 361-369.	1.2	3
657	Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions. World Journal of Urology, 2020, 38, 517-529.	1.2	31
658	Re: Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study. World Journal of Urology, 2020, 38, 803-804.	1.2	0
659	18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. Journal of Nuclear Medicine, 2020, 61, 337-343.	2.8	11
660	Novices in MRI-targeted prostate biopsy benefit from structured reporting of MRI findings. World Journal of Urology, 2020, 38, 1729-1734.	1.2	5
661	There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. European Urology Oncology, 2020, 3, 112-118.	2.6	40
662	Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for Prostate Cancer: A Systematic Review. Journal of the American College of Radiology, 2020, 17, 486-495.	0.9	7
663	Effect of Augmented Antimicrobial Prophylaxis and Rectal Swab Culture–guided Targeted Prophylaxis on the Risk of Sepsis Following Transrectal Prostate Biopsy. European Urology Focus, 2020, 6, 95-101.	1.6	14
664	T-staging of prostate cancer: Identification of useful signs to standardize detection of posterolateral extraprostatic extension on prostate MRI. Clinical Imaging, 2020, 59, 1-7.	0.8	17
665	Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 10-20.	2.6	63
666	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
667	MRI for clinically suspected prostate cancer—the disparity between private and public sectors. Irish Journal of Medical Science, 2020, 189, 461-465.	0.8	0
668	A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. European Urology Oncology, 2020, 3, 262-269.	2.6	28
669	Magnetic resonance imaging–guided targeted prostate biopsy: Comparison between computer–software–based fusion versus cognitive fusion technique in biopsy–naïve patients. International Journal of Urology, 2020, 27, 67-71.	0.5	17
670	Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics. European Radiology, 2020, 30, 806-815.	2.3	65
671	Development of a model to predict prostate cancer at the apex (PCAP model) in patients undergoing robot-assisted radical prostatectomy. World Journal of Urology, 2020, 38, 813-819.	1.2	7
672	PI–RADS: Past, present, and future. Journal of Magnetic Resonance Imaging, 2020, 52, 33-53.	1.9	37

#	Article	IF	Citations
673	Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?. World Journal of Urology, 2020, 38, 531-545.	1.2	24
674	Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. European Urology Focus, 2020, 6, 242-248.	1.6	7
675	Financial implications of biparametric prostate MRI. Prostate Cancer and Prostatic Diseases, 2020, 23, 88-93.	2.0	41
676	Optimising the number of cores for <scp>magnetic resonance imaging</scp>â€guided targeted and systematic transperineal prostate biopsy. BJU International, 2020, 125, 260-269.	1.3	60
677	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nature Reviews Urology, 2020, 17, 41-61.	1.9	207
678	Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2020, 6, 463-478.	1.6	72
679	Detection and localisation of primary prostate cancer using ⁶⁸ gallium prostateâ€specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU International, 2020, 126, 83-90.	1.3	69
680	Impact of using 29ÂMHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. World Journal of Urology, 2020, 38, 1201-1206.	1.2	42
681	Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population. World Journal of Urology, 2020, 38, 1207-1214.	1.2	37
682	How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naÃ¯ve men with PI-RADs v2 scoreâ€‰â‰¤â€‰3?. International Journal of Clinical Oncology, 2020, 25, 175-186.	1.0	18
683	Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?. Clinical Radiology, 2020, 75, 157.e1-157.e7.	0.5	13
684	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. European Urology, 2020, 77, 311-317.	0.9	99
685	Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?. Clinical Genitourinary Cancer, 2020, 18, 50-55.	0.9	5
686	Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplanar ultrasound fusion: description of technique and early results. World Journal of Urology, 2020, 38, 1943-1949.	1.2	39
687	Hemiâ€ablative lowâ€doseâ€rate prostate brachytherapy for unilateral localised prostate cancer. BJU International, 2020, 125, 383-390.	1.3	11
688	Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine, 2020, 58, 326-339.	1.4	123
689	Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock. BJU International, 2020, 125, 340-342.	1.3	7
690	Fully automated localization of prostate peripheral zone tumors on apparent diffusion coefficient map MR images using an ensemble learning method. Journal of Magnetic Resonance Imaging, 2020, 51, 1223-1234.	1.9	10

#	Article	IF	Citations
691	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machineâ€Learning Techniques. Journal of Magnetic Resonance Imaging, 2020, 51, 1540-1553.	1.9	3
692	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. European Urology Oncology, 2020, 3, 648-656.	2.6	18
693	Likert vs PIâ€RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer. BJU International, 2020, 125, 49-55.	1.3	42
694	Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer. American Journal of Roentgenology, 2020, 214, 825-834.	1.0	2
695	Prostate MRIâ€"TRUS fusion biopsy: a review of the state of the art procedure. Abdominal Radiology, 2020, 45, 2176-2183.	1.0	16
696	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naÃ¯ve men. Scandinavian Journal of Urology, 2020, 54, 7-13.	0.6	0
697	Performing Precise Biopsy in Naive Patients With Equivocal PI-RADS, Version 2, Score 3, Lesions: An MRI-based Nomogram to Avoid Unnecessary Surgical Intervention. Clinical Genitourinary Cancer, 2020, 18, 367-377.	0.9	10
698	Performance of an Automated Workflow for Magnetic Resonance Imaging of the Prostate. Investigative Radiology, 2020, 55, 277-284.	3.5	7
699	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 2020, 125, 506-514.	1.3	32
700	Does prostate magnetic resonance imaging (MRI) reporting system affect performance of MRI in men with a clinical suspicion of prostate cancer?. BJU International, 2020, 125, 4-5.	1.3	4
702	Artificial intelligence in multiparametric prostate cancer imaging with focus on deep-learning methods. Computer Methods and Programs in Biomedicine, 2020, 189, 105316.	2.6	44
703	Targeted and Systematic Biopsy for Diagnosis and Management of Prostate Cancer. Clinical Oncology, 2020, 32, 144-148.	0.6	3
704	A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 401-409.	0.8	10
705	Reading MRI of the Prostate. , 2020, , .		3
706	A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50Âng/ml. Annals of Surgical Oncology, 2020, 27, 1284-1295.	0.7	7
707	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 145, 102860.	2.0	73
708	Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsyâ€naÃ¯ve Japanese men compared with the standard biopsy. International Journal of Urology, 2020, 27, 140-146.	0.5	11
709	Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?. European Urology Oncology, 2020, 3, 216-223.	2.6	35

#	Article	IF	Citations
710	Rectal Swabs for Detecting Multidrug Resistant Bacteria Prior to Transrectal Prostate Fusion Biopsy: A Prospective Evaluation of Risk Factor Screening and Microbiologic Findings. Urology, 2020, 136, 127-132.	0.5	4
711	Added value of diffusion–weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. BJU International, 2020, 125, 391-398.	1.3	8
712	What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. European Urology Focus, 2020, 6, 201-202.	1.6	3
713	The decision of targeted, systematic or combined biopsy in a biopsy naïve patient for the diagnosis of prostate cancer, can be made on the basis of multiparametric magnetic resonance imaging. Journal of Clinical Urology, 2020, 13, 198-204.	0.1	0
714	Developments in MRI-targeted prostate biopsy. Current Opinion in Urology, 2020, 30, 1-8.	0.9	10
716	Prostate cancer assessment using MR elastography of fresh prostatectomy specimens at 9.4 T. Magnetic Resonance in Medicine, 2020, 84, 396-404.	1.9	13
717	Multiparametric MRI and auto-fixed volume of interest-based radiomics signature for clinically significant peripheral zone prostate cancer. European Radiology, 2020, 30, 1313-1324.	2.3	40
718	Impact of peri-prostatic fat measurements using MRI on the prediction of prostate cancer with transrectal ultrasound-guided biopsy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 37.e1-37.e9.	0.8	4
719	Tracking Changes in Clinical Practice Patterns Following Prebiopsy Biparametric Prostate MRI. Academic Radiology, 2020, 27, 1255-1260.	1.3	1
720	Editorial Comment to Focal salvage low–dose–rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique. International Journal of Urology, 2020, 27, 155-156.	0.5	0
721	Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies. Urologia Internationalis, 2020, 104, 205-213.	0.6	4
722	Prostate MRI with PI-RADS v2.1: initial detection and active surveillance. Abdominal Radiology, 2020, 45, 2133-2142.	1.0	6
723	A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. British Journal of Radiology, 2020, 93, 20190760.	1.0	8
724	Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis. Urologia Internationalis, 2020, 104, 187-198.	0.6	7
725	Determination of Gleason score discrepancy for risk stratification in magnetic resonance-ultrasound fusion prostate biopsy. Acta Radiologica, 2020, 61, 1134-1142.	0.5	2
726	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. European Urology, 2020, 77, 481-490.	0.9	36
727	Making MRI available for patients with cardiac implantable electronic devices: growing need and barriers to change. European Radiology, 2020, 30, 1378-1384.	2.3	24
728	Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. International Journal of Clinical Oncology, 2020, 25, 732-740.	1.0	7

#	Article	IF	Citations
729	MRI-targeted biopsy for detecting prostate cancer: have the guidelines changed our practices and our prostate cancer detection rate?. International Urology and Nephrology, 2020, 52, 611-618.	0.6	9
730	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. European Urology, 2020, 77, 469-480.	0.9	59
731	External validation of novel magnetic resonance imaging–based models for prostate cancer prediction. BJU International, 2020, 125, 407-416.	1.3	20
732	Can high resolution micro-ultrasound replace MRI in the diagnosis of prostate cancer?. European Urology Focus, 2020, 6, 419-423.	1.6	33
733	MRI-targeted biopsy versus standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis of randomized controlled trials. Abdominal Radiology, 2020, 45, 3283-3292.	1.0	1
734	Safety and efficacy of guided biopsy. , 2020, , 431-444.		0
735	When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. Canadian Urological Association Journal, 2020, 15, 115-121.	0.3	7
736	Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis. European Urology Open Science, 2020, 20, 37-47.	0.2	27
737	Understanding the diagnosis of prostate cancer. Medical Journal of Australia, 2020, 213, 424-429.	0.8	4
738	Comparison of PI-RADS Versions 2.0 and 2.1 for MRI-based Calculation of the Prostate Volume. Academic Radiology, 2021, 28, 1548-1556.	1.3	8
739	Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study. European Urology Focus, 2021, 7, 1019-1026.	1.6	39
740	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European Urology Oncology, 2021, 4, 971-979.	2.6	56
741	Post Prostatectomy Pathologic Findings of Patients With Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative Magnetic Resonance Imaging. Urology, 2020, 146, 183-188.	0.5	2
742	Performance of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A Meta-analysis of Prospective Studies. Urology, 2020, 146, 189-195.	0.5	9
743	Re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol 2020;77:733–41. European Urology, 2020, 78, e198-e199.	0.9	0
744	Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement. PLoS ONE, 2020, 15, e0239975.	1.1	21
745	A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151045.	0.7	3
746	The "Is mpMRI Enough"or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. European Urology Focus, 2021, 7, 1027-1034.	1.6	17

#	Article	IF	Citations
747	Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective. Oncology and Therapy, 2020, 8, 197-207.	1.0	2
749	The role of multiparametric resonance and biopsy in prostate cancer detection: comparison with definitive histological report after laparoscopic/robotic radical prostatectomy. Abdominal Radiology, 2020, 45, 4178-4184.	1.0	30
750	Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesionâ‰¥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience. Clinical Genitourinary Cancer, 2021, 19, 275-279.	0.9	1
751	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	1.2	10
752	Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. Clinical Radiology, 2020, 75, 950-956.	0.5	10
753	Evaluation of Fluorescent Confocal Microscopy for Intraoperative Analysis of Prostate Biopsy Cores. European Urology Focus, 2020, 7, 1254-1259.	1.6	20
754	What to expect from a non-suspicious prostate MRI? A review. Progres En Urologie, 2020, 30, 986-999.	0.3	3
755	Detection of urinary prostate specific antigen by a lateral flow biosensor predicting repeat prostate biopsy outcome. Sensors and Actuators B: Chemical, 2020, 325, 128812.	4.0	13
756	Use of Prostate Systematic and Targeted Biopsy on the Basis of Bi-Parametric Magnetic Resonance Imaging in Biopsy-NaÃ¯ve Patients. Journal of Investigative Surgery, 2022, 35, 92-97.	0.6	1
757	In Vivo Quantification of Water Diffusion, Stiffness, and Tissue Fluidity in Benign Prostatic Hyperplasia and Prostate Cancer. Investigative Radiology, 2020, 55, 524-530.	3.5	26
758	Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey. Urologia Internationalis, 2020, 104, 731-740.	0.6	11
759	Multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging-guided biopsy in the diagnostic pathway of prostate cancer. Der Radiologe, 2020, 60, 63-69.	1.7	2
760	Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. European Urology Focus, 2021, 7, 1292-1299.	1.6	30
761	Reply to Jianhui Du, Yueguang Liu, and Weigang Yanâ€™s Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009. European Urology, 2020, 78, e65-e66.	0.9	0
762	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€"6. European Urology, 2020, 78, 310-313.	0.9	9
763	3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasoundâ€"Guided Biopsy. American Journal of Roentgenology, 2020, 215, 660-666.	1.0	12
764	Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer. Seminars in Oncology Nursing, 2020, 36, 151052.	0.7	3
765	Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy. Translational Andrology and Urology, 2020, 9, 1252-1261.	0.6	19

#	ARTICLE	IF	CITATIONS
766	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Scientific Reports, 2020, 10, 9407.	1.6	3
767	PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 431.e9-431.e13.	0.8	19
768	Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept. Diagnostics, 2020, 10, 951.	1.3	33
769	Attitudes and experience of urology trainees in interpreting prostate magnetic resonance imaging. Canadian Urological Association Journal, 2020, 15, E293-E298.	0.3	1
770	Multicenter transperineal MRI-TRUS fusion guided outpatient clinic prostate biopsies under local anesthesia. Urologic Oncology: Seminars and Original Investigations, 2020, 39, 432.e1-432.e7.	0.8	15
771	A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer and Prostatic Diseases, 2021, 24, 596-611.	2.0	58
772	EDITORIAL COMMENT. Urology, 2020, 146, 195.	0.5	0
773	EDITORIAL COMMENT. Urology, 2020, 146, 187-188.	0.5	0
774	Identification and Validation of Leucine-rich Î±-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science, 2020, 21, 51-60.	0.2	13
775	The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 433.e1-433.e7.	0.8	10
776	MRI guided procedure planning and 3D simulation for partial gland cryoablation of the prostate: a pilot study. 3D Printing in Medicine, 2020, 6, 33.	1.7	3
777	Value of systematic sampling in an mp-MRI targeted prostate biopsy strategy. Translational Andrology and Urology, 2020, 9, 1501-1509.	0.6	8
778	Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway. Abdominal Radiology, 2020, 45, 4166-4177.	1.0	10
779	PSA-based machine learning model improves prostate cancer risk stratification in a screening population. World Journal of Urology, 2021, 39, 1897-1902.	1.2	27
780	Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Canadian Urological Association Journal, 2020, 15, E11-E16.	0.3	48
781	Evaluating the efficacy of a low-cost cognitive MRI-targeted prostate biopsy protocol: is there still a role for lower volume centers in the Prostate Imaging Reporting and Data System (PI-RADS) version 2 era?. International Urology and Nephrology, 2020, 52, 2043-2050.	0.6	2
782	Epidemiology, Staging and Management of Prostate Cancer. Medical Sciences (Basel, Switzerland), 2020, 8, 28.	1.3	55
783	Focal therapy, time to join the multi-disciplinary team discussion?. Translational Andrology and Urology, 2020, 9, 1526-1534.	0.6	4

#	Article	IF	Citations
784	Quality Comparison of 3 Tesla multiparametric MRI of the prostate using a flexible surface receiver coil versus conventional surface coil plus endorectal coil setup. Abdominal Radiology, 2020, 45, 4260-4270.	1.0	10
785	Robotic-assisted transrectal MRI-guided biopsy. Technical feasibility and role in the current diagnosis of prostate cancer: an initial single-center experience. Abdominal Radiology, 2020, 45, 4150-4159.	1.0	13
786	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. Nature Reviews Urology, 2020, 17, 499-512.	1.9	15
787	Rethinking prostate cancer screening: could MRI be an alternative screening test?. Nature Reviews Urology, 2020, 17, 526-539.	1.9	19
788	Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model. International Journal of Urology, 2020, 27, 866-873.	0.5	2
789	Magnetic Resonance Imaging Improves Selection for Active Surveillance and Can Extend the Interval Between Biopsies. European Urology, 2020, 78, 518-519.	0.9	2
790	Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?. Prostate Cancer and Prostatic Diseases, 2020, 23, 589-595.	2.0	8
791	A radiomics machine learning-based redefining score robustly identifies clinically significant prostate cancer in equivocal PI-RADS score 3 lesions. Abdominal Radiology, 2020, 45, 4223-4234.	1.0	30
792	Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. Urology, 2020, 144, 164-170.	0.5	4
793	Can transrectal prostate ultrasound compete with multiparametric MRI in the detection of clinically significant prostate cancer?. Translational Andrology and Urology, 2020, 9, 1492-1500.	0.6	6
794	Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. Translational Andrology and Urology, 2020, 9, 1415-1427.	0.6	9
795	Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer. Diagnostics, 2020, 10, 578.	1.3	13
796	Resonancia magnética de próstata: guía práctica de interpretación e informe según PI-RADS versión 2.1. Radiologia, 2020, 62, 437-451.	0.3	0
797	Negative first follow‐up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment. BJU International, 2021, 128, 72-78.	1.3	3
798	Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis. BMJ Open, 2020, 10, e039735.	0.8	0
799	Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy. World Journal of Urology, 2021, 39, 2453-2461.	1.2	8
800	Real life data of MRI-targeted biopsy – experience from a single nonacademic centre using cognitive fusion and 1.5 tesla scanning. Scandinavian Journal of Urology, 2020, 54, 387-392.	0.6	1
801	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. Scientific Reports, 2020, 10, 17177.	1.6	4

#	ARTICLE	IF	CITATIONS
802	Deep Radiomic Analysis to Predict Gleason Score in Prostate Cancer. IEEE Access, 2020, 8, 167767-167778.	2.6	22
803	PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. Diagnostics, 2020, 10, 806.	1.3	9
804	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. European Urology Focus, 2021, 7, 1268-1273.	1.6	6
805	Current status of PSMA PET imaging in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 7-11.	0.7	3
806	Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. American Journal of Roentgenology, 2020, 215, 1098-1103.	1.0	17
807	Heart transplantation in patients with localized prostate cancerâ€"Are we denying a lifeâ€saving therapy due to an indolent tumor?. Clinical Transplantation, 2020, 34, e14080.	0.8	2
808	Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score. Journal of Vascular and Interventional Radiology, 2020, 31, 1619-1626.	0.2	1
809	Advances in the diagnostic options for prostate cancer. Postgraduate Medicine, 2020, 132, 52-62.	0.9	1
811	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. European Urology Oncology, 2022, 5, 187-194.	2.6	20
812	A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. BMC Urology, 2020, 20, 138.	0.6	29
813	Clinical utility of combined T2-weighted imaging and T2-mapping in the detection of prostate cancer: a multi-observer study. Quantitative Imaging in Medicine and Surgery, 2020, 10, 1811-1822.	1.1	7
814	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. Scandinavian Journal of Urology, 2020, 54, 382-386.	0.6	2
815	Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning. Current Urology Reports, 2020, 21, 38.	1.0	10
816	Multiparametric magnetic resonance imaging of the prostate at 1.5-Tesla without endorectal coil: Can it be used to detect clinically significant prostate cancer in men with medical devices that are contraindicated at 3-Tesla?. Canadian Urological Association Journal, 2020, 15, E180-E183.	0.3	0
817	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. World Journal of Urology, 2020, 39, 1879-1887.	1.2	15
818	Clinical impact of PET imaging in prostate cancer management. Current Opinion in Urology, 2020, Publish Ahead of Print, 649-653.	0.9	1
819	The role of radiomics in prostate cancer radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 900-912.	1.0	24
820	Diagnostic accuracy of bi-parametric magnetic resonance imaging in suspected prostate cancer: Correlation of scan results with biopsy findings in a series of 266 patients. Journal of Clinical Urology, 2021, 14, 437-446.	0.1	0

#	ARTICLE	IF	CITATIONS
821	Quantifying the Effect of Location Matching on Accuracy of Multiparametric Magnetic Resonance Imaging Prior to Prostate Biopsy—A Multicentre Study. European Urology Open Science, 2020, 20, 28-36.	0.2	1
822	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US—guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. Radiology Imaging Cancer, 2020, 2, e190078.	0.7	6
823	How radiology units in the UK can obtain the required resources to deliver a sustainable service for prostate cancer patients. British Journal of Health Care Management, 2020, 26, 1-3.	0.1	0
824	Transperineal Versus Transrectal Targeted Biopsy With Use of Electromagnetically-tracked MR/US Fusion Guidance Platform for the Detection of Clinically Significant Prostate Cancer. Urology, 2020, 146, 278-286.	0.5	20
825	Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis. FASEB Journal, 2020, 34, 14150-14159.	0.2	7
827	Histology results of systematic prostate biopsies by in-bore magnetic resonance imaging vs. transrectal ultrasound. Canadian Urological Association Journal, 2020, 15, E244-E247.	0.3	3
828	Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports, 2020, 8, 1.	0.4	2
829	How Fast Can We Go: Abbreviated Prostate MR Protocols. Current Urology Reports, 2020, 21, 59.	1.0	5
830	Multiparametric Ultrasound for Targeting Prostate Cancer: Combining ARFI, SWEI, QUS and B-Mode. Ultrasound in Medicine and Biology, 2020, 46, 3426-3439.	0.7	11
831	Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. Abdominal Radiology, 2020, 45, 4012-4022.	1.0	18
832	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. European Urology, 2020, 78, 163-170.	0.9	60
833	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. European Radiology, 2020, 30, 5404-5416.	2.3	185
834	Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men. Translational Andrology and Urology, 2020, 9, 601-608.	0.6	12
835	Multiple instance learning combined with label invariant synthetic data for guiding systematic prostate biopsy: a feasibility study. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 1023-1031.	1.7	8
836	Improving detection of prostate cancer foci via information fusion of MRI and temporal enhanced ultrasound. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 1215-1223.	1.7	20
837	Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. European Urology, 2020, 78, 304-306.	0.9	44
838	New Screening Test Improves Detection of Prostate Cancer Using Circulating Tumor Cells and Prostate-Specific Markers. Frontiers in Oncology, 2020, 10, 582.	1.3	38
839	Personalized strategies in population screening for prostate cancer. International Journal of Cancer, 2020, 147, 2977-2987.	2.3	19

#	ARTICLE	IF	CITATIONS
840	Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system. Scientific Reports, 2020, 10, 7722.	1.6	39
841	Establishing a novel prediction model for improving the positive rate of prostate biopsy. Translational Andrology and Urology, 2020, 9, 574-582.	0.6	5
842	Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL. Prostate Cancer and Prostatic Diseases, 2020, 23, 607-614.	2.0	97
843	Contrast-enhanced ultrasound evaluation of the prostate before transrectal ultrasound-guided biopsy can improve diagnostic sensitivity. Medicine (United States), 2020, 99, e19946.	0.4	11
844	Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. European Urology, 2020, 78, 469-470.	0.9	2
845	Radiomics: Quantitative Radiology transforming Oncology Care. British Journal of Radiology, 2020, 93, 20200333.	1.0	1
846	Can Biparametric Prostate Magnetic Resonance Imaging Fulfill its PROMIS?. European Urology, 2020, 78, 512-514.	0.9	6
847	MRI in the Management of Prostate Cancer. Seminars in Ultrasound, CT and MRI, 2020, 41, 366-372.	0.7	7
848	External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 847.e9-847.e16.	0.8	11
849	Repeatability of Quantitative Imaging Features in Prostate Magnetic Resonance Imaging. Frontiers in Oncology, 2020, 10, 551.	1.3	9
850	Multiparametric MRI–ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic–assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy. BJU International, 2020, 126, 568-576.	1.3	17
851	Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient – a systematic review and meta analysis. BMC Cancer, 2020, 20, 482.	1.1	17
852	Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer. Current Opinion in Oncology, 2020, 32, 223-231.	1.1	7
853	Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 846.e9-846.e16.	0.8	20
854	Registration of presurgical MRI and histopathology images from radical prostatectomy via RAPSODI. Medical Physics, 2020, 47, 4177-4188.	1.6	28
855	The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?. Clinical Genitourinary Cancer, 2020, 18, e698-e704.	0.9	24
856	Advances in Prostate Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 407-414.	0.6	3
857	Oncological control following partial gland ablation for intermediate-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 671-677.	0.8	8

#	ARTICLE	IF	CITATIONS
858	Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. BMJ Open, 2020, 10, e034611.	0.8	7
859	Prostate–specific membrane antigen theranostics in advanced prostate cancer: an evolving option. BJU International, 2020, 126, 525-535.	1.3	14
860	Prostate MRI Essentials. , 2020, , .		1
861	Computed Tomography-Aortography Versus Color-Duplex Ultrasound for Surveillance of Endovascular Abdominal Aortic Aneurysm Repair. Circulation: Cardiovascular Imaging, 2020, 13, e009886.	1.3	16
862	Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. European Radiology, 2020, 30, 6274-6284.	2.3	22
863	Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. European Urology, 2020, 78, 307-309.	0.9	7
864	Automated Classification of Significant Prostate Cancer on MRI: A Systematic Review on the Performance of Machine Learning Applications. Cancers, 2020, 12, 1606.	1.7	54
865	PI-RADS: what is new and how to use it. Abdominal Radiology, 2020, 45, 3951-3960.	1.0	14
866	Development of a multivariable risk model integrating urinary cell DNA methylation and cell–free RNA data for the detection of significant prostate cancer. Prostate, 2020, 80, 547-558.	1.2	17
868	Diagnostic Value of Transrectal Shear Wave Elastography for Prostate Cancer Detection in Peripheral Zone: Comparison with Magnetic Resonance Imaging. Journal of Endourology, 2020, 34, 558-566.	1.1	12
869	Is it worth carrying out ultrasound–magnetic resonance imaging fusion targeted biopsy on Prostate Imaging Reporting and Data System score≥3 prostate lesions?. International Journal of Urology, 2020, 27, 431-438.	0.5	1
870	MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2. Abdominal Radiology, 2020, 45, 2235-2243.	1.0	5
871	Arguments against using an abbreviated or biparametric prostate MRI protocol. Abdominal Radiology, 2020, 45, 3982-3989.	1.0	9
872	Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice. European Radiology, 2020, 30, 4039-4049.	2.3	49
873	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	13.9	515
874	Comparison of complications after transrectal and transperineal prostate biopsy: a national population–based study. BJU International, 2020, 126, 97-103.	1.3	77
875	Free-breathing dynamic contrast-enhanced magnetic resonance of interstitial lung fibrosis. Magnetic Resonance Imaging, 2020, 69, 16-21.	1.0	9
876	EDITORIAL COMMENT. Urology, 2020, 137, 131-132.	0.5	0

#	ARTICLE	IF	CITATIONS
877	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	1.1	27
878	Current techniques of prostate biopsy: an update from past to present. Translational Andrology and Urology, 2020, 9, 1510-1517.	0.6	6
879	Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. European Radiology, 2020, 30, 6042-6051.	2.3	20
880	Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI. European Radiology, 2020, 30, 6582-6592.	2.3	61
881	Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer. Frontiers in Oncology, 2020, 10, 888.	1.3	33
882	Nomograms using a small panel of genes for predicting the diagnosis and aggressiveness of prostate cancer. Cellular Oncology (Dordrecht), 2020, 43, 1215-1218.	2.1	1
883	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134.	0.6	485
884	The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy. Biomedicines, 2020, 8, 173.	1.4	6
885	Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters. Cancers, 2020, 12, 1767.	1.7	72
886	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208–16. European Urology, 2020, 78, e131-e132.	0.9	1
887	A Comparison of Cancer Detection Rates Between Template Systematic Biopsies Obtained Using Magnetic Resonance Imaging-Ultrasound Fusion Machine and Freehand Transrectal Ultrasound-Guided Systematic Biopsies. Journal of Endourology, 2020, 34, 1095-1098.	1.1	3
888	The current role of PET/CT in urological malignances. Clinical and Translational Imaging, 2020, 8, 313-347.	1.1	2
889	What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?. Prostate International, 2020, 8, 112-115.	1.2	13
890	Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography–fusion Biopsy. European Urology Focus, 2021, 7, 1300-1307.	1.6	44
891	Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20Âng/ml before the initial biopsy. Scientific Reports, 2020, 10, 10963.	1.6	21
893	Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium. Pathology and Oncology Research, 2020, 26, 2605-2612.	0.9	6
894	68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. Journal of Nuclear Medicine, 2020, 61, 1314-1319.	2.8	47
895	Effect of Echo Times on Prostate Cancer Detection on T2-Weighted Images. Academic Radiology, 2020, 27, 1555-1563.	1.3	2

#	Article	IF	Citations
896	Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy. BJU International, 2020, 126, 6-11.	1.3	12
897	Stimulated-echo diffusion-weighted imaging with moderate b values for the detection of prostate cancer. European Radiology, 2020, 30, 3236-3244.	2.3	6
898	Infectious complications of prostate biopsy: winning battles but not war. World Journal of Urology, 2020, 38, 2743-2753.	1.2	25
899	Prostatic-specific antigen density behavior according to multiparametric magnetic resonance imaging result. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 410-417.	0.8	10
900	External validation of the Martini nomogram for prediction of side-specific extraprostatic extension of prostate cancer in patients undergoing robot-assisted radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 372-378.	0.8	14
901	Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy. Ultrasound in Medicine and Biology, 2020, 46, 1197-1207.	0.7	9
902	All change in the prostate cancer diagnostic pathway. Nature Reviews Clinical Oncology, 2020, 17, 372-381.	12.5	64
903	Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence. Scientific Reports, 2020, 10, 3121.	1.6	17
904	Prostate Cancer Imaging Research: The Emerging Importance of Patient-Centered Outcomes. Journal of the American College of Radiology, 2020, 17, 484-485.	0.9	0
905	Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 636.e7-636.e12.	0.8	7
906	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU International, 2020, 125, 861-866.	1.3	19
907	Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. Prostate Cancer and Prostatic Diseases, 2020, 23, 232-243.	2.0	20
908	Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1. European Radiology, 2020, 30, 3383-3392.	2.3	58
909	The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone. European Journal of Radiology, 2020, 125, 108865.	1.2	8
910	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 148, 102861.	2.0	29
911	Can multiparametric magnetic resonance of the prostate avoid biopsies in patients with elevated PSA and surgical indication for benign prostatic enlargement?. Abdominal Radiology, 2020, 45, 3278-3282.	1.0	3
912	A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRIâ€"US fusion biopsy for prostate-cancer detection. Prostate Cancer and Prostatic Diseases, 2020, 23, 449-456.	2.0	17
913	To the Horizon: The Brink of an AI Revolution in Prostate Cancer?. American Journal of Medicine, 2020, 133, e65-e66.	0.6	0

#	Article	IF	Citations
914	Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross‐sectional study of the additive diagnostic value of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU International, 2020, 125, 515-524.	1.3	51
915	Prostate cancer in kidney transplant recipients â€" a nationwide register study. BJU International, 2020, 125, 679-685.	1.3	19
916	68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1843-1851.	3.3	67
917	Re: can prostate cancer be NICE?. Clinical Radiology, 2020, 75, 232-233.	0.5	1
918	Targeted and Systematic Biopsy for the Diagnosis and Management of Prostate Cancer â€" A Case for Lesion Targeted-Only Biopsies. Clinical Oncology, 2020, 32, 136-143.	0.6	1
919	Targeted and systematic cognitive freehand‐guided transperineal biopsy: is there still a role for systematic biopsy?. BJU International, 2020, 126, 280-285.	1.3	15
920	Five-year Outcomes of Magnetic Resonance Imagingâ€"based Active Surveillance for Prostate Cancer: A Large Cohort Study. European Urology, 2020, 78, 443-451.	0.9	94
921	Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009. European Urology, 2020, 78, e64.	0.9	0
922	What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. American Journal of Roentgenology, 2020, 214, 1211-1219.	1.0	4
923	Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer. Radiologia Medica, 2020, 125, 827-837.	4.7	10
924	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Canadian Urological Association Journal, 2020, 14, E453-E457.	0.3	11
925	Education of prostate MR imaging: commentary. Abdominal Radiology, 2020, 45, 4112-4113.	1.0	0
926	Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer. Expert Review of Medical Devices, 2020, 17, 435-442.	1.4	9
927	Review of the accuracy of multiâ€parametric MRI prostate in detecting prostate cancer within a local reporting service. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 379-384.	0.9	8
928	The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008â€"2019. BJU International, 2020, 126, 133-141.	1.3	40
929	Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features. BJU International, 2020, 126, 237-239.	1.3	5
930	Accuracy of ADC ratio in discriminating true and false positives in multiparametric prostatic MRI. European Journal of Radiology, 2020, 128, 109024.	1.2	4
931	Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 734.e19-734.e25.	0.8	32

#	Article	IF	Citations
932	MRIâ€targeted prostate biopsy: key considerations for pathologists. Histopathology, 2020, 77, 18-25.	1.6	3
933	microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer, 2020, 19, 63.	7.9	28
934	Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. European Urology Focus, 2021, 7, 764-771.	1.6	32
935	Quantifying the effect of biopsy lateral decubitus patient positioning compared to supine prostate MRI scanning on prostate translocation and distortion. Canadian Urological Association Journal, 2020, 14, E445-E452.	0.3	1
936	Round table: arguments in supporting abbreviated or biparametric MRI of the prostate protocol. Abdominal Radiology, 2020, 45, 3974-3981.	1.0	22
937	Manual prostate cancer segmentation in MRI: interreader agreement and volumetric correlation with transperineal template core needle biopsy. European Radiology, 2020, 30, 4806-4815.	2.3	15
938	Independent external validation of nomogram to predict extracapsular extension in patients with prostate cancer. European Radiology, 2020, 30, 5004-5010.	2.3	9
939	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. Contemporary Clinical Trials, 2020, 93, 105999.	0.8	20
940	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. European Urology, 2020, 78, 503-511.	0.9	27
941	Effects of â€œreal lifeâ€•prostate MRI inter-observer variability on total needle samples and indication for biopsy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e13-793.e18.	0.8	9
942	Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI. Prostate Cancer, 2020, 2020, 1-6.	0.4	4
943	Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging. BioMed Research International, 2020, 2020, 1-7.	0.9	0
944	Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol. Methods and Protocols, 2020, 3, 26.	0.9	4
945	Early Diagnosis of Prostate Cancer from the Perspective of Chinese Physicians. Journal of Cancer, 2020, 11, 3264-3273.	1.2	9
946	Performance of PI-RADS v2 assessment categories assigned prior to MR-US fusion biopsy in a new fusion biopsy program. Clinical Imaging, 2020, 64, 29-34.	0.8	3
947	Preoperative Prediction of Ki-67 Status in Breast Cancer with Multiparametric MRI Using Transfer Learning. Academic Radiology, 2021, 28, e44-e53.	1.3	28
948	Review article: MRI-targeted biopsies for prostate cancer diagnosis and management. World Journal of Urology, 2021, 39, 57-63.	1.2	11
949	Quality of Prostate MRI: Is the PI-RADS Standard Sufficient?. Academic Radiology, 2021, 28, 199-207.	1.3	44

#	ARTICLE	IF	CITATIONS
950	Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy. Tumori, 2021, 107, 55-63.	0.6	8
951	Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 88-95.	2.0	1
952	Impact of mandated prospectively reported apparent diffusion coefficient values on the rates of positivity for clinically significant prostate cancer by PI-RADS score. Acta Radiologica, 2021, 62, 139-144.	0.5	1
953	Quantitative Prostate <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2021, 53, 1632-1645.	1.9	35
954	Comparing confirmatory biopsy outcomes between MRIâ€targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU International, 2021, 127, 340-348.	1.3	12
955	Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. Journal of Magnetic Resonance Imaging, 2021, 53, 13-22.	1.9	16
956	Making a case â€œagainstâ€ focal therapy for intermediate-risk prostate cancer. World Journal of Urology, 2021, 39, 719-728.	1.2	7
957	Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2021, 19, 3-11.e1.	0.9	4
958	Prognostic performance of magnetic resonance imaging-guided biopsy in defining prostate cancer anterior lesions. World Journal of Urology, 2021, 39, 1473-1479.	1.2	6
959	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World Journal of Urology, 2021, 39, 1115-1119.	1.2	23
960	Role of multiparametric prostate MRI in the management of prostate cancer. World Journal of Urology, 2021, 39, 651-659.	1.2	24
961	Comparison of Biparametric and Multiparametric <scp>MRI</scp> for Clinically Significant Prostate Cancer Detection With <scp>PIâ€RADS</scp> Version 2.1. Journal of Magnetic Resonance Imaging, 2021, 53, 283-291.	1.9	69
962	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. European Urology Focus, 2021, 7, 102-110.	1.6	28
963	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. PharmacoEconomics - Open, 2021, 5, 77-88.	0.9	3
964	Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?. World Journal of Urology, 2021, 39, 1463-1471.	1.2	7
965	The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy. World Journal of Urology, 2021, 39, 1889-1895.	1.2	14
966	Magnetic resonance imaging-guided prostate biopsyâ€"A review of literature. Asian Journal of Urology, 2021, 8, 105-116.	0.5	7
967	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 354-359.	2.8	16

#	ARTICLE	IF	CITATIONS
968	Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment. European Radiology, 2021, 31, 302-313.	2.3	24
969	Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy. American Journal of Roentgenology, 2021, 216, 683-690.	1.0	19
970	68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 483-492.	3.3	47
971	How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1. Acta Radiologica, 2021, 62, 839-847.	0.5	18
972	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naÃ¯ve patients: follow-up of a PRECISION trial-like retrospective cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 406-413.	2.0	9
973	Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?â€"A Systematic Diagnostic Test Accuracy Review. European Urology Oncology, 2021, 4, 426-436.	2.6	19
974	Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis. British Journal of Radiology, 2021, 94, 20191050.	1.0	16
975	PI-RADS Version 2.1: A Critical Review, From the <i>AJR</i> Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology, 2021, 216, 20-32.	1.0	36
976	Optimized <scp>MRI</scp> Assessment for Clinically Significant Prostate Cancer: A <scp>STARD</scp>â€Compliant Twoâ€Center Study. Journal of Magnetic Resonance Imaging, 2021, 53, 1210-1219.	1.9	5
977	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naÃ¯ve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. European Urology, 2021, 79, 20-29.	0.9	13
978	MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. European Radiology, 2021, 31, 2696-2705.	2.3	40
979	Automatic segmentation of prostate magnetic resonance imaging using generative adversarial networks. Clinical Imaging, 2021, 70, 1-9.	0.8	11
980	Recent Advances and Current Role of Transperineal Prostate Biopsy. Urologic Clinics of North America, 2021, 48, 25-33.	0.8	23
981	Editorial Comment to Threeâ€dimensional analysis of systematic biopsyâ€derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonanceâ€ultrasound image fusion systems. International Journal of Urology, 2021, 28, 129-130.	0.5	0
982	Target Biopsy and Core Number in Prostate Biopsy. Ultrasound in Medicine and Biology, 2021, 47, 848-849.	0.7	0
983	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)â€"do we still need contrast media?. European Radiology, 2021, 31, 3754-3764.	2.3	10
984	Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVIDâ€19) pandemic: an international accelerated consensus statement. BJU International, 2021, 127, 729-741.	1.3	9
985	Prospect and adversity of artificial intelligence in urology. , 2021, , 309-337.		1

#	ARTICLE	IF	CITATIONS
986	Salvage Therapy for Prostate Cancer. , 2021, , .		0
987	AUTHOR REPLY. Urology, 2021, 147, 211-212.	0.5	0
988	Comparison of Prostate MRI Lesion Segmentation Agreement Between Multiple Radiologists and a Fully Automatic Deep Learning System. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2021, 193, 559-573.	0.7	18
989	A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. European Radiology, 2021, 31, 4386-4389.	2.3	17
990	Chest CT in the Emergency Department for Diagnosis of COVID-19 Pneumonia: Dutch Experience. Radiology, 2021, 298, E98-E106.	3.6	47
991	Current Trends in Artificial Intelligence Application for Endourology and Robotic Surgery. Urologic Clinics of North America, 2021, 48, 151-160.	0.8	19
992	A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. EBioMedicine, 2021, 63, 103163.	2.7	32
993	ProsRegNet: A deep learning framework for registration of MRI and histopathology images of the prostate. Medical Image Analysis, 2021, 68, 101919.	7.0	46
994	Is a targeted biopsy-only approach for prostate cancer diagnosis ready for the prime time?. Nature Reviews Urology, 2021, 18, 75-76.	1.9	1
995	Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 366.e19-366.e28.	0.8	1
996	Ultrasonic Interfacial Engineering of Red Phosphorous–Metal for Eradicating MRSA Infection Effectively. Advanced Materials, 2021, 33, e2006047.	11.1	93
997	Following Up on an Improperly Drawn Screening Test: The PSA Dilemma. American Journal of Medicine, 2021, 134, e145-e146.	0.6	0
998	Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer. Prostate International, 2021, 9, 107-112.	1.2	21
999	A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy. BJUI Compass, 2021, 2, 126-133.	0.7	17
1000	The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region. BJUI Compass, 2021, 2, 178-187.	0.7	3
1001	Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer. BJU International, 2021, 127, 6-12.	1.3	5
1002	Comparison of TRUS and combined MRI-targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology. International Journal of Clinical Practice, 2021, 75, e13797.	0.8	7
1003	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304â€"6. European Urology, 2021, 79, e14-e15.	0.9	0

#	Article	IF	Citations
1004	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24, 398-405.	2.0	2
1005	The role of immune PSA complex (iXip) in the prediction of prostate cancer. Biomarkers, 2021, 26, 26-30.	0.9	2
1006	Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. Urology, 2021, 147, 205-212.	0.5	23
1007	Improved Characterization of Diffusion in Normal and Cancerous Prostate Tissue Through Optimization of Multicompartmental Signal Models. Journal of Magnetic Resonance Imaging, 2021, 53, 628-639.	1.9	17
1008	Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. Prostate Cancer and Prostatic Diseases, 2021, 24, 169-176.	2.0	24
1009	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). Journal of the National Cancer Institute, 2021, 113, 632-640.	3.0	9
1010	Commentary on â€œMRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosisâ€. American Journal of Roentgenology, 2021, 216, 584-584.	1.0	0
1011	Acceptance, Indications and Chances of Focal Therapy in Localized Prostate Cancer: A Real-World Perspective of Urologists in Germany. Journal of Endourology, 2021, 35, 444-450.	1.1	2
1012	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). European Radiology, 2021, 31, 716-728.	2.3	31
1013	Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naÃ¯ve Patients and Patients with Prior Biopsies. European Urology Focus, 2021, 7, 39-46.	1.6	31
1014	Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. European Urology Focus, 2021, 7, 86-94.	1.6	28
1015	The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. European Urology Focus, 2021, 7, 325-331.	1.6	34
1016	Role of MRI for the detection of prostate cancer. World Journal of Urology, 2021, 39, 637-649.	1.2	6
1017	Modern Approach in Radiological Diagnosis of Prostate Cancer (Systematic Review of International) Tj ETQq1 1 0.784314 rgBT /Overl 373-384.	0.1	0
1018	Developing a coordinate-based strategy to support cognitive targeted prostate biopsies and correlative spatial-histopathological outcome analysis. Asian Journal of Andrology, 2021, 23, 231.	0.8	0
1019	Effect of lesion diameter and prostate volume on prostate cancer detection rate of magnetic resonance imaging: Transrectal-ultrasonography-guided fusion biopsies using cognitive targeting. Turkish Journal of Urology, 2021, 47, 22-29.	1.3	5
1020	Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer. World Journal of Men?s Health, 2021, 39, 38.	1.7	2
1021	The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Scientific Reports, 2021, 11, 1801.	1.6	4

#	ARTICLE	IF	CITATIONS
1022	Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An 'Evidence-Based Practice' review of the literature. Abdominal Radiology, 2021, 46, 2770-2778.	1.0	11
1023	Innovating Metabolic Biomarkers for Hyperpolarized NMR. , 2021, , 151-179.		0
1024	Genetic predisposition to prostate cancer: an update. Familial Cancer, 2022, 21, 101-114.	0.9	18
1025	MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review. Translational Andrology and Urology, 2021, 10, 3117-3129.	0.6	6
1026	Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy NaÃ¯ve Patients?. Frontiers in Oncology, 2020, 10, 603384.	1.3	8
1027	Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detection. Scientific Reports, 2021, 11, 2525.	1.6	7
1028	Impact of different phased-array coils on the quality of prostate magnetic resonance images. European Journal of Radiology Open, 2021, 8, 100327.	0.7	3
1030	Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature. Urologia Internationalis, 2021, 105, 520-524.	0.6	1
1031	PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer. European Urology Oncology, 2022, 5, 321-327.	2.6	14
1032	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. Cancer Biology and Medicine, 2021, 18, 604-615.	1.4	4
1033	The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer. Molecular and Clinical Oncology, 2021, 14, 56.	0.4	4
1034	The Management of Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 3-23.	0.0	0
1035	Probability of Prostate Cancer Diagnosis following Negative Systematic and Targeted MRI: Transrectal Ultrasound Fusion Biopsy: A Real-Life Observational Study. Urologia Internationalis, 2021, 105, 446-452.	0.6	0
1036	Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy. Medicina (Lithuania), 2021, 57, 57.	0.8	9
1037	Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1. Clinical Hemorheology and Microcirculation, 2021, 76, 503-511.	0.9	3
1038	Feasibility of Novel Three-Dimensional Magnetic Resonance Fingerprinting of the Prostate Gland: Phantom and Clinical Studies. Korean Journal of Radiology, 2021, 22, 1332.	1.5	11
1039	Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance. Korean Journal of Radiology, 2021, 22, 559.	1.5	3
1040	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World Journal of Urology, 2021, 39, 3259-3264.	1.2	5

#	Article	IF	Citations
1041	Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach. Korean Journal of Radiology, 2021, 22, 1087.	1.5	7
1042	The accuracy of prostate cancer diagnosis in biopsy-naive patients using combined magnetic resonance imaging and transrectal ultrasound fusion-targeted prostate biopsy. Translational Andrology and Urology, 2021, 10, 2982-2989.	0.6	3
1043	Characterisation of Prostate Lesions Using Transrectal Shear Wave Elastography (SWE) Ultrasound Imaging: A Systematic Review. Cancers, 2021, 13, 122.	1.7	17
1044	Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study. Investigative and Clinical Urology, 2021, 62, 416.	1.0	3
1045	Efficacy of 68Ga-PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	1.1	3
1046	Synthesizing VERDICT Maps from Standard DWI Data Using GANs. Lecture Notes in Computer Science, 2021, , 58-67.	1.0	1
1047	Weakly Supervised Registration ofÂProstate MRI and Histopathology Images. Lecture Notes in Computer Science, 2021, , 98-107.	1.0	7
1048	A review on the role of tissue-based molecular biomarkers for active surveillance. World Journal of Urology, 2022, 40, 27-34.	1.2	5
1049	The role of surgery in high risk and advanced prostate cancer: A narrative review. Turkish Journal of Urology, 2021, 47, S56-S64.	1.3	1
1050	Magnetic Resonance Imaging Detection of Glucose-Stimulated Zinc Secretion in the Enlarged Dog Prostate as a Potential Method for Differentiating Prostate Cancer From Benign Prostatic Hyperplasia. Investigative Radiology, 2021, 56, 450-457.	3.5	6
1051	Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3315-3324.	3.3	47
1052	Comparison of initial and second opinion reads of multiparametric magnetic resonance imaging of the prostate for transperineal template-guided biopsies with MRI-Ultrasound fusion. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e1-781.e7.	0.8	4
1053	Identification of denatured and normal biological tissues based on compressed sensing and refined composite multi-scale fuzzy entropy during high intensity focused ultrasound treatment*. Chinese Physics B, 2021, 30, 028704.	0.7	6
1054	Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?. Frontiers in Oncology, 2021, 11, 643051.	1.3	4
1055	The GÃ—TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scandinavian Journal of Urology, 2021, 55, 116-124.	0.6	27
1057	Patient- and tumor-level risk factors for MRI-invisible prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 794-801.	2.0	12
1058	MR-Guided Adaptive Radiotherapy for Bladder Cancer. Frontiers in Oncology, 2021, 11, 637591.	1.3	25
1059	Transperineal prostate biopsy: The modern gold standard to prostate cancer diagnosis. Turkish Journal of Urology, 2021, 47, S19-S26.	1.3	13

#	ARTICLE	IF	CITATIONS
1060	How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?. European Urology Oncology, 2022, 5, 135-137.	2.6	11
1061	Prostate cancer detection with magnetic resonance imaging (MRI)/cognitive fusion biopsy: Comparing standard and targeted prostate biopsy with final prostatectomy histology. Canadian Urological Association Journal, 2021, 15, E483-E487.	0.3	4
1062	Advances in the selection of patients with prostate cancer for active surveillance. Nature Reviews Urology, 2021, 18, 197-208.	1.9	21
1063	Role of primary care in the management of prostate cancer. The Prescriber, 2021, 32, 11-17.	0.1	2
1064	Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy. European Urology Focus, 2022, 8, 121-127.	1.6	13
1065	Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre. Prostate Cancer and Prostatic Diseases, 2021, 24, 549-557.	2.0	1
1066	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. BMC Urology, 2021, 21, 18.	0.6	3
1067	A Multi-Center, Multi-Vendor Study to Evaluate the Generalizability of a Radiomics Model for Classifying Prostate cancer: High Grade vs. Low Grade. Diagnostics, 2021, 11, 369.	1.3	26
1068	Radiomics and Prostate MRI: Current Role and Future Applications. Journal of Imaging, 2021, 7, 34.	1.7	32
1069	Study protocol for a single-centre non-inferior randomised controlled trial on a novel three-dimensional matrix positioning-based cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy for the detection rate of clinically significant prostate cancer in men without a prior biopsy. BMJ Open, 2021, 11, e041427.	0.8	0
1070	Assessment of magnetic resonance imaging (MRI)-fusion prostate biopsy with concurrent standard systematic ultrasound-guided biopsy among men requiring repeat biopsy. Canadian Urological Association Journal, 2021, 15, E495-E500.	0.3	0
1071	Ablative options for prostate cancer management. Turkish Journal of Urology, 2021, 47, S49-S55.	1.3	2
1072	Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. Cancers, 2021, 13, 552.	1.7	21
1073	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
1074	Role of pre-biopsy multiparametric MRI in prostate cancer diagnosis: Evidence from the literature. Turkish Journal of Urology, 2021, 47, S65-S70.	1.3	2
1075	Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. Current Opinion in Oncology, 2021, 33, 244-251.	1.1	4
1076	Deep Learning Regression for Prostate Cancer Detection and Grading in Bi-Parametric MRI. IEEE Transactions on Biomedical Engineering, 2021, 68, 374-383.	2.5	77
1077	One-year experience of government-funded magnetic resonance imaging prior to prostate biopsy: A case for omitting biopsy in men with a negative magnetic resonance imaging. Journal of Clinical Urology, 0, , 205141582110043.	0.1	0

#	ARTICLE	IF	CITATIONS
1079	Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology. European Urology Oncology, 2022, 5, 314-320.	2.6	15
1080	Comparative Effectiveness of Techniques in Targeted Prostate Biopsy. Cancers, 2021, 13, 1449.	1.7	10
1081	Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer. JAMA Network Open, 2021, 4, e2037657.	2.8	34
1082	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography. JAMA Oncology, 2021, 7, 395.	3.4	87
1083	Pitfalls in Prostate Cancer Magnetic Resonance Imaging. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 080-088.	0.1	0
1085	Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI. Scientific Reports, 2021, 11, 6048.	1.6	10
1086	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. Scientific Reports, 2021, 11, 1286.	1.6	21
1087	Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. Archivio Italiano Di Urologia Andrologia, 2021, 93, 92-100.	0.4	9
1088	Community-Based Screening for Prostate Cancer. JAMA Oncology, 2021, 7, 402.	3.4	0
1089	Assessment of prostate imaging reporting and data system version 2.1 false-positive category 4 and 5 lesions in clinically significant prostate cancer. Abdominal Radiology, 2021, 46, 3410-3417.	1.0	4
1090	Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041. European Urology, 2021, 79, e98-e99.	0.9	1
1091	Techniques and Outcomes of MRI-TRUS Fusion Prostate Biopsy. Current Urology Reports, 2021, 22, 27.	1.0	13
1092	Diffusion Is Directional: Innovative Diffusion Tensor Imaging to Improve Prostate Cancer Detection. Diagnostics, 2021, 11, 563.	1.3	5
1093	Clinically Significant Prostate Cancer Detection With Biparametric MRI: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2021, 216, 608-621.	1.0	25
1094	Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study). Prostate Cancer and Prostatic Diseases, 2021, 24, 688-696.	2.0	9
1095	Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion. Journal of Medicinal Chemistry, 2021, 64, 4179-4195.	2.9	16
1096	Voxel-level Classification of Prostate Cancer on Magnetic Resonance Imaging: Improving Accuracy Using <scp>Four-Compartment</scp> Restriction Spectrum Imaging. Journal of Magnetic Resonance Imaging, 2021, 54, 975-984.	1.9	12
1097	Multiparametric prostate MRI and structured reporting: benefits and challenges in the PI-RADS era. Chinese Journal of Academic Radiology, 2021, 4, 21-40.	0.4	2

#	ARTICLE	IF	CITATIONS
1098	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A population‐based analysis. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 649-654.	0.9	4
1099	Performance of Prostate Health Index in Biopsy Naïve Black Men. Journal of Urology, 2021, 205, 718-724.	0.2	12
1100	For men enrolled in active surveillance, pre-biopsy biparametric magnetic resonance imaging significantly reduces the risk of reclassification and disease progression after 1 year. Scandinavian Journal of Urology, 2021, 55, 215-220.	0.6	2
1101	Artificial Intelligence in Magnetic Resonance Imaging–based Prostate Cancer Diagnosis: Where Do We Stand in 2021?. European Urology Focus, 2022, 8, 409-417.	1.6	21
1102	Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix. Diagnostics, 2021, 11, 623.	1.3	1
1103	Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy. BJUI Compass, 2021, 2, 194-201.	0.7	7
1104	Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios. Prostate Cancer and Prostatic Diseases, 2021, 24, 662-673.	2.0	8
1105	Radiomics Models Based on Apparent Diffusion Coefficient Maps for the Prediction of High‐Grade Prostate Cancer at Radical Prostatectomy: Comparison With Preoperative Biopsy. Journal of Magnetic Resonance Imaging, 2021, 54, 1892-1901.	1.9	16
1106	A <scp>4K</scp> score/<scp>MRI</scp>‐based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Reports, 2021, 4, e1357.	0.6	16
1107	Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study. Abdominal Radiology, 2021, 46, 4381-4387.	1.0	0
1108	Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial. Cancers, 2021, 13, 1985.	1.7	10
1109	How does a prebiopsy mri approach for prostate cancer diagnosis affect prostatectomy upgrade rates?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 784.e11-784.e16.	0.8	1
1110	Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy. Cancers, 2021, 13, 2102.	1.7	5
1111	Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening. Pharmacoeconomics, 2021, 39, 589-600.	1.7	11
1112	Deep learning–accelerated T2-weighted imaging of the prostate: Reduction of acquisition time and improvement of image quality. European Journal of Radiology, 2021, 137, 109600.	1.2	74
1114	The Value of Low Prostate Imaging–Reporting and Data System (PI-RADS) Scores in Preventing Unnecessary Prostate Biopsies. Medicina (Lithuania), 2021, 57, 413.	0.8	0
1115	Correlation of Likert scores III–V with increasingly worse pathology in radical prostatectomy specimens significant only for men aged <60 or PSAD >0.15, with age <60 as good as PSAD <0.15 at discriminating lower risk in Likert III. Journal of Clinical Urology, 0, , 205141582199510.	0.1	0
1116	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. European Urology Oncology, 2022, 5, 176-186.	2.6	24

#	Article	IF	Citations
1117	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 784.e1-784.e9.	0.8	7
1118	Are Multiparametric Magnetic Resonance Imaging and Guided Biopsies Needed in Men with Normal Digital Rectal Examination and Prostatic-specific Antigen >20â€‰ng/ml?. European Urology Oncology, 2021, 4, 334-335.	2.6	1
1119	Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naÃ¯ve Men. European Urology Oncology, 2021, 4, 855-862.	2.6	15
1120	Indications for prostate multiparametric magnetic resonance imaging: changes over 7Âyears in a single referral centre. BJU International, 2021, 128, 165-167.	1.3	0
1121	Prostate Cancer Diagnostic Algorithm as a â€œRoad Mapâ€•from the First Stratification of the Patient to the Final Treatment Decision. Life, 2021, 11, 324.	1.1	3
1122	The Primacy of High B-Value 3T-DWI Radiomics in the Prediction of Clinically Significant Prostate Cancer. Diagnostics, 2021, 11, 739.	1.3	14
1123	Standardisation of prostate multiparametric MRI across a hospital network: a London experience. Insights Into Imaging, 2021, 12, 52.	1.6	11
1124	Local anaesthetic transperineal (LATP) prostate biopsy using a probeâ€mounted transperineal access system: a multicentre prospective outcome analysis. BJU International, 2021, 128, 311-318.	1.3	28
1125	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 771-774.	3.0	39
1126	Factors associated with higher prostate biopsy yield: when is software-assisted fusion MRI-targeting necessary?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 234.e15-234.e19.	0.8	3
1127	Atypical small acinar proliferation and its significance in pathological reports in modern urological times. Asian Journal of Urology, 2021, 9, 12-17.	0.5	3
1129	Short Time Delay Between Previous Prostate Biopsy for Prostate Cancer Assessment and Holmium Laser Enucleation of the Prostate Correlates with Worse Perioperative Outcomes. European Urology Focus, 2022, 8, 563-571.	1.6	6
1130	Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer. Anticancer Research, 2021, 41, 2183-2186.	0.5	3
1131	Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. Journal of Urology, 2021, 205, 967-976.	0.2	35
1132	Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China. Medical Science Monitor, 2021, 27, e930234.	0.5	0
1134	Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection. PLoS ONE, 2021, 16, e0249532.	1.1	9
1135	Editorial for â€œA Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathologyâ€Radiology Fusionâ€• Journal of Magnetic Resonance Imaging, 2021, 54, 472-473.	1.9	3
1136	Options for Curative Treatment of Localized Prostate Cancer. Deutsches Ärzteblatt International, 2021, 118, .	0.6	7

#	Article	IF	Citations
1137	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3702-3711.	3.3	15
1138	MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study. European Radiology, 2021, 31, 7575-7583.	2.3	40
1139	Spatial Decomposition For Robust Domain Adaptation In Prostate Cancer Detection. , 2021, , .		1
1140	Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncology, 2021, 7, 534.	3.4	99
1141	Reasons for missing clinically significant prostate cancer by targeted magnetic resonance imaging/ultrasound fusion-guided biopsy. European Journal of Radiology, 2021, 137, 109587.	1.2	9
1142	Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). Diagnostics, 2021, 11, 742.	1.3	11
1143	A Novel Deep Learning Based Computer-Aided Diagnosis System Improves the Accuracy and Efficiency of Radiologists in Reading Biparametric Magnetic Resonance Images of the Prostate. Investigative Radiology, 2021, 56, 605-613.	3.5	49
1144	Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis. World Journal of Urology, 2021, 39, 3861-3866.	1.2	17
1145	Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer. Journal of Urology, 2021, 205, 1352-1360.	0.2	3
1147	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. European Urology Focus, 2021, 7, 522-531.	1.6	10
1148	Automated detection of aggressive and indolent prostate cancer on magnetic resonance imaging. Medical Physics, 2021, 48, 2960-2972.	1.6	27
1149	Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database. BMC Cancer, 2021, 21, 573.	1.1	2
1150	Magnetically driven treatments: optimizing performance by mitigation of eddy currents. Nanomedicine, 2021, 16, 895-907.	1.7	2
1152	Identification of a serum biomarker signature associated with metastatic prostate cancer. Proteomics - Clinical Applications, 2021, 15, 2000025.	0.8	3
1153	Focal therapy for prostate cancer—ready to be a standard of care?. Prostate Cancer and Prostatic Diseases, 2021, 24, 931-932.	2.0	1
1154	The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy. BMC Urology, 2021, 21, 82.	0.6	3
1155	Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. European Urology Oncology, 2021, 4, 863-865.	2.6	1
1156	Past, present and future magnetic resonance diagnosis of prostate cancer. Onkourologiya, 2021, 17, 142-152.	0.1	0

#	Article	IF	Citations
1157	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. European Radiology, 2021, 31, 9567-9578.	2.3	34
1158	High spectral and spatial resolution MRI of prostate cancer: a pilot study. Magnetic Resonance in Medicine, 2021, 86, 1505-1513.	1.9	3
1159	Urine Biomarkers for Prostate Cancer Diagnosis and Progression. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, 159-170.	0.2	0
1160	Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer. PLoS ONE, 2021, 16, e0251961.	1.1	5
1161	Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. BJUI Compass, 2021, 2, 188-193.	0.7	7
1162	Costâ€effectiveness of multiparametric magnetic resonance imaging and MRIâ€guided biopsy in a populationâ€based prostate cancer screening setting using a microâ€simulation model. Cancer Medicine, 2021, 10, 4046-4053.	1.3	4
1163	IVIMâ€"DKIÂfor differentiation between prostate cancer and benign prostatic hyperplasia: comparison of 1.5ÂT vs. 3ÂT MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 609-620.	1.1	7
1164	Radiogenomics in prostate cancer evaluation. Current Opinion in Urology, 2021, 31, 424-429.	0.9	6
1165	A Prospective Study on the Efficacy of Cognitive Targeted Transrectal Ultrasound Prostate Biopsy in Diagnosing Clinically Significant Prostate Cancer. Research and Reports in Urology, 2021, Volume 13, 207-213.	0.6	0
1166	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics, 2021, 11, 882.	1.3	13
1167	Current Diagnostics for Prostate Cancer. , 0, , 43-58.		2
1168	Cognitively targeted transperineal prostate biopsy in patients with previous abdominoperineal excision of the rectum. Journal of Clinical Urology, 2023, 16, 86-90.	0.1	0
1169	The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 297.e9-297.e16.	0.8	2
1170	Computer-Aided Diagnosis Improves the Detection of Clinically Significant Prostate Cancer on Multiparametric-MRI: A Multi-Observer Performance Study Involving Inexperienced Readers. Diagnostics, 2021, 11, 973.	1.3	11
1171	Multiparametric magnetic resonance imaging and combined prostate biopsy: opportunities, advantages and pitfalls. Medical Visualization, 2021, 25, 138-152.	0.1	1
1172	Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. European Urology Focus, 2021, 7, 503-505.	1.6	5
1173	Tumor Topography for Diagnosis of Prostate Cancer. American Journal of Roentgenology, 2021, 216, W25-W25.	1.0	0
1174	Prospective study of diagnostic accuracy in the detection of highâ€grade prostate cancer in biopsyâ€naÃ¯ve patients with clinical suspicion of prostate cancer who underwent the Select MDx test. Prostate, 2021, 81, 857-865.	1.2	9

#	Article	IF	Citations
1175	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. BJU International, 2021, 128, 702-712.	1.3	0
1176	Incidence, predictive factors and oncological outcomes of incidental prostate cancer after endoscopic enucleation of the prostate: a systematic review and meta-analysis. World Journal of Urology, 2022, 40, 87-101.	1.2	12
1177	Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients. Yeni Ãœroloji Dergisi, 2021, 16, 140-147.	0.1	0
1178	Fully Automatic Deep Learning in Bi-institutional Prostate Magnetic Resonance Imaging. Investigative Radiology, 2021, 56, 799-808.	3.5	27
1179	Can high b-value 3.0ÂT biparametric MRI with the Simplified Prostate Image Reporting and Data System (S-PI-RADS) be used in biopsy-naÃ¯ve men?. Clinical Imaging, 2021, , .	0.8	6
1180	Diagnostic accuracy of high b-value diffusion weighted imaging for patients with prostate cancer: a diagnostic comprehensive analysis. Aging, 2021, 13, 16404-16424.	1.4	1
1181	The future direction of imaging in prostate cancer: MRI with or without contrast injection. Andrology, 2021, 9, 1429-1443.	1.9	15
1182	New imaging modalities to consider for men with prostate cancer on active surveillance. World Journal of Urology, 2022, 40, 51-59.	1.2	11
1183	Glioblastoma Surgery Imagingâ€"Reporting and Data System: Standardized Reporting of Tumor Volume, Location, and Resectability Based on Automated Segmentations. Cancers, 2021, 13, 2854.	1.7	5
1184	IMPACT OF COVID-19 ON CANCER CARE. , 2021, , 239-243.		0
1185	Diagnostic accuracy of the Novel 29 MHz micro-ultrasound â€œExactVuTMâ€•for the detection of clinically significant prostate cancer: A prospective single institutional study. A step forward in the diagnosis of prostate cancer. Archivio Italiano Di Urologia Andrologia, 2021, 93, 132-138.	0.4	8
1186	The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 832.e1-832.e7.	0.8	16
1187	mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: Our experience in 950 cases. Archivio Italiano Di Urologia Andrologia, 2021, 93, 139-142.	0.4	6
1188	The utility of magnetic resonance imaging in prostate cancer diagnosis in the Australian setting. BJUI Compass, 2021, 2, 377-384.	0.7	3
1189	Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology. Prostate International, 2021, 9, 61-65.	1.2	8
1190	Multiparametric magnetic resonance imaging of the prostate: Lights and shadows. Urologia, 2021, 88, 280-286.	0.3	5
1191	Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncology, 2021, 17, 2225-2241.	1.1	14
1192	Survey of denoising, segmentation and classification of magnetic resonance imaging for prostate cancer. Multimedia Tools and Applications, 2021, 80, 29199-29249.	2.6	4

#	Article	IF	Citations
1193	Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?. Asian Journal of Urology, 2021, 8, 343-353.	0.5	12
1194	Naive patients with suspicious prostate cancer and positive multiparametric magnetic resonance imaging (mp-MRI): is it time for fusion target biopsy alone?. Journal of Clinical Urology, 0, , 205141582110237.	0.1	3
1195	Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers, 2021, 13, 3381.	1.7	25
1196	Economic Evaluation of Transperineal versus Transrectal Devices for Local Anaesthetic Prostate Biopsies. PharmacoEconomics - Open, 2021, 5, 737-753.	0.9	3
1198	Arterial spin labelling as a gadolinium-free alternative in the detection of prostate cancer. Magnetic Resonance Imaging, 2021, 80, 33-38.	1.0	5
1199	Value of MRI to Improve Deep Learning Model That Identifies High-Grade Prostate Cancer. Comment on Gentile et al. Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model. Diagnostics 2021, 11, 335. Diagnostics, 2021, 11, 1213.	1.3	0
1200	Can Prostate-Specific Antigen Density Be an Index to Distinguish Patients Who Can Omit Repeat Prostate Biopsy in Patients with Negative Magnetic Resonance Imaging?. Cancer Management and Research, 2021, Volume 13, 5467-5475.	0.9	3
1201	Evaluation of clinical and mpMRI findings of irreversible electroporation therapy for the treatment of localized prostate cancer: Preliminary results. , 2021, 47, 299-304.		1
1202	Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. Translational Andrology and Urology, 2021, 10, 3091-3103.	0.6	23
1203	A review of the research progress of interventional medical equipment and methods for prostate cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2303.	1.2	5
1204	Focal Therapy for Prostate Cancer: Complications and Their Treatment. Frontiers in Surgery, 2021, 8, 696242.	0.6	13
1205	Development of an auxiliary device for ultrasound-guided aspiration of pelvic cystic masses: a simulation study. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3165-3174.	1.1	0
1206	Development and validation of a nomogram based on multiparametric magnetic resonance imaging and elastography-derived data for the stratification of patients with prostate cancer. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3252-3262.	1.1	4
1208	Editorial for â€œPreliminary Exploration of the Application of Vesical <scp>Imagingâ€Reporting</scp> and Data System (<scp>VIâ€RADS</scp>) in Postâ€Treatment Patients with Bladder Cancer: A Prospective Singleâ€Center Studyâ€. Journal of Magnetic Resonance Imaging, 2022, 55, 287-288.	1.9	1
1209	Accelerated T2-Weighted TSE Imaging of the Prostate Using Deep Learning Image Reconstruction: A Prospective Comparison with Standard T2-Weighted TSE Imaging. Cancers, 2021, 13, 3593.	1.7	47
1210	Reply to Anwar R. Padhani, Ivo G. Schoots, Jelle O. Barentsz. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.04.009. European Urology Oncology, 2021, 4, 866-866.	2.6	0
1211	Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?. British Journal of Radiology, 2021, 94, 20210312.	1.0	1
1212	Artificial Intelligence Compared to Radiologists for the Initial Diagnosis of Prostate Cancer on Magnetic Resonance Imaging: A Systematic Review and Recommendations for Future Studies. Cancers, 2021, 13, 3318.	1.7	32

#	ARTICLE	IF	CITATIONS
1213	Patient Perspectives and Understanding of MRI-directed Prostate Cancer Diagnosis. Urology, 2021, 153, 6-7.	0.5	0
1214	The role of targeted biopsy methods in the prostate cancer diagnosis. Onkourologiya, 2021, 17, 157-167.	0.1	0
1215	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS ONE, 2021, 16, e0252040.	1.1	8
1216	Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies. Urologia Internationalis, 2022, 106, 83-89.	0.6	2
1217	The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 831.e19-831.e27.	0.8	11
1218	A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting. Current Medical Research and Opinion, 2021, 37, 1617-1625.	0.9	4
1219	1.5 vs 3 Tesla Magnetic Resonance Imaging. Investigative Radiology, 2021, 56, 680-691.	3.5	12
1220	Comparison of Sensitivity and Specificity of Biparametric versus Multiparametric Prostate MRI in the Detection of Prostate Cancer in 431 Men with Elevated Prostate-Specific Antigen Levels. Diagnostics, 2021, 11, 1223.	1.3	10
1221	MRI Targeted Prostate Biopsy Techniques: *AJR* Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 217, 1263-1281.	1.0	7
1222	Magnetic resonance imaging /ultrasonography fusion transperineal prostate biopsy for prostate cancer: Initial experience at a Middle Eastern tertiary medical centre. Arab Journal of Urology Arab Association of Urology, 2021, 19, 454-459.	0.7	1
1223	Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound€guided prostate biopsy. Prostate, 2021, 81, 983-991.	1.2	3
1226	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. Cancers, 2021, 13, 3570.	1.7	9
1227	Prostate Cancer Detection Using 3-D Shear Wave Elasticity Imaging. Ultrasound in Medicine and Biology, 2021, 47, 1670-1680.	0.7	8
1228	Intelligent Computer-Aided Prostate Cancer Diagnosis Systems: State-of-the-Art and Future Directions. Mathematical Problems in Engineering, 2021, 2021, 1-17.	0.6	1
1229	Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?. Diagnostics, 2021, 11, 1335.	1.3	8
1230	Editorial for â€œBiparametric Magnetic Resonance Imagingâ€Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesionâ€. Journal of Magnetic Resonance Imaging, 2022, 56, 425-426.	1.9	0
1231	MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer. Diagnostics, 2021, 11, 1551.	1.3	1
1232	Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?. Journal of Urology, 2022, 207, 95-107.	0.2	29

#	Article	IF	Citations
1233	Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 519-528.	2.6	10
1234	The Clinical and Pathologic Relevance of a Prostate MRI Diagnosis of â€œProstatitisâ€. Urology, 2021, 154, 233-236.	0.5	0
1235	Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk. European Urology, 2021, 80, 263-265.	0.9	3
1236	Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly. Molecular Oncology, 2021, 15, 2565-2579.	2.1	5
1237	Haralick texture features extracted from Ga-68 PSMA PET/CT to differentiate normal prostate from prostate cancer. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 1347-1354.	0.5	3
1238	Pathological features of Prostate Imaging Reporting and Data System (PIâ€RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. BJU International, 2022, 129, 621-626.	1.3	4
1239	Usefulness of Prostate-Specific Antigen Density as an Indicator for Recommending Prebiopsy Magnetic Resonance Imaging to Prevent Missed Prostate Cancer Diagnoses. The Korean Journal of Urological Oncology, 2021, 19, 155-163.	0.1	1
1241	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. European Urology, 2021, 80, 703-711.	0.9	108
1242	Bioelectric Impedance Analysis Test Improves the Detection of Prostate Cancer in Biopsy Candidates: A Multifeature Decision Support System. Frontiers in Oncology, 2021, 11, 555277.	1.3	2
1243	Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer: an Updated Systematic Review. Clinical Oncology, 2021, 33, e599-e612.	0.6	8
1244	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. European Urology Oncology, 2021, 4, 731-739.	2.6	51
1245	Fully automated detection of prostate transition zone tumors on T2â€weighted and apparent diffusion coefficient (ADC) map MR images using Uâ€Net ensemble. Medical Physics, 2021, 48, 6889-6900.	1.6	7
1246	The current recommendation for the management of isolated highâ€grade prostatic intraepithelial neoplasia. BJU International, 2022, 129, 627-633.	1.3	4
1247	Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome. Urologia Internationalis, 2022, 106, 791-797.	0.6	1
1248	Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	5
1249	Optimal biopsy approach for detection of clinically significant prostate cancer. British Journal of Radiology, 2022, 95, 20210413.	1.0	11
1250	Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study. European Urology Open Science, 2021, 30, 16-24.	0.2	4
1251	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value in Health, 2021, 24, 1111-1117.	0.1	9

#	Article	IF	Citations
1252	Diagnostic Performance of ⁶⁸Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. Radiology, 2021, 301, 379-386.	3.6	28
1253	Expedited Workflow for "One-Stop" Magnetic Resonance Imaging and Image Fusion Prostate Biopsy: Implementation and Lessons Learned. Seminars in Roentgenology, 2021, 56, 406-409.	0.2	0
1254	Increasing Utilization of MRI Before Prostate Biopsy in Black and Non-Black Men: An Analysis of the SEER-Medicare Cohort. American Journal of Roentgenology, 2021, 217, 389-394.	1.0	17
1255	Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. Current Oncology Reports, 2021, 23, 130.	1.8	4
1256	Predictive Factors for Acute Urinary Retention After Transperineal Template-Guided Mapping Biopsy. The Korean Journal of Urological Oncology, 2021, 19, 148-154.	0.1	1
1257	Improving workflow in prostate MRI: AI-based decision-making on biparametric or multiparametric MRI. Insights Into Imaging, 2021, 12, 112.	1.6	11
1258	Results from a PI-RADS-based MRI-directed diagnostic pathway for biopsy-naive patients in a non-university hospital. Abdominal Radiology, 2021, 46, 5639-5646.	1.0	2
1259	When to Discuss Prostate Cancer Screening With Average-Risk Men. American Journal of Preventive Medicine, 2021, 61, 294-298.	1.6	1
1260	Prostate MRI and the value of experience: An intrareader variability study. Asian Journal of Urology, 2021, , .	0.5	0
1261	Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 58.e9-58.e9.	0.8	0
1262	Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy. Urologia Internationalis, 2022, 106, 90-96.	0.6	3
1263	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	0.9	181
1264	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. BJU International, 2022, 129, 325-336.	1.3	15
1265	Feasibility of diffusion weighting with a local inside-out nonlinear gradient coil for prostate MRI. Medical Physics, 2021, 48, 5804-5818.	1.6	4
1266	Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria. Urologic Oncology: Seminars and Original Investigations, 2021, , .	0.8	5
1267	MRI Fusion Transperineal Prostate Biopsy Instructions and Troubleshooting. Journal of Endourology, 2021, 35, S-2-S-6.	1.1	3
1268	Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 174-179.	2.0	22
1269	A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer. European Urology, 2021, 80, 690-692.	0.9	5

#	Article	IF	Citations
1270	Zonal anatomy of the prostate using magnetic resonance imaging, morphometrics, and radiomic features: impact of age-related changes. British Journal of Radiology, 2022, 95, 20210156.	1.0	4
1271	Diffusion-weighted imaging in prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 533-547.	1.1	9
1272	Image-Guided Targeted Prostate Biopsies. Techniques in Vascular and Interventional Radiology, 2021, 24, 100777.	0.4	1
1273	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. New England Journal of Medicine, 2021, 385, 908-920.	13.9	184
1274	Artificial Intelligence in Prostate Imaging. Advances in Clinical Radiology, 2021, 3, 15-22.	0.1	0
1275	Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. Urology, 2021, 155, 20-25.	0.5	4
1276	Lymphocyteâ€toâ€monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy. Prostate, 2021, 81, 1278-1286.	1.2	4
1277	The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. European Urology Focus, 2021, , .	1.6	8
1278	A risk model for detecting clinically significant prostate cancer based on bi-parametric magnetic resonance imaging in a Japanese cohort. Scientific Reports, 2021, 11, 18829.	1.6	3
1279	Differentiating prostate cancer from benign prostatic hyperplasia using whole-lesion histogram and texture analysis of diffusion- and T2-weighted imaging. Cancer Imaging, 2021, 21, 54.	1.2	9
1280	Detection and PI-RADS classification of focal lesions in prostate MRI: Performance comparison between a deep learning-based algorithm (DLA) and radiologists with various levels of experience. European Journal of Radiology, 2021, 142, 109894.	1.2	20
1281	A Cascaded Deep Learningâ€"Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. Academic Radiology, 2022, 29, 1159-1168.	1.3	21
1282	Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. Cancers, 2021, 13, 4742.	1.7	5
1283	Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis. Value in Health, 2022, 25, 133-146.	0.1	8
1284	Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer and Prostatic Diseases, 2022, 25, 296-301.	2.0	40
1285	A Prospective Study Comparing Cancer Detection Rates of Transperineal Prostate Biopsies Performed by Junior Urologists versus a Senior Consultant in a Real-World Setting. Urologia Internationalis, 2022, 106, 884-890.	0.6	1
1286	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open, 2021, 11, e048144.	0.8	10
1287	Prostate Cancer Radiogenomicsâ€"From Imaging to Molecular Characterization. International Journal of Molecular Sciences, 2021, 22, 9971.	1.8	55

#	Article	IF	Citations
1288	Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. European Urology, 2021, 80, 573-574.	0.9	1
1289	Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis. British Journal of Radiology, 2022, 95, 20210509.	1.0	12
1290	Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Prostate Biopsy: Diagnostic Accuracy from a Single Center Retrospective Study. Cancers, 2021, 13, 4833.	1.7	4
1292	Effectiveness of magnetic resonance imagingâ€"targeted biopsy for detection of prostate cancer in comparison with systematic biopsy in our countries with low prevalence of prostate cancer: our first experience after 3Âyears. Prostate International, 2021, 9, 140-144.	1.2	4
1293	Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. BMC Urology, 2021, 21, 131.	0.6	7
1294	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240
1295	Utility of PSA Density in Predicting Upgraded Gleason Score in Men on Active Surveillance With Negative MRI. Urology, 2021, 155, 96-100.	0.5	7
1296	In-Bore Versus Fusion MRIâ€"Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. American Journal of Roentgenology, 2021, 217, 1123-1130.	1.0	16
1297	Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. Medical Image Analysis, 2021, 73, 102153.	7.0	19
1298	Stromaâ€derived extracellular vesicle mRNA signatures inform histological nature of prostate cancer. Journal of Extracellular Vesicles, 2021, 10, e12150.	5.5	10
1299	Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison. Clinical Imaging, 2021, 78, 98-103.	0.8	2
1300	Should men undergo MRI before prostate biopsy â€" CON. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 92-95.	0.8	1
1301	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 729.e1-729.e6.	0.8	6
1302	A Fully Automatic Artificial Intelligence System Able to Detect and Characterize Prostate Cancer Using Multiparametric MRI: Multicenter and Multi-Scanner Validation. Frontiers in Oncology, 2021, 11, 718155.	1.3	16
1303	Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy. American Journal of Roentgenology, 2021, 217, 908-918.	1.0	6
1304	Improvement of PI-RADS-dependent prostate cancer classification by quantitative image assessment using radiomics or mean ADC. Magnetic Resonance Imaging, 2021, 82, 9-17.	1.0	19
1305	An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imagingâ€"based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses. European Urology, 2021, 80, 398-399.	0.9	1
1306	Comparison and prediction of artefact severity due to total hip replacement in 1.5ÂT versus 3ÂT MRI of the prostate. European Journal of Radiology, 2021, 144, 109949.	1.2	12

#	Article	IF	Citations
1307	Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil. Value in Health Regional Issues, 2021, 26, 89-97.	0.5	1
1308	Correlation between prostate imaging reporting and data system version 2, prostate-specific antigen levels, and local staging in biopsy-proven carcinoma prostate: A retrospective study. International Journal of Applied & Basic Medical Research, 2021, 11, 32.	0.2	0
1309	Clinical utility of current biomarkers for prostate cancer detection. Investigative and Clinical Urology, 2021, 62, 1.	1.0	16
1310	Recent Automatic Segmentation Algorithms of MRI Prostate Regions: A Review. IEEE Access, 2021, 9, 97878-97905.	2.6	21
1311	Unsupervised Domain Adaptation with Semantic Consistency Across Heterogeneous Modalities for MRI Prostate Lesion Segmentation. Lecture Notes in Computer Science, 2021, , 90-100.	1.0	2
1312	Training Deep Networks for Prostate Cancer Diagnosis Using Coarse Histopathological Labels. Lecture Notes in Computer Science, 2021, , 680-689.	1.0	7
1313	Morphology-Guided Prostate MRI Segmentation with Multi-slice Association. Lecture Notes in Computer Science, 2021, , 507-516.	1.0	2
1314	Contemporary application of artificial intelligence in prostate cancer: an i-TRUE study. Therapeutic Advances in Urology, 2021, 13, 175628722098664.	0.9	5
1315	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. European Urology Oncology, 2022, 5, 537-543.	2.6	13
1316	Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics. Medicina (Lithuania), 2021, 57, 91.	0.8	15
1317	Analysis of the usefulness of magnetic resonance imaging and clinical parameters in the detection of prostate cancer in the first systematic biopsy combined with targeted cognitive biopsy. Central European Journal of Urology, 2021, 74, 321-326.	0.2	1
1318	Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?. Therapeutic Advances in Urology, 2021, 13, 175628722199718.	0.9	14
1319	MRI and Targeted Biopsies Compared to Transperineal Mapping Biopsies Prior to Focal Ablation in Recurrent Prostate Cancer after Radiotherapy. SSRN Electronic Journal, 0, , .	0.4	0
1320	Clinical PET/MR. Recent Results in Cancer Research, 2020, 216, 747-764.	1.8	16
1321	Harnessing Uncertainty in Domain Adaptation for MRI Prostate Lesion Segmentation. Lecture Notes in Computer Science, 2020, , 510-520.	1.0	17
1322	CorrSigNet: Learning CORRelated Prostate Cancer SIGnatures from Radiology and Pathology Images for Improved Computer Aided Diagnosis. Lecture Notes in Computer Science, 2020, , 315-325.	1.0	10
1324	Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies. Current Clinical Urology, 2018, , 217-227.	0.0	1
1325	Magnetic Resonance Imaging of the Prostate in the PI-RADS Era. IDKD Springer Series, 2018, , 99-115.	0.8	3

#	Article	IF	Citations
1326	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologistsâ€™ training. , 2020, 30, 5404.		1
1327	PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Clinical and Translational Oncology, 2021, 23, 172-178.	1.2	16
1328	AnÃ¡lisis del escenario microscÃ³pico de una biopsia prostÃ¡tica negativa como predictor del riesgo de cÃ¡ncer de prÃ³stata. Una revisiÃ³n sistemÃ¡tica. Actas UrolÃ³gicas EspaÃ±olas, 2019, 43, 337-347.	0.3	3
1329	La resonancia magnÃ©tica como herramienta para el diagnÃ³stico del cÃ¡ncer de prÃ³stata: nuevas evidencias y posicionamiento de la ESUT (EAU Section of Uro-Technology). Actas UrolÃ³gicas EspaÃ±olas, 2020, 44, 148-155.	0.3	2
1330	Magnetic resonance as imaging diagnostic tool in prostate cancer: New evidences-The EAU section of uro-technology position. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2020, 44, 148-155.	0.2	1
1331	Selecting proper combination of mpMRI sequences for prostate cancer classification using multi-input convolutional neuronal network. Physica Medica, 2020, 80, 92-100.	0.4	13
1332	Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 697-713.	2.6	84
1333	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. European Urology, 2020, 78, 402-414.	0.9	183
1334	What Are We Missing? Magnetic Resonance Imagingâ€"negative Clinically Significant Prostate Cancer in PROMIS. European Urology, 2020, 78, 171-172.	0.9	1
1335	Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?. Journal of Urology, 2019, 201, 268-277.	0.2	64
1336	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiotherapy and Oncology, 2020, 149, 240-245.	0.3	10
1337	Role of Multiparametric Magnetic Resonance Imaging Prostate Specific Antigen Density and PI-RADSâ„¢ Score in Predicting Up Staging in Men on Active Surveillance. Urology Practice, 2019, 6, 117-122.	0.2	2
1338	Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. Scandinavian Journal of Urology, 2021, 55, 27-32.	0.6	4
1339	Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. Journal of Urology, 2020, 203, 706-712.	0.2	152
1340	Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 224-230.	0.2	85
1341	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.2	19
1342	Comparison of MRI, PSMA PET/CT, and Fusion PSMA PET/MRI for Detection of Clinically Significant Prostate Cancer. Journal of Computer Assisted Tomography, 2021, 45, 210-217.	0.5	15
1343	Multiparametric Magnetic Resonance Imaging of the Prostate. Investigative Radiology, 2017, 52, 538-546.	3.5	56

#	Article	IF	Citations
1345	Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance-ultrasound fusion images. International Journal of Urology, 2020, 27, 760-766.	0.5	4
1346	PROSTATEx Challenges for computerized classification of prostate lesions from multiparametric magnetic resonance images. Journal of Medical Imaging, 2018, 5, 1.	0.8	98
1347	Errors in prostate core biopsy diagnosis in an era of specialisation and double reporting. Journal of Clinical Pathology, 2021, 74, 327-330.	1.0	1
1348	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	3.9	180
1349	Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Research, 2020, 10, 15.	1.1	14
1350	Current Role of Focal Therapy for Prostate Cancer. , 2018, , 53-62.		1
1351	The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload. British Journal of Radiology, 2020, 93, 20190929.	1.0	18
1352	Pitfalls of Prostate Imaging Reporting and Data System Version 2: a Pictorial Essay. Hong Kong Journal of Radiology, 0, , 280-291.	0.1	1
1353	Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques. World Journal of Clinical Cases, 2019, 7, 1403-1409.	0.3	8
1354	Cylindrical illumination with angular coupling for whole-prostate photoacoustic tomography. Biomedical Optics Express, 2019, 10, 1405.	1.5	8
1355	Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy. World Journal of Oncology, 2019, 10, 218-225.	0.6	10
1356	Differences in negative predictive value of prostate MRI based in men with suspected or known cancer. Radiologia Brasileira, 2019, 52, 281-286.	0.3	3
1357	Can biopsy be avoided in patients with clinical suspicion of prostate cancer and a negative result on multiparametric magnetic resonance imaging?. Radiologia Brasileira, 2019, 52, V-VI.	0.3	2
1358	Gleason Probability Maps: A Radiomics Tool for Mapping Prostate Cancer Likelihood in MRI Space. Tomography, 2019, 5, 127-134.	0.8	39
1359	Systematic sampling during MRI-US fusion prostate biopsy can overcome errors of targeting—prospective single center experience after 300 cases in first biopsy setting. Translational Andrology and Urology, 2020, 9, 2510-2518.	0.6	5
1360	From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Translational Andrology and Urology, 2017, 6, 604-607.	0.6	7
1361	What is an acceptable false negative rate in the detection of prostate cancer?. Translational Andrology and Urology, 2018, 7, 54-60.	0.6	13
1362	Transperineal prostate biopsy: a review of technique. Translational Andrology and Urology, 2020, 9, 3009-3017.	0.6	29

#	Article	IF	Citations
1363	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. Current Medicinal Chemistry, 2020, 27, 7090-7111.	1.2	9
1364	Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A). JMIR Research Protocols, 2018, 7, e132.	0.5	7
1365	Role of apparent diffusion coefficient values in prostate diseases characterization on diffusion-weighted magnetic resonance imaging. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 154-160.	3.9	11
1366	Radiological Wheeler staging system: a retrospective cohort analysis to improve the local staging of prostate cancer with multiparametric MRI. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 264-272.	3.9	9
1368	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. Health Technology Assessment, 2018, 22, 1-176.	1.3	70
1369	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. Health Technology Assessment, 2018, 22, 1-96.	1.3	33
1370	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
1371	A nurse practitioner model for the assessment of suspected prostate cancer referrals is safe, cost and time efficient. Ecancermedicalscience, 2019, 13, 994.	0.6	9
1372	MRI-Targeted Prostate Biopsy: What Radiologists Should Know. Korean Journal of Radiology, 2020, 21, 1087.	1.5	9
1373	Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies. Cancers, 2020, 12, 285.	1.7	12
1374	Diagnostic performance of a nomogram incorporating cribriform morphology for the prediction of adverse pathology in prostate cancer at radical prostatectomy. Oncology Letters, 2020, 20, 2797-2805.	0.8	4
1375	Focal Ablation of Prostate Cancer. Reviews in Urology, 2018, 20, 145-157.	0.9	7
1376	Men's health 2018: BPH, prostate cancer, erectile dysfunction, supplements. Cleveland Clinic Journal of Medicine, 2018, 85, 871-880.	0.6	5
1377	Role of transrectal ultrasound elastography in the diagnosis of prostate carcinoma. Journal of Medical Ultrasound, 2020, 28, 173.	0.2	10
1378	Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice. Investigative and Clinical Urology, 2020, 61, 28.	1.0	4
1379	Complementing the active surveillance criteria with multiparametric magnetic resonance imaging. Investigative and Clinical Urology, 2020, 61, 573.	1.0	2
1380	Diagnostic Accuracy and Value of Magnetic Resonance Imaging–Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging. Cancer Research and Treatment, 2020, 52, 714-721.	1.3	9
1381	Score 3 prostate lesions: a gray zone for PI-RADS v2. Turkish Journal of Urology, 2017, 43, 237-240.	1.3	42

#	Article	IF	Citations
1382	Value of prostate-specific antigen density in negative or equivocal lesions on multiparametric magnetic resonance imaging. Turkish Journal of Urology, 2020, 46, 367-372.	1.3	8
1383	Improving the Diagnosis of Clinically Significant Prostate Cancer with Magnetic Resonance Imaging. Journal of the Belgian Society of Radiology, 2018, 102, .	0.1	7
1384	Cancer detection rates and inter-examiner variability of MRI/TRUS fusion targeted biopsy and systematic transrectal biopsy. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2020, 164, 314-319.	0.2	5
1385	Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 506-513.	2.3	33
1386	Identifying prostate cancer and its clinical risk in asymptomatic men using machine learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data. ELife, 2020, 9, .	2.8	12
1387	Prostate Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 791-803.	0.1	0
1388	A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. Canadian Urological Association Journal, 2021, 16, .	0.3	4
1389	Multiparametric MRI and Radiomics in Prostate Cancer: A Review of the Current Literature. Diagnostics, 2021, 11, 1829.	1.3	12
1390	Multiparametric Prostate MRI in Biopsy-NaÃ¯ve Men: A Prospective Evaluation of Performance and Biopsy Strategies. Frontiers in Oncology, 2021, 11, 745657.	1.3	6
1391	Imaging of prostate cancer. Deutsches A&#x0308;rzteblatt International, 2021, , .	0.6	8
1392	Gleason grade accuracy of transperineal and transrectal prostate biopsies in MRI-naÃ¯ve patients. International Urology and Nephrology, 2021, 53, 2445-2452.	0.6	5
1393	A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population. Cancer Research and Treatment, 2021, 53, 1148-1155.	1.3	5
1394	Network Analysis Integrating microRNA Expression Profiling with MRI Biomarkers and Clinical Data for Prostate Cancer Early Detection: A Proof of Concept Study. Biomedicines, 2021, 9, 1470.	1.4	5
1395	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	1.2	3
1396	Prostate zones and cancer: lost in transition?. Nature Reviews Urology, 2022, 19, 101-115.	1.9	25
1397	Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open, 2021, 4, e2128646.	2.8	8
1398	Single-center versus multi-center biparametric MRI radiomics approach for clinically significant peripheral zone prostate cancer. Insights Into Imaging, 2021, 12, 150.	1.6	15
1399	Evolution of Focal Therapy in Prostate Cancer. Urologic Clinics of North America, 2022, 49, 129-152.	0.8	5

#	Article	IF	Citations
1400	Screening of Prostate Cancer. , 2017, , 1-12.		0
1402	Prostate MRI Technique. , 2018, , 1-22.		0
1403	Most of patients with localized prostate cancer will be treated in the future? | Opinion: No. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 584-587.	0.7	1
1404	Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 579-583.	0.7	0
1406	Diagnostic Performance of Multiparametric Magnetic Resonance Imaging and Fusion Targeted Biopsy to Detect Significant Prostate Cancer. Anticancer Research, 2017, 37, 6871-6877.	0.5	3
1407	Radical Prostatectomy in the Metastatic Setting. , 2018, , 169-184.		0
1408	Les bases de données médicales et les innovations technologiques peuvent améliorer la pertinence du diagnostic précoce du cancer de la prostate. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1839-1852.	0.0	0
1409	Editorial Comment. Journal of Urology, 2018, 200, 1028-1029.	0.2	0
1410	Multiparametrische Prostata-MRT: Vorzüge und Grenzen. Deutsches A&#x0308;rzteblatt International, 0, , .	0.6	0
1411	Initial Experience of Transperineal Biopsy After Multiparametric Magnetic Resonance Imaging in Korea; Comparison With Transrectal Biopsy. The Korean Journal of Urological Oncology, 2018, 16, 110-118.	0.1	0
1412	Response Assessment. , 2019, , 95-106.		0
1413	Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management. Springer Theses, 2019, , 1-29.	0.0	0
1414	MRI-Ultrasound Fusion Prostate Biopsy. , 2019, , 303-314.		0
1415	Are we ready to adopt the European Association of Urology recommendations on multiparametric magnetic resonance imaging in the early detection of prostate cancer?. Investigative and Clinical Urology, 2019, 60, 225.	1.0	0
1416	Diagnosis of Osteosarcopenia â€" Imaging. , 2019, , 243-263.		0
1417	Urological neoplasia. , 2019, , 252-406.		1
1418	Prostate Imaging Self-assessment and Mentoring (PRISM): a prototype self-assessment scheme. , 2019, , .		0
1419	Tesseract-medical imaging: open-source browser-based platform for artificial intelligence deployment in medical imaging. , 2019, , .		2

#	Article	IF	Citations
1420	Serial Comparison of Cancer Detection Rate Between Transrectal Ultrasound Sonography Guided Biopsy and Magnetic Resonance Imaging for Repeat Biopsy by a Propensity Score Matching Cohort: A Single Center Experience. The Korean Journal of Urological Oncology, 2019, 17, 60-65.	0.1	0
1422	Level of Prostate Cancer Diagnosis Using MRI-TRUS Fusion Biopsy in Patients with a Negative History of TRUS Biopsy. Nephro-Urology Monthly, 2019, 11, .	0.0	0
1423	Usage of PI-RADS v2.1 system for prostate MRI: a practical approach. Medical Visualization, 2019, , 107-125.	0.1	1
1424	Clinical implications of prostatic capsular abutment or bulging on multiparametric magnetic resonance imaging. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 502-507.	3.9	6
1425	Evaluación de la biopsia de fusión elástica vs. biopsia sistemática para la detección del cáncer de próstata: resultados de un estudio multicéntrico en 1.119 pacientes. Actas Urológicas Españolas, 2019, 43, 431-438.	0.3	2
1426	Bemoeilijkte mictie bij mannen. Praktische Huisartsgeneeskunde, 2020, , 475-491.	0.0	0
1428	Detection and Local Staging of Prostate Cancer by 68Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology. Advances in Molecular Imaging, 2020, 10, 15-29.	0.3	0
1429	Aging and Cancer: Concepts and Prospects. , 2020, , 1-6.		0
1430	Evolution of prostate cancer diagnosis: retrospective analysis of magnetic resonance imaging/ultrasound fusion guided biopsies protocol in routine practice and patients management. Translational Andrology and Urology, 2020, 9, 629-636.	0.6	1
1431	Tracked Foley catheter for motion compensation during fusion image-guided prostate procedures: a phantom study. European Radiology Experimental, 2020, 4, 24.	1.7	0
1432	Enfoque diagnóstico del cáncer de próstata: epidemiología, factores de riesgo, detección precoz, biopsias. EMC - Urología, 2020, 52, 1-12.	0.0	0
1433	Benefits of pre‐biopsy multi‐parametric magnetic resonance imaging scanning in the initial assessment of prostate cancer. International Journal of Urological Nursing, 2021, 15, 33-38.	0.1	2
1434	Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. European Urology, 2020, 78, 291-292.	0.9	1
1436	MODERN OPPORTUNITIES OF PET/CT IN THE DIAGNOSIS OF PROSTATE CANCER. Siberian Journal of Oncology, 2021, 20, 115-122.	0.1	0
1437	Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. Cancers, 2021, 13, 5360.	1.7	13
1438	Assessing the diagnostic performance of systematic freehand precisionpoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 4.e9-4.e17.	0.8	0
1439	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. Frontiers in Oncology, 2021, 11, 771787.	1.3	23
1441	MRI-Guided In-Bore and MRI-Targeted US (Fusion) Biopsy. , 2020, , 129-145.		0

#	ARTICLE	IF	CITATIONS
1443	Semi-automated PIRADS scoring via mpMRI analysis. Journal of Medical Imaging, 2020, 7, 064501.	0.8	1
1445	Identification of interstitial lung diseases using deep learning. International Journal of Electrical and Computer Engineering, 2020, 10, 6283.	0.5	4
1446	Use of Multiparametrric Magnetic Resonance Imaging (mpMRI) for Prostate Cancer: A Journey from 1.5 to 10 Tesla. , 2021, , 99-108.		0
1447	Evaluation of Multiparametric MRI of the Prostate: Impact of Standardized Examination Protocols and the Endorectal Coil. Open Journal of Medical Imaging, 2020, 10, 30-41.	0.1	1
1448	Biparametric MRI of Prostate: Can We Shorten the MR Imaging Protocol?. , 2020, , 49-58.		0
1449	A Primer on Prostate MRI for theÂPracticing Urologist: Update on theÂCurrent Literature. , 2020, , 89-96.		0
1450	The Value of Incorporating Multiparametric MRI for Active Surveillance in Patients with Prostate Cancer. , 2020, , 79-87.		0
1451	MRT der Prostata und strukturierte Befundung mittels PIRADS. , 2020, , 185-193.		0
1452	Urologic Imaging. , 2020, , 201-256.		1
1453	Re; Singh S, Patil S, Tamhankar AS, Ahluwalia P, Gautam G. Low-risk prostate cancer in India: Is active surveillance a valid treatment option? Indian J Urol 2020;36:184-90. Indian Journal of Urology, 2020, 36, 332.	0.2	0
1454	Usefulness of Bi-Parametric Magnetic Resonance Imaging with b=1,800 s/mm2 Diffusion-Weighted Imaging for Diagnosing Clinically Significant Prostate Cancer. World Journal of Men?s Health, 2020, 38, 370.	1.7	1
1455	Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam. Croatian Medical Journal, 2020, 61, 49-54.	0.2	3
1457	Diagnostic Trials. , 2021, , 1-28.		1
1458	Correlation Between mpMRI Staging and Final Surgical Pathology in Prostate Cancer. Journal of Molecular Biology Research, 2020, 10, 6.	0.1	0
1460	Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels. Scientific Reports, 2021, 11, 21951.	1.6	4
1461	Noninferiority of Monoparametric MRI Versus Multiparametric MRI for the Detection of Prostate Cancer. Investigative Radiology, 2021, Publish Ahead of Print, .	3.5	3
1462	Selective identification and localization of indolent and aggressive prostate cancers via CorrSigNIA: an MRI-pathology correlation and deep learning framework. Medical Image Analysis, 2022, 75, 102288.	7.0	25
1463	The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naÂ¯ve men according to PSA levels: AÂpropensity score matching analysis. Prostate International, 2022, 10, 45-49.	1.2	5

#	ARTICLE	IF	CITATIONS
1464	Outcome of 5-year follow-up in men with negative findings on initial biparametric MRI. Heliyon, 2021, 7, e08325.	1.4	4
1465	Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test. JAMA Network Open, 2021, 4, e2132388.	2.8	14
1466	The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers. Life, 2021, 11, 1172.	1.1	1
1467	Ultrasound for Prostate Biopsy. , 2021, , 199-212.		0
1468	Characterization of B0-field fluctuations in prostate MRI. Physics in Medicine and Biology, 2020, 65, 21NT01.	1.6	1
1469	Focal Salvage Therapy for Prostate Cancer Recurrence After Primary Radiotherapy. , 2021, , 161-180.		0
1470	Prostate MRI: Practical guidelines for interpreting and reporting according to PI-RADS version 2.1. Radiologia, 2020, 62, 437-451.	0.3	0
1471	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, 270-275.	0.3	6
1472	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. Reviews in Urology, 2019, 21, 85-92.	0.9	3
1473	Prostate Cancer Academy 2019 Selected Summaries. Reviews in Urology, 2019, 21, 166-171.	0.9	0
1474	What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review. Acta Biomedica, 2019, 90, 423-426.	0.2	7
1475	The Role of Multiparametric MRI and MRI-targeted Biopsy in Detecting Clinically Significant Prostate Cancer in the Community Setting: A Retrospective Study. Reviews in Urology, 2020, 22, 57-66.	0.9	2
1476	Different clinical significance of ASAP/HGPIN pattern in systematic vs. MRI-US fusion guided prostate biopsy. Experimental and Therapeutic Medicine, 2020, 20, 195.	0.8	1
1477	Patients' experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. Ecancermedicalscience, 2020, 14, 1127.	0.6	0
1478	A Trend Toward Aggressive Prostate Cancer. Reviews in Urology, 2020, 22, 102-109.	0.9	2
1479	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72-78.	0.2	0
1480	MRI-targeted prostate biopsy: the next step forward!. Medicine and Pharmacy Reports, 2021, 94, 145-157.	0.2	0
1481	Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. American Journal of Translational Research (discontinued), 2021, 13, 3868-3889.	0.0	4

#	Article	IF	Citations
1482	Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology, 2022, 302, 368-377.	3.6	14
1483	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonanceâ€"Ultrasound Fusion Guided Biopsy Using Local Anesthesia. European Urology, 2022, 81, 110-117.	0.9	17
1484	Utilizing Preoperative Magnetic Resonance Imaging to Self-assess Enucleation Ratio in Holmium Laser Enucleation of the Prostate. Urology, 2022, 160, 176-181.	0.5	2
1485	Visualization and Quantification of the Extracellular Matrix in Prostate Cancer Using an Elastin Specific Molecular Probe. Biology, 2021, 10, 1217.	1.3	2
1486	Implications of a Novel Biopsy Downloading System on Prostate Cancer Detection Rate, Surveillance and Focal Therapy â€" A Prospective Study. Urology, 2021, , .	0.5	0
1487	How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. Acta Radiologica Open, 2021, 10, 205846012110607.	0.3	1
1488	Fast T2â€Weighted Imaging With Deep Learningâ€Based Reconstruction: Evaluation of Image Quality and Diagnostic Performance in Patients Undergoing Radical Prostatectomy. Journal of Magnetic Resonance Imaging, 2022, 55, 1735-1744.	1.9	17
1489	Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on 68ÂGa-PSMA-11 PET/CT in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1523-1534.	3.3	19
1490	PI-QUAL v.1: the first step towards good-quality prostate MRI. European Radiology, 2022, 32, 876-878.	2.3	10
1491	Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology, 2022, 8, 41.	3.4	25
1492	Are sex disparities in COVID-19 a predictable outcome of failing menâ€™s health provision?. Nature Reviews Urology, 2022, 19, 47-63.	1.9	15
1493	Evaluating the performance of clinical and radiological data in predicting prostate cancer in prostate imaging reporting and data system version 2.1 category 3 lesions of the peripheral and the transition zones. International Urology and Nephrology, 2022, 54, 263-271.	0.6	3
1494	Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e1-104.e7.	0.8	4
1495	Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review. British Journal of Radiology, 2022, 95, 20210633.	1.0	20
1496	The impact of multiparametric MRI features to identify the presence of prevalent cribriform pattern in the peripheral zone tumors. Radiologia Medica, 2022, 127, 174-182.	4.7	3
1497	The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. Frontiers in Artificial Intelligence, 2021, 4, 769582.	2.0	2
1498	Recent Advances in Systematic and Targeted Prostate Biopsies. Research and Reports in Urology, 2021, Volume 13, 799-809.	0.6	8
1499	Construction and Evaluation of Intelligent Medical Diagnosis Model Based on Integrated Deep Neural Network. Computational Intelligence and Neuroscience, 2021, 2021, 1-10.	1.1	8

#	Article	IF	Citations
1500	Towards targeted ultrasound-guided prostate biopsy by incorporating model and label uncertainty in cancer detection. International Journal of Computer Assisted Radiology and Surgery, 2022, 17, 121-128.	1.7	5
1501	Fusion US/MRI prostate biopsy using a computer aided diagnostic (CAD) system. Minerva Urology and Nephrology, 2021, 73, 616-624.	1.3	5
1502	Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer. Prostate, 2022, 82, 254-259.	1.2	3
1503	A Multicenter Single-Arm Objective Performance Criteria Trial to Determine the Efficacy and Safety of High-Frequency Irreversible Electroporation as Primary Treatment for Localized Prostate Cancer: A Study Protocol. Frontiers in Oncology, 2021, 11, 760003.	1.3	2
1504	Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer. British Journal of Radiology, 2022, 95, 20210840.	1.0	1
1505	A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer. BJU International, 2021, , .	1.3	1
1506	Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI. American Journal of Roentgenology, 2022, 218, 859-866.	1.0	7
1507	Comment on: "Fusion US/MRI prostate biopsy using a computer aided diagnostic (CAD) system". Minerva Urology and Nephrology, 2021, 73, 686-688.	1.3	1
1508	Usefulness of grayscale values measuring hypoechoic lesions for predicting prostate cancer: An experimental pilot study. Prostate International, 2022, 10, 28-33.	1.2	4
1509	The utility of prostate MRI within active surveillance: description of the evidence. World Journal of Urology, 2022, 40, 71-77.	1.2	6
1510	Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2821-2832.	3.3	15
1511	From Geometric Models to AI in Computer-Assisted Interventions. , 2022, , 3-9.		1
1512	Multimodal imaging of prostate cancer. PoĂ¥i, 2020, 9, 68-79.	0.1	0
1513	Initial Prostate Biopsy of Grade Group One. Urological Science, 2020, 31, 170-176.	0.2	0
1514	Role of MRI in Prostate Cancer Assessment. , 2021, , 81-94.		0
1517	Aging and Cancer: Concepts and Prospects. , 2021, , 215-220.		0
1518	Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis. BMJ Open, 2022, 12, e050376.	0.8	2
1519	Does the type of biopsy used for diagnosis impact subsequent treatment selection in prostate cancer patients?. Aging Male, 2022, 25, 23-28.	0.9	2

#	Article	IF	Citations
1520	Use of high-resolution micro-ultrasound to predict extraprostatic extension of prostate cancer prior to surgery: a prospective single-institutional study. World Journal of Urology, 2022, 40, 435-442.	1.2	16
1521	Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics. European Journal of Radiology, 2022, 147, 110145.	1.2	16
1522	Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data. European Urology Open Science, 2022, 36, 1-8.	0.2	13
1523	The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters, 2022, 526, 304-310.	3.2	16
1524	Papel y Evolución de la Resonancia Magnética Multiparamétrica en la Detección del Cáncer de Próstata. , 2020, 8, 1-6.		0
1525	Seeing the Complete Picture: Imaging in Prostate Cancer. European Medical Journal Urology, 0, , 19-21.	0.0	0
1526	Different clinical significance of ASAP/HGPIN pattern in systematic vs. MRI–US fusion guided prostate biopsy. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	2
1527	Patients' experience with MRI-guided in-bore biopsy versus TRUS-guided biopsy in prostate cancer: a pilot study. Ecancermedicalscience, 2020, 14, 1127.	0.6	0
1528	MRI-targeted prostate biopsy: the next step forward!. Medicine and Pharmacy Reports, 2021, 94, 145-157.	0.2	1
1529	A System for Co-Registration of High-Resolution Ultrasound, Magnetic Resonance Imaging, and Whole-Mount Pathology for Prostate Cancer. , 2021, 2021, 3890-3893.		0
1530	High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform. Advances in Urology, 2021, 2021, 1-7.	0.6	8
1531	Machine and Deep Learning Prediction Of Prostate Cancer Aggressiveness Using Multiparametric MRI. Frontiers in Oncology, 2021, 11, 802964.	1.3	27
1532	Machine Learning in Prostate MRI for Prostate Cancer: Current Status and Future Opportunities. Diagnostics, 2022, 12, 289.	1.3	28
1533	US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. Abdominal Radiology, 2022, 47, 1133.	1.0	0
1534	A single centre service evaluation of the pre-biopsy mpMRI pathway for prostate cancer diagnosis. Journal of Clinical Urology, 0, , 205141582110659.	0.1	0
1535	Pain control according to the periprostatic nerve block site in magnetic resonance imaging/transrectal targeted prostate biopsy. Scientific Reports, 2022, 12, 772.	1.6	1
1536	PCaGuard: A Software Platform to Support Optimal Management of Prostate Cancer. Applied Clinical Informatics, 2022, 13, 091-099.	0.8	8
1537	Predictors of disparity between targeted and in-zone systematic cores during transrectal MR/US-fusion prostate biopsy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 162.e1-162.e7.	0.8	1

#	ARTICLE	IF	CITATIONS
1538	Cost-Effectiveness of Prostate Cancer Detection in Biopsy-Naïve Men: Ultrasound Shear Wave Elastography vs. Multiparametric Diagnostic Magnetic Resonance Imaging. Healthcare (Switzerland), 2022, 10, 254.	1.0	1
1539	Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study. European Radiology, 2022, 32, 2330-2339.	2.3	11
1540	Diagnostic performance of fusion (US/MRI guided) prostate biopsy: propensity score matched comparison of elastic versus rigid fusion system. World Journal of Urology, 2022, 40, 991.	1.2	1
1541	MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data. British Journal of Cancer, 2022, 126, 502-513.	2.9	28
1542	Improving the diagnosis of prostate cancer by telomerase-positive circulating tumor cells: A prospective pilot study. EClinicalMedicine, 2022, 43, 101161.	3.2	13
1543	STHLM3-MRI study: Role of magnetic resonance imaging-targeted biopsy in prostate cancer screening. Indian Journal of Urology, 2022, 38, 71.	0.2	1
1544	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study. Diagnostics, 2022, 12, 231.	1.3	5
1545	Value of T_2 Mapping MRI for Prostate Cancer Detection and Classification. Journal of Magnetic Resonance Imaging, 2022, 56, 413-422.	1.9	8
1546	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. Clinical Genitourinary Cancer, 2022, 20, e339-e345.	0.9	6
1547	A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI. Prostate Cancer and Prostatic Diseases, 2022, 25, 727-734.	2.0	5
1548	Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline. Canadian Urological Association Journal, 2021, 16, 16-23.	0.3	7
1549	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. BJU International, 2022, 130, 193-199.	1.3	13
1550	Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data. Frontiers in Oncology, 2021, 11, 811866.	1.3	4
1551	A critical analysis of deficiencies in the quality of information contained in prostate multiparametric MRI requests and reports. Irish Journal of Medical Science, 2022, , 1.	0.8	1
1552	Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial. European Urology, 2022, 81, 543-544.	0.9	0
1553	Detection rates of urogenital cancers and benign pathology in men presenting with hematospermia. Current Urology, 2022, Publish Ahead of Print, .	0.4	0
1554	MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patient–physician decision tool. Journal of Clinical Urology, 0, , 205141582110659.	0.1	4
1555	The Emerging Role of Next-Generation Imaging in Prostate Cancer. Current Oncology Reports, 2022, 24, 33-42.	1.8	7

#	Article	IF	Citations
1556	Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance. Future Oncology, 2022, , .	1.1	0
1557	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. Cancers, 2022, 14, 781.	1.7	8
1558	Predicting the diagnosis of prostate cancer with a scoring system based on novel biomarkers. BMC Urology, 2022, 22, 13.	0.6	4
1559	ProstAttention-Net: A deep attention model for prostate cancer segmentation by aggressiveness in MRI scans. Medical Image Analysis, 2022, 77, 102347.	7.0	44
1560	Magnetic resonance imaging radiomics in prostate cancer radiology: what is currently known?. Digital Diagnostics, 2022, 2, 441-452.	0.3	3
1561	Detection of ISUP â‰¥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study). BMJ Open, 2022, 12, e051274.	0.8	3
1562	A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided biopsy in the detection of prOstate cancer. PLoS ONE, 2022, 17, e0263345.	1.1	2
1563	Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Medicine, 2022, 20, 54.	2.3	42
1564	The impact of healthâ€policyâ€driven subsidisation of prostate magnetic resonance imaging on transperineal prostate biopsy practice and outcomes. BJUI Compass, 0, , .	0.7	2
1565	Impact of Surgeonâ€™s Experience in Rigid Versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores. Cancers, 2022, 14, 886.	1.7	3
1566	Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Research, 2022, 12, 10.	1.1	14
1567	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. British Journal of Cancer, 2022, 126, 1004-1009.	2.9	2
1568	Deep Learning Reconstruction Enables Highly Accelerated Biparametric <scp>MR</scp> Imaging of the Prostate. Journal of Magnetic Resonance Imaging, 2022, 56, 184-195.	1.9	23
1570	Combined mpMRI/US fusion targeted and concurrent standard biopsies in the detection of prostate cancer: a retrospective study. American Journal of Translational Research (discontinued), 2021, 13, 12107-12113.	0.0	0
1571	False-positive mpMRI and true-negative 68Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report. Translational Andrology and Urology, 2022, 11, 561-566.	0.6	2
1572	Predictors of clinically significant prostate cancer in biopsy-naÃ¯ve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator. Therapeutic Advances in Urology, 2022, 14, 175628722210885.	0.9	3
1573	PET imaging of prostate cancer. , 2022, , .		0
1574	Combination of <scp>MRI</scp> prostate and <scp>18Fâ€DCFPyl PSMA PET</scp>/<scp>CT</scp> detects all clinically significant prostate cancers in treatmentâ€naive patients: An international multicentre retrospective study. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 927-935.	0.9	5

#	Article	IF	Citations
1575	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. PLoS ONE, 2022, 17, e0259672.	1.1	2
1576	Deep learning for fully automatic detection, segmentation, and Gleason grade estimation of prostate cancer in multiparametric magnetic resonance images. Scientific Reports, 2022, 12, 2975.	1.6	34
1577	Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 429-431.	2.0	5
1578	MR Imaging in Real Time Guiding of Therapies in Prostate Cancer. Life, 2022, 12, 302.	1.1	3
1579	TRUS Biopsy vs Transperineal Biopsy for Suspicion of Prostate Cancer. Urology, 2022, 164, 18-20.	0.5	3
1580	Initial experience and cancer detection rates of office-based transperineal magnetic resonance imaging-ultrasound fusion prostate biopsy under local anesthesia. Canadian Urological Association Journal, 2022, 16, .	0.3	1
1581	The role of MRI in prostate cancer: current and future directions. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 503-521.	1.1	7
1582	<scp>Prostateâ€specific</scp> antigen testing testing in the modern era. ANZ Journal of Surgery, 2022, 92, 330-332.	0.3	0
1583	Bi-parametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors. Acta Radiologica Open, 2022, 11, 205846012210855.	0.3	2
1584	Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications. , 2022, 54, 12-16.		0
1585	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. European Urology, 2022, 81, 598-605.	0.9	9
1586	Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction. Cancer Medicine, 2022, , .	1.3	1
1587	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	1.2	8
1588	The Barcelona Predictive Model of Clinically Significant Prostate Cancer. Cancers, 2022, 14, 1589.	1.7	13
1589	Time-Dependent Diffusion MRI for Quantitative Microstructural Mapping of Prostate Cancer. Radiology, 2022, 303, 578-587.	3.6	15
1590	Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. Lancet Oncology, The, 2022, 23, 428-438.	5.1	25
1591	Current Value of Biparametric Prostate MRI with Machine-Learning or Deep-Learning in the Detection, Grading, and Characterization of Prostate Cancer: A Systematic Review. Diagnostics, 2022, 12, 799.	1.3	16
1592	Prostate cancer treatment costs increase more rapidly than for any other cancerâ€"how to reverse the trend?. EPMA Journal, 2022, 13, 1-7.	3.3	26

#	ARTICLE	IF	CITATIONS
1593	Progress in prostate cancer prevention. European Journal of Cancer Prevention, 2022, 31, 554-557.	0.6	5
1594	The role of novel imaging in prostate cancer focal therapy: treatment and follow-up. Current Opinion in Urology, 2022, 32, 231-238.	0.9	1
1595	The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis. Frontiers in Oncology, 2022, 12, 843735.	1.3	45
1596	Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?. Archivio Italiano Di Urologia Andrologia, 2022, 94, 32-36.	0.4	1
1597	Predictors of Unfavorable Pathology in Patients with Incidental (pT1a–T1b) Prostate Cancer. European Urology Focus, 2022, , .	1.6	3
1598	Early detection of cancer. Science, 2022, 375, eaay9040.	6.0	291
1599	Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?. European Urology, 2022, 82, 1-2.	0.9	7
1600	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science, 2022, 38, 32-39.	0.2	2
1601	Integrating zonal priors and pathomic MRI biomarkers for improved aggressive prostate cancer detection on MRI. , 2022, , .		1
1602	Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study. Cancer Management and Research, 2022, Volume 14, 1395-1407.	0.9	5
1603	Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial. Cancers, 2022, 14, 1888.	1.7	12
1604	Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2774-2785.	3.3	5
1605	Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Frontiers in Oncology, 2022, 12, 864111.	1.3	4
1606	MRI/US fusion transperineal versus transrectal biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the Middle East. , 2022, 48, 98-105.		3
1607	Alternatives for MRI in Prostate Cancer Diagnostics—Review of Current Ultrasound-Based Techniques. Cancers, 2022, 14, 1859.	1.7	6
1608	Time point-independent tumor positivity of 68Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer. Annals of Nuclear Medicine, 2022, , 1.	1.2	0
1610	Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study. Frontiers in Oncology, 2022, 12, 785684.	1.3	1
1611	Real-Time MRI-Guided Prostate Interventions. Cancers, 2022, 14, 1860.	1.7	6

#	Article	IF	Citations
1612	Abbreviated MR Protocols in Prostate MRI. Life, 2022, 12, 552.	1.1	0
1613	Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology. Radiation Oncology, 2022, 17, 65.	1.2	20
1614	Reply to Wei Qiang's et al. Letter to the Editor re: Impact of mpMRI–targeted biopsy on intraoperative nerve–sparing (NeuroSAFE) during robot–assisted laparoscopic radical prostatectomy. Prostate, 2022, 82, 943-945.	1.2	0
1615	PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone. Frontiers in Oncology, 2022, 12, 861928.	1.3	3
1616	Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. BMJ Open, 2022, 12, e059847.	0.8	0
1617	Association of prostate zonal volume with location and aggressiveness of clinically significant prostate cancer: A multiparametric MRI study according to PI-RADS version 2.1. European Journal of Radiology, 2022, 150, 110268.	1.2	2
1618	Urological cancers. , 2021, , 168-192.		0
1619	Deep Learning Enables Prostate MRI Segmentation: A Large Cohort Evaluation With Inter-Rater Variability Analysis. Frontiers in Oncology, 2021, 11, 801876.	1.3	6
1620	Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions. Life, 2021, 11, 1432.	1.1	3
1621	The best prostate biopsy sampling system—fusion and systematic biopsy: A single center experience. Urologia, 2021, , 039156032110371.	0.3	0
1622	Value of Magnetic Resonance Imaging Compared With Urine-Based Markers in the Detection of Prostate Cancer. Value in Health, 2021, , .	0.1	0
1623	Classification of Clinically Significant Prostate Cancer on Multi-Parametric MRI: A Validation Study Comparing Deep Learning and Radiomics. Cancers, 2022, 14, 12.	1.7	21
1624	Predicting the Performance of Concurrent Systematic Random Biopsies during Image Fusion Targeted Sampling of Multi-Parametric MRI Detected Prostate Cancer. A Prospective Study (PRESET Study). Cancers, 2022, 14, 1.	1.7	26
1625	Prostate cancer detection rate in men undergoing transperineal template–guided saturation and targeted prostate biopsy. Prostate, 2022, 82, 388-396.	1.2	15
1626	Histopathological Analysis of False-positive Lesions in mpMRI/TRUS Fusion Prostate Biopsy. In Vivo, 2022, 36, 496-500.	0.6	4
1627	Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging–based Detection of Prostate Cancer. European Urology Focus, 2022, 8, 1187-1191.	1.6	3
1628	Artificial Intelligence for Automated Cancer Detection on Prostate MRI: Opportunities and Ongoing Challenges, From the *AJR* Special Series on AI Applications. American Journal of Roentgenology, 2022, 219, 188-194.	1.0	11
1629	Management of Osteoblastoma and Giant Osteoid Osteoma with Percutaneous Thermoablation Techniques. Journal of Clinical Medicine, 2021, 10, 5717.	1.0	8

#	ARTICLE	IF	CITATIONS
1630	The urologist's learning curve of "in-bore" magnetic resonance-guided prostate biopsy. BMC Urology, 2021, 21, 169.	0.6	2
1631	Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. Cancer Reports, 2022, 5, e1492.	0.6	3
1632	Current state of prostate-specific membrane antigen PET/CT imaging–targeted biopsy techniques for detection of clinically significant prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 776-780.	0.9	10
1633	AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning. Cancers, 2021, 13, 6138.	1.7	10
1634	Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model. European Urology Focus, 2022, 8, 1204-1210.	1.6	2
1635	Cognitive magnetic resonance imaging-ultrasound fusion transperineal targeted biopsy combined with randomized biopsy in detection of prostate cancer. World Journal of Clinical Cases, 2021, 9, 11183-11192.	0.3	0
1636	Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies. International Journal of Molecular Sciences, 2021, 22, 13605.	1.8	3
1637	Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e052277.	0.8	1
1638	MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern. Prostate, 2022, 82, 452-463.	1.2	7
1639	Predicting the Grade of Prostate Cancer Based on a Biparametric MRI Radiomics Signature. Contrast Media and Molecular Imaging, 2021, 2021, 1-10.	0.4	10
1640	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology, 2022, 164, 184-190.	0.5	8
1642	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq1 1 0.784314 rgBT /Overlo		
1643	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 187-198.	2.0	7
1644	A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data. Cancers, 2022, 14, 1995.	1.7	5
1645	Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers. Frontiers in Chemistry, 2022, 10, 830133.	1.8	4
1646	Prostate MRI: Is Endorectal Coil Necessary?—A Review. Life, 2022, 12, 569.	1.1	5
1647	Early experience in avoiding biopsies for biopsy-naïve men with clinical suspicion of prostate cancer but non-suspicious biparametric magnetic resonance imaging results and prostate-specific antigen density < 0.15 ng/mL^2: A 2-year follow-up study. Acta Radiologica Open, 2022, 11, 205846012210948.	0.3	2
1648	Can multi-parametric magnetic resonance imaging and prostate-specific antigen density accurately stratify patients prior to prostate biopsy?. Journal of Clinical Urology, 0, , 205141582210848.	0.1	1

#	Article	IF	Citations
1649	Recent advances of multi-modal ultrasound in image-guided prostate-targeted biopsy. Journal of Interventional Medicine, 2022, , .	0.2	0
1652	The added influence of genomics and postâ€MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance. Prostate, 2022, , .	1.2	0
1653	Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate. Scientific Reports, 2022, 12, 6746.	1.6	4
1654	Pseudoprospective Paraclinical Interaction of Radiology Residents With a Deep Learning System for Prostate Cancer Detection. Investigative Radiology, 2022, Publish Ahead of Print, .	3.5	6
1655	PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE.. Acta Clinica Croatica, 2019, 58, 7-11.	0.1	0
1656	Focal therapy for localized prostate cancer â€" Current status. Indian Journal of Urology, 2022, 38, 7.	0.2	0
1657	Safety and feasibility of freehand transperineal prostate biopsy under local anesthesia: Our initial experience. Indian Journal of Urology, 2022, 38, 34.	0.2	0
1658	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72.	0.2	1
1661	Race-insurance disparities in prostate patients' magnetic resonance imaging biopsies and their subsequent cancer care: a New York State cohort study.. American Journal of Clinical and Experimental Urology, 2021, 9, 435-455.	0.4	0
1662	Paradigm Shift in Prostate Cancer Diagnosis: Pre-Biopsy Prostate Magnetic Resonance Imaging and Targeted Biopsy. Korean Journal of Radiology, 2022, 23, 625.	1.5	6
1663	Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. BJUI Compass, 2022, 3, 344-353.	0.7	4
1664	Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer. Prostate International, 2022, 10, 152-157.	1.2	3
1665	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10 years of practice in a single institution. World Journal of Urology, 2022, 40, 1661-1668.	1.2	4
1666	Evaluating the diagnostic role of inâ€bore magnetic resonance imaging guided prostate biopsy: a singleâ€centre study. ANZ Journal of Surgery, 2022, , .	0.3	0
1667	Inter-Reader Variability Using PI-RADS v2 Versus PI-RADS v2.1: MostÂNew Disagreement Stems from Scores 1 and 2. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2022, 194, 852-861.	0.7	3
1668	Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer and Prostatic Diseases, 2023, 26, 353-359.	2.0	8
1669	Ex Vivo Fluorescence Confocal Microscopy (FCM) of Prostate Biopsies Rethought: Opportunities of Intraoperative Examinations of MRI-Guided Targeted Biopsies in Routine Diagnostics. Diagnostics, 2022, 12, 1146.	1.3	1
1670	Optimized grade group for reporting prostate cancer grade in systematic and MRIâ€targeted biopsies. Prostate, 2022, 82, 1125-1132.	1.2	3

#	ARTICLE	IF	CITATIONS
1671	Tumour microenvironment and focal therapy for prostate cancer. Current Opinion in Urology, 2022, 32, 248-253.	0.9	1
1672	Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis. Clinical Oncology, 2022, 34, 630-641.	0.6	4
1673	Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores. World Journal of Urology, 2022, , .	1.2	1
1674	Association of Patient and Imaging-Related Factors with False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions. Urology, 2022, , .	0.5	2
1675	Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. Prostate, 2022, 82, 1170-1175.	1.2	5
1676	Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems. Clinical Radiology, 2022, 77, 541-547.	0.5	1
1677	Biopsy-Integrated 3D Magnetic Resonance Imaging Modeling of Prostate Cancer and Its Application for Gleason Grade and Tumor Laterality Assessment. Archives of Pathology and Laboratory Medicine, 2022, , .	1.2	0
1678	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	2.3	8
1679	Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena. Journal of Hematology and Oncology, 2022, 15, 48.	6.9	6
1680	Prostate MRI Qualification: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 691-702.	1.0	16
1681	Exploring the value of using patient-oriented MRI reports in clinical practice â€" a pilot study. Supportive Care in Cancer, 2022, 30, 6857-6876.	1.0	2
1682	Assessment of elastographic Q-analysis score combined with Prostate Imaging-Reporting and Data System (PI-RADS) based on transrectal ultrasound (TRUS)/multi-parameter magnetic resonance imaging (MP-MRI) fusion-guided biopsy in differentiating benign and malignant prostate. Quantitative Imaging in Medicine and Surgery, 2022, 12, 3569-3579.	1.1	1
1683	Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology. Scientific Reports, 2022, 12, 6964.	1.6	2
1685	Office-Based, Single-Sided, Low-Field MRI-Guided Prostate Biopsy. Cureus, 2022, , .	0.2	1
1686	Integration of magnetic resonance imaging into prostate cancer nomograms. Therapeutic Advances in Urology, 2022, 14, 175628722210963.	0.9	0
1687	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
1688	Prostat Kanserinin SaptanmasÄ± ve Derecelendirilmesinde Voksel Ä°Ã§i TutarsÄ±z Hareket (IVIM) Parametrelerinin TanÄ±sal DeÄŸeri. Sakarya Medical Journal, 0, , .	0.1	0
1689	Clinical Utility of Combining Prostate Health Index and PI-RADS Version 2 to Improve Detection of Clinically Significant Prostate Cancer. The Korean Journal of Urological Oncology, 2022, 20, 107-114.	0.1	0

#	ARTICLE	IF	CITATIONS
1690	Comparison of Systematic, Targeted and Combined Prostate Biopsy: Our Clinical Outcomes. Ãœroonkoloji BÃ¼lteni, 2022, 21, 40-44.	0.1	0
1691	A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 379.e1-379.e8.	0.8	3
1692	Fusion versus cognitive MRI-guided prostate biopsies in diagnosing clinically significant prostate cancer. Journal of Clinical Urology, 0, , 205141582210850.	0.1	0
1693	Prostate Cancer Imaging: What We Already Know and What Is on the Horizon. Radiographics, 2022, 42, E123-E124.	1.4	1
1694	Bridging the gap between prostate radiology and pathology through machine learning. Medical Physics, 2022, 49, 5160-5181.	1.6	10
1695	Diagnosing prostate cancer in asymptomatic patients. BMJ, The, 0, , e071076.	3.0	6
1696	Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors. Diagnostics, 2022, 12, 1300.	1.3	9
1697	Role of molecular imaging in the detection of localized prostate cancer. Therapeutic Advances in Urology, 2022, 14, 175628722211050.	0.9	1
1698	The Roles of Cloud-Based Systems on the Cancer-Related Studies: A Systematic Literature Review. IEEE Access, 2022, 10, 64126-64145.	2.6	3
1699	Minimally Invasive Procedures in the Diagnosis and Treatment of Localized Prostate Cancer: an Interventional Radiologistâ€™s Perspective. Current Oncology Reports, 2022, 24, 1433-1441.	1.8	1
1700	Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer. Radiographics, 0, , .	1.4	2
1701	Read-out Segmented Echo Planar Imaging with Two-Dimensional Navigator Correction (RESOLVE): An Alternative Sequence to Improve Image Quality on Diffusion-Weighted Imaging of Prostate. British Journal of Radiology, 2022, 95, .	1.0	6
1703	Combination of biparametric magnetic resonance imaging with prostateâ€specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and longâ€term followâ€up results. International Journal of Urology, 0, , .	0.5	0
1704	Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement. Abdominal Radiology, 2022, 47, 2917-2927.	1.0	6
1705	The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3. Frontiers in Oncology, 0, 12, .	1.3	0
1706	A prostate biopsy risk calculator based on <scp>MRI</scp>: development and comparison of the Prospective Loyola University multiparametric MRI <scp>(PLUM)</scp> and Prostate Biopsy Collaborative Group (PBCG) <scp>risk calculators</scp>. BJU International, 2023, 131, 227-235.	1.3	4
1708	Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomographyâ€"targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2022, 5, 390-400.	2.6	23
1709	Selecting patients for magnetic resonance imaging cognitive versus ultrasound fusion biopsy of the prostate: A withinâ€patient comparison. BJUI Compass, 2022, 3, 443-449.	0.7	2

#	Article	IF	Citations
1710	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. British Journal of Cancer, 2022, 127, 1394-1402.	2.9	25
1711	A Prospective Pilot Study Investigating Performance of 18F-Fluciclovine PET Imaging for Detection of Prostate Cancer 2 Years Following Primary Partial Gland Cryoablation. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	2
1712	Schema and cancer detection rates for transperineal prostate biopsy templates: a review. Therapeutic Advances in Urology, 2022, 14, 175628722211050.	0.9	3
1713	Image-guided <i>in-Vivo</i> Needle-Based Confocal Laser Endomicroscopy in the Prostate: Safety and Feasibility Study in 2 Patients. Technology in Cancer Research and Treatment, 2022, 21, 153303382210931.	0.8	0
1715	Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions. Diagnostics, 2022, 12, 1565.	1.3	14
1716	Pooled outcomes of performing freehand transperineal prostate biopsy with the PrecisionPoint Transperineal Access System. BJUI Compass, 2022, 3, 434-442.	0.7	2
1717	Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters. Minerva Urology and Nephrology, 2023, 75, .	1.3	4
1718	Better To Rule In or Rule Out Significant Prostate Cancer? The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography to Magnetic Resonance Imaging Diagnostic Pathways for Prostate Cancer. European Urology Oncology, 2022, 5, 401-402.	2.6	1
1719	Application of Multiple Ultrasonic Techniques in the Diagnosis of Prostate Cancer. Frontiers in Oncology, 0, 12, .	1.3	1
1720	How MRI is changing prostate cancer management: a focus on early detection and active surveillance. Progres En Urologie, 2022, 32, 6S19-6S25.	0.3	2
1721	Pushing Fluids: A Case for Liquid Biomarkers Before Imaging in Preâ€"Prostate Biopsy Decision-making. European Urology Focus, 2022, , .	1.6	1
1722	Improved Visualization of Prostate Cancer Using Multichannel Computed Diffusion Images: Combining ADC and DWI. Diagnostics, 2022, 12, 1592.	1.3	0
1723	Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes. Prostate International, 2022, 10, 188-193.	1.2	2
1724	Prospective analysis of pain expectancy and experience during MR-fusion prostate biopsy: does reality match patientsâ€™ expectancy?. World Journal of Urology, 2022, 40, 2239-2244.	1.2	8
1725	68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement. European Journal of Hybrid Imaging, 2022, 6, .	0.6	5
1726	Making an art into a science: a mathematical â€œLikert toolâ€•can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer. Acta Radiologica, 2023, 64, 1245-1254.	0.5	1
1727	Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. International Urology and Nephrology, 2022, 54, 2521-2528.	0.6	3
1728	Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models. Diagnostics, 2022, 12, 1631.	1.3	0

#	ARTICLE	IF	CITATIONS
1729	Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation. JAMA Surgery, 2022, 157, 693.	2.2	16
1730	Tracking Prostate Carcinogenesis over Time through Urine Proteome Profiling in an Animal Model: An Exploratory Approach. International Journal of Molecular Sciences, 2022, 23, 7560.	1.8	0
1731	Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 408.e9-408.e18.	0.8	3
1732	Prostate Cancer Diagnosis: Biopsy Approaches. , 0, , 141-168.		4
1733	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open, 2022, 7, 100518.	2.0	10
1734	MRI/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy â€" Effectiveness and accuracy of a combined approach in daily clinical practice. European Journal of Radiology, 2022, 154, 110432.	1.2	5
1735	Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population. European Journal of Radiology, 2022, 154, 110431.	1.2	18
1736	A prospective study of cancer detection rates following early repeat imaging and biopsy of PI-RADS 4 and 5 regions of interest exhibiting no clinically significant prostate cancer on prior biopsy. Canadian Urological Association Journal, 2022, 16, .	0.3	2
1737	Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. Radiology, 2022, 305, 390-398.	3.6	13
1738	Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle trackingâ€"what is the additional value?. International Urology and Nephrology, 2022, 54, 2477-2483.	0.6	3
1739	Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer with Multiparametric versus Hybrid Multidimensional MRI. Radiology, 2022, 305, 399-407.	3.6	8
1740	Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure. BMJ Surgery, Interventions, and Health Technologies, 2022, 4, e000122.	0.6	0
1741	Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 587-608.	1.1	3
1742	Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 3497.	1.7	9
1743	A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis. World Journal of Urology, 2023, 41, 653-662.	1.2	9
1744	Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between <scp>MRI</scp> â€Based Radiomics Model and <scp>PIâ€RADS</scp> Category. Journal of Magnetic Resonance Imaging, 0, , .	1.9	4
1745	A concurrent, deep learningâ€"based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists. European Radiology, 2023, 33, 64-76.	2.3	12
1746	Training deep neural networks with noisy clinical labels: toward accurate detection of prostate cancer in US data. International Journal of Computer Assisted Radiology and Surgery, 2022, 17, 1697-1705.	1.7	3

#	Article	IF	Citations
1747	Kognitif Füzyon Prostat Biyopsisinde Deneyim Kanser Tespit Oranını Etkiliyor Mu? İlk ve Son 60 Vakanın Karşılaştırılması. Abant İzzet Baysal Tıp Fakültesi Dergisi, 0, , .	0.0	0
1748	Diagnosis of clinically significant prostate cancer after negative multiparametric magnetic resonance imaging. Central European Journal of Urology, 2022, , .	0.2	2
1749	Diagnostic Trials. , 2022, , 1171-1197.		0
1750	The role of PSA density in the MRI pathway for prostate cancer diagnostics. Prostate Cancer and Prostatic Diseases, 2023, 26, 437-438.	2.0	2
1751	Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2022, , .	0.9	0
1752	Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
1753	Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort. Cancers, 2022, 14, 3558.	1.7	2
1754	Tasks for artificial intelligence in prostate MRI. European Radiology Experimental, 2022, 6, .	1.7	13
1755	Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy. World Journal of Urology, 2022, 40, 2431-2438.	1.2	7
1756	Learning curve for magnetic resonance imaging/ultrasound fusion prostate biopsy in detecting prostate cancer using cumulative sum analysis. Current Urology, 2023, 17, 159-164.	0.4	2
1757	Canadian Association of Radiologists Prostate MRI White Paper. Canadian Association of Radiologists Journal, 2022, 73, 626-638.	1.1	1
1758	Automatic segmentation of prostate MRI based on 3D pyramid pooling Unet. Medical Physics, 2023, 50, 906-921.	1.6	4
1759	Liquid Markers Should Precede Imaging in Pre–prostate Biopsy Decision-making: Con. European Urology Focus, 2022, 8, 895-896.	1.6	0
1760	Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot. Cancer Letters, 2022, 548, 215883.	3.2	2
1761	Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach. Applied Health Economics and Health Policy, 2022, 20, 867-880.	1.0	3
1762	Combination of PI-RADS score and mRNA urine test—A novel scoring system for improved detection of prostate cancer. PLoS ONE, 2022, 17, e0271981.	1.1	6
1763	Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy. Scientific Reports, 2022, 12, .	1.6	7
1764	The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics. British Journal of Radiology, 2022, 95, .	1.0	5

#	Article	IF	Citations
1765	Frozen section utilization to omit systematic biopsy in diagnosing high risk prostate cancer. Scientific Reports, 2022, 12, .	1.6	0
1766	Performance of multiparametric prostate magnetic resonance imaging validated by targeted and systematic transperineal biopsies. BJUI Compass, 0, , .	0.7	0
1767	Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 451.e9-451.e14.	0.8	1
1768	Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study. Radiology, 2022, 305, 623-630.	3.6	8
1769	An Magnetic Resonance Imagingâ€"directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: â€œLess Is Moreâ€. European Urology Open Science, 2022, 43, 68-73.	0.2	4
1770	PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer. BMJ Open, 2022, 12, e061815.	0.8	3
1771	Biparametric prostate MRI: impact of a deep learning-based software and of quantitative ADC values on the inter-reader agreement of experienced and inexperienced readers. Radiologia Medica, 2022, 127, 1245-1253.	4.7	13
1772	Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening. European Urology Open Science, 2022, 44, 69-75.	0.2	3
1773	Impact of dynamic contrast-enhanced MRI in 1.5ÂT versus 3ÂT MRI for clinically significant prostate cancer detection. European Journal of Radiology, 2022, 156, 110520.	1.2	4
1774	Prostate Cancer Screening and Biopsy. , 2022, , 101-115.		0
1775	Strategising Template-Guided Needle Placement forÂMR-targeted Prostate Biopsy. Lecture Notes in Computer Science, 2022, , 149-158.	1.0	1
1776	Towards Confident Detection ofÂProstate Cancer Using High Resolution Micro-ultrasound. Lecture Notes in Computer Science, 2022, , 411-420.	1.0	3
1777	Intraoperative Evaluation and Management of High-Risk Prostate Cancer during Robot-Assisted Radical Prostatectomy. , 2022, , 241-249.		0
1778	The Impact ofÂUsing Voxel-Level Segmentation Metrics onÂEvaluating Multifocal Prostate Cancer Localisation. Lecture Notes in Computer Science, 2022, , 128-138.	1.0	2
1779	Research Progress of Artificial Intelligence in Early Diagnosis of Prostate Cancer. Advances in Clinical Medicine, 2022, 12, 8035-8042.	0.0	0
1780	The effectiveness of laboratory and radiological diagnosis of localized and locally advanced prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2022, 11, 20.	0.0	0
1781	Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial. Indian Journal of Urology, 2022, 38, 321.	0.2	0
1782	Assessment of the Utility of Multiparametric Magnetic Resonance Imaging for Initial Detection of Prostate Cancer. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1840-1845.	0.1	1

#	Article	IF	Citations
1783	Magnetic resonance elastography of malignant tumors. Frontiers in Physics, 0, 10, .	1.0	3
1784	An independent practice validation of the Prostate Imaging Reporting and Data System version 2 scoring system and the introduction of PDP (prostate-specific antigen density Ã— PI-RADSv2) score to assist with further risk assessment. Current Urology, 0, Publish Ahead of Print, .	0.4	1
1786	Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions. Cancers, 2022, 14, 4174.	1.7	4
1788	Simulation and Analysis of Ring Shape Metalâ€"Insulator-Metal Plasmonic Biosensors for the Detection of Prostate-Specific Antigen (PSA). Plasmonics, 2022, 17, 2197-2204.	1.8	3
1789	The rapid assessment for prostate imaging and diagnosis (<scp>RAPID</scp>) prostate cancer diagnostic pathway. BJU International, 2023, 131, 461-470.	1.3	7
1790	Fully automated detection and localization of clinically significant prostate cancer on MR images using a cascaded convolutional neural network. Frontiers in Oncology, 0, 12, .	1.3	3
1791	Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial. International Journal of Radiation Oncology Biology Physics, 2023, 115, 305-316.	0.4	15
1792	Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer. Clinical Imaging, 2022, , .	0.8	0
1793	Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial. European Urology Oncology, 2023, 6, 49-55.	2.6	5
1794	Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study. Frontiers in Oncology, 0, 12, .	1.3	1
1795	Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer. PET Clinics, 2022, , .	1.5	1
1796	Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?. Prostate Cancer and Prostatic Diseases, 2023, 26, 47-49.	2.0	4
1797	Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study. PLoS ONE, 2022, 17, e0274014.	1.1	1
1798	Can a prostate biopsy be safely deferred on PI-RADS 1,2 or 3 lesions seen on pre-biopsy mp-MRI?. Arab Journal of Urology Arab Association of Urology, 2023, 21, 10-17.	0.7	1
1800	Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nature Reviews Urology, 2023, 20, 9-22.	1.9	17
1801	Inter-reader agreement of the prostate imaging reporting and data system version v2.1 for detection of prostate cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	8
1802	MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection. Urology, 2023, 171, 172-178.	0.5	4
1803	Comparison of single-shot EPI and multi-shot EPI in prostate DWI at 3.0ÂT. Scientific Reports, 2022, 12, .	1.6	9

#	ARTICLE	IF	CITATIONS
1804	Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer. EJNMMI Research, 2022, 12, .	1.1	6
1805	Granulomatous Prostatitis, the Great Mimicker of Prostate Cancer: Can Multiparametric MRI Features Help in This Challenging Differential Diagnosis?. Diagnostics, 2022, 12, 2302.	1.3	5
1806	A better way to biopsy in prostate cancer. Nature, 2022, 609, S34-S35.	13.7	2
1807	Combined MRI and PSA Strategy Improves Biopsy Decisions Compared with PSA Only: Longitudinal Observations of a Cohort of Patients with a PSA Level Less Than 20 ng/mL. Academic Radiology, 2022, , .	1.3	0
1809	The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer. Cancer Imaging, 2022, 22, .	1.2	3
1810	Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI. Prostate, 2023, 83, 56-63.	1.2	1
1811	Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review. Cancers, 2022, 14, 4747.	1.7	8
1812	Comparative Performance of Deep Learning and Radiologists for the Diagnosis and Localization of Clinically Significant Prostate Cancer at MRI: A Systematic Review. Life, 2022, 12, 1490.	1.1	4
1813	Value of magnetic resonance imaging/ultrasound fusion prostate biopsy to select patients for focal therapy. World Journal of Urology, 2022, 40, 2689-2694.	1.2	1
1814	A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy. BJU International, 2023, 131, 408-423.	1.3	2
1815	The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP). Current Oncology, 2022, 29, 6373-6382.	0.9	0
1816	Cost-efficient analysis of a portable low field magnetic resonance imaging system for prostate cancer diagnosis. Frontiers in Urology, 0, 2, .	0.2	0
1817	Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naÃ¯ve and previous negative biopsy patients. Frontiers in Surgery, 0, 9, .	0.6	3
1818	Improving Prostate Cancer Detection With MRI: A Multi-Reader, Multi-Case Study Using Computer-Aided Detection (CAD). Academic Radiology, 2023, 30, 1340-1349.	1.3	1
1819	Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. Pharmacoeconomics, 2022, 40, 1207-1220.	1.7	3
1820	Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy. Urology, 2023, 171, 164-171.	0.5	3
1821	Evaluating the Downstream Revenues of a Self-Pay Bi-Parametric Prostate MRI Program. Urology, 2022, , .	0.5	0
1822	Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest. World Journal of Urology, 0, , .	1.2	0

#	ARTICLE	IF	CITATIONS
1823	Modern paradigms for prostate cancer detection and management. Medical Journal of Australia, 2022, 217, 424-433.	0.8	13
1824	Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still Out. European Urology Open Science, 2022, 45, 50-51.	0.2	1
1825	Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy. Asian Journal of Andrology, 2022, .	0.8	0
1826	The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations. Investigative and Clinical Urology, 2022, 63, 631.	1.0	3
1827	A review of artificial intelligence in prostate cancer detection on imaging. Therapeutic Advances in Urology, 2022, 14, 175628722211287.	0.9	12
1828	Diagnosis and Pathologic Reporting of Prostate Cancer in the Era of MRI-Targeted Prostate Biopsy. Surgical Pathology Clinics, 2022, 15, 609-616.	0.7	0
1829	Integrins are enriched on aberrantly fucosylated tumourâ€derived urinary extracellular vesicles. , 2022, 1, .		3
1830	Radiologistsâ€™ contribution to variation in detecting clinically significant prostate cancer in men with prostate MRI. Journal of the American College of Radiology, 2022, , .	0.9	1
1831	MRI-based analysis of different clinically significant prostate cancer detection rate of prostate imaging reporting and data system score 4 in the peripheral zone. Abdominal Radiology, 0, , .	1.0	0
1832	Effect of magnetic resonance imaging pre-processing on the performance of model-based prostate tumor probability mapping. Physics in Medicine and Biology, 0, , .	1.6	0
1833	Performance of Artificial Intelligenceâ€Aided Diagnosis System for Clinically Significant Prostate Cancer with MRI: A Diagnostic Comparison Study. Journal of Magnetic Resonance Imaging, 2023, 57, 1352-1364.	1.9	5
1834	PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics, 2022, 12, 2594.	1.3	21
1835	^{18}Fâ€DCFPyL positron emission tomography/magnetic resonance imagingâ€guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis. Prostate, 2023, 83, 142-150.	1.2	2
1836	The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review. Cancers, 2022, 14, 5036.	1.7	10
1837	Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study. Frontiers in Oncology, 0, 12, .	1.3	0
1838	Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy. Prostate, 0, , .	1.2	2
1839	Multiparametric MRI Fusion-Guided Prostate Biopsy for Detection of Clinically Significant Prostate Cancer Eliminates the Systemic Prostate Biopsy. Applied Sciences (Switzerland), 2022, 12, 10151.	1.3	2
1841	Prostate-specific Antigen Density Cutoff of 0.15Âng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past?. European Urology Focus, 2023, 9, 291-297.	1.6	10

#	Article	IF	Citations
1843	Comparison of 18F-PSMA-1007 PET/CT With 68Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer. Clinical Nuclear Medicine, 2023, 48, e1-e8.	0.7	6
1844	Prostate gland volume estimation: anteroposterior diameters measured on axial versus sagittal ultrasonography and magnetic resonance images. Ultrasonography, 2023, 42, 154-164.	1.0	1
1845	Prostate cancer in transgender women: considerations for screening, diagnosis and management. British Journal of Cancer, 2023, 128, 177-189.	2.9	7
1846	Individualized Decision Making in Transperineal Prostate Biopsy: Should All Men Undergo an Additional Systematic Biopsy?. Cancers, 2022, 14, 5230.	1.7	0
1848	Role of MRI, Ultrasound, and Computed Tomography in the Management of Prostate Cancer. PET Clinics, 2022, 17, 565-583.	1.5	5
1849	Ultrasoundâ€based radiomics score for preâ€biopsy prediction of prostate cancer to reduce unnecessary biopsies. Prostate, 2023, 83, 109-118.	1.2	5
1850	Evaluation of an automated phenotyping algorithm for rheumatoid arthritis. Journal of Biomedical Informatics, 2022, 135, 104214.	2.5	2
1851	Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences. World Journal of Urology, 0, , .	1.2	1
1852	Significance of non-standardized magnetic resonance imaging abnormalities and subsequent targeted prostate cancer biopsy for pathologists: A retrospective observational study. Pathology Research and Practice, 2022, 240, 154188.	1.0	3
1853	Strong semantic segmentation for Covid-19 detection: Evaluating the use of deep learning models as a performant tool in radiography. Radiography, 2023, 29, 109-118.	1.1	3
1854	MRI versus non-MRI diagnostic pathways before radical prostatectomy: Impact on nerve-sparing, positive surgical margins, and biochemical recurrence. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
1855	Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study. JAMA Oncology, 2023, 9, 88.	3.4	14
1856	Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open, 2022, 12, e059482.	0.8	8
1857	Review of commercially available biomarkers in the diagnosis of prostate cancer. Journal of Education, Health and Sport, 2022, 12, 192-197.	0.0	0
1858	Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI. European Radiology, 2023, 33, 2519-2528.	2.3	3
1860	The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. European Urology Focus, 2023, 9, 584-591.	1.6	2
1862	A Pilot Study of ^{68}Ga-PSMA11 and ^{68}Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine, 2023, 64, 744-750.	2.8	6
1863	Narrative reviewâ€"focal therapy: are we ready to change the prostate cancer treatment paradigm?. Annals of Translational Medicine, 2023, 11, 24-24.	0.7	1

#	ARTICLE	IF	CITATIONS
1864	Magnetic Resonance Imaging in Prostate Cancer. , 2022, , 29-42.		0
1865	Assessing the Role of High-resolution Microultrasound Among NaÃ¯ve Patients with Negative Multiparametric Magnetic Resonance Imaging and a Persistently High Suspicion of Prostate Cancer. European Urology Open Science, 2023, 47, 73-79.	0.2	4
1866	Automated Patient-level Prostate Cancer Detection with Quantitative Diffusion Magnetic Resonance Imaging. European Urology Open Science, 2023, 47, 20-28.	0.2	8
1867	Combined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer. Urologic Clinics of North America, 2023, 50, 91-107.	0.8	0
1868	Exploring new frontiers in prostate cancer research:ÂReport from the 2022 Coffeyâˆ¼Holden prostate cancer academy meeting. Prostate, 2023, 83, 207-226.	1.2	0
1869	Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 727-741.	3.3	6
1870	Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nature Reviews Urology, 2023, 20, 23-47.	1.9	20
1871	Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1â€"2 prostate cancer at MRI-targeted biopsy: a multicenter analysis. World Journal of Urology, 2023, 41, 427-434.	1.2	1
1872	Site-specific concordance of targeted and systematic biopsy cores at the index lesion on multiparametric magnetic resonance: can we spare the double-tap?. World Journal of Urology, 2023, 41, 27-33.	1.2	3
1873	Advantageous Detection of Significant Prostate Cancer Using a Low-Field, Office-Based MRI System. Cureus, 2022, , .	0.2	0
1874	Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study. World Journal of Urology, 2023, 41, 19-25.	1.2	5
1875	Can We Identify Patients in Danger of Delayed Treatment? Management of COVID-19 Pandemic Backlog in Urology Care in Poland. International Journal of Environmental Research and Public Health, 2022, 19, 16547.	1.2	1
1876	How clinical research nursing is shaping the future of urology trials. British Journal of Nursing, 2022, 31, 1136-1142.	0.3	0
1877	Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial. Radiology, 0, , .	3.6	2
1878	The use of [68] Gaâ€PSMA PET/CT to stratify patients with PIâ€RADS 3 lesions according to clinically significant prostate cancer risk. Prostate, 0, , .	1.2	2
1879	Should Transperineal Prostate Biopsy Be the Standard of Care?. Current Urology Reports, 0, , .	1.0	2
1880	Diagnostic Performance of MRI for Prediction of Recurrent Prostate Cancer after High-intensity Focused Ultrasound: A Systematic Review and Meta-analysis. Prostate International, 2022, , .	1.2	1
1881	Development and validation of a predictive model for diagnosing prostate cancer after transperineal prostate biopsy. Frontiers in Oncology, 0, 12, .	1.3	1

#	Article	IF	Citations
1882	Ability of <scp>⁶⁸Ga–PSMA PET</scp>/<scp>CT SUVmax</scp> to differentiate <scp>ISUP GG2</scp> from <scp>GG3</scp> in intermediate–risk prostate cancer: A single–center retrospective study of 147 patients. Cancer Medicine, 2023, 12, 7140-7148.	1.3	3
1884	Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. New England Journal of Medicine, 2022, 387, 2126-2137.	13.9	99
1885	The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: A Will Rogers phenomenon. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 106.e9-106.e16.	0.8	3
1886	Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions. Cancers, 2022, 14, 6156.	1.7	4
1887	Findings from an international survey of urology trainee experience with prostate biopsy. BJU International, 2023, 131, 705-711.	1.3	2
1888	Dual attention guided multiscale neural network trained with curriculum learning for noninvasive prediction of Gleason Grade Group from MRI. Medical Physics, 2023, 50, 2279-2289.	1.6	3
1890	A dynamic-static combination model based on radiomics features for prostate cancer using multiparametric MRI. Physics in Medicine and Biology, 2023, 68, 015008.	1.6	1
1891	High-resolution 3D T2-weighted SPACE sequence with compressed sensing for the prostate gland: diagnostic performance in comparison with conventional T2-weighted images. Abdominal Radiology, 0, , .	1.0	0
1892	Is Upgrade in Gleason Score After Radical Prostatectomy Predictable with Preoperative Multiparametric Prostate MRI?: Comparison of ADC, K-trans, Tumor size and PI-RADS Score. Iİ‡zmir Democracy University Health Sciences Journal, 0, , .	0.4	0
1893	The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study. World Journal of Urology, 2023, 41, 455-461.	1.2	3
1894	Radiomics and artificial intelligence. , 2023, , 365-401.		0
1895	PI-RADSAI: introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI. British Journal of Cancer, 2023, 128, 1019-1029.	2.9	6
1896	Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. European Urology, 2023, 83, 249-256.	0.9	10
1898	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain and Modulation via Direct Interactions with DNA Abasic Sites: Understanding the Mechanisms Involved in Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2023, 24, 1270.	1.8	3
1899	Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance. Urologic Oncology: Seminars and Original Investigations, 2023, , .	0.8	0
1900	A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer. BioMed Research International, 2023, 2023, 1-10.	0.9	2
1901	Tissue distribution of ethanol after intraprostatic injection using a porous needle. Frontiers in Oncology, 0, 12, .	1.3	0
1902	Cancer-directed surgery brings survival benefits for patients with advanced prostate cancer: a population-based propensity-score matching study. Journal of Cancer, 2023, 14, 231-238.	1.2	1

#	ARTICLE	IF	CITATIONS
1903	Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance. World Journal of Urology, 2023, 41, 463-469.	1.2	4
1904	Impact of prebiopsy MRI on prostate cancer staging: Results from the Norwegian Prostate Cancer Registry. BJUI Compass, 0, , .	0.7	2
1905	Genitourinary imaging. , 2023, , 289-312.		1
1906	Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?â€"A single-center retrospective study. Translational Andrology and Urology, 2023, 12, 83-89.	0.6	1
1907	Machine Learning Algorithm Accuracy Using Single- versus Multi-Institutional Image Data in the Classification of Prostate MRI Lesions. Applied Sciences (Switzerland), 2023, 13, 1088.	1.3	3
1908	Landmarks in the evolution of prostate biopsy. Nature Reviews Urology, 2023, 20, 241-258.	1.9	11
1909	Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology, 2023, 83, 463-471.	0.9	7
1910	bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study. Frontiers in Surgery, 0, 9, .	0.6	0
1911	SINGLE CENTRE RETROSPECTIVE STUDY COMPARING MAGNETIC RESONANCE-TRANSRECTAL ULTRASOUND (TRUS) FUSION TARGETED AND SYSTEMATIC BIOPSY VERSUS CONVENTIONAL TRUS SYSTEMATIC BIOPSY FOR DETECTING PROSTATE CANCER. , 2022, , 4-9.		0
1912	Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance. Journal of Clinical Medicine, 2023, 12, 216.	1.0	4
1913	Comparison Between Amide Proton Transfer Magnetic Resonance Imaging Using 3-Dimensional Acquisition and Diffusion-Weighted Imaging for Characterization of Prostate Cancer: A Preliminary Study. Journal of Computer Assisted Tomography, 2023, 47, 178-185.	0.5	1
1914	A General Bayesian Functional Spatial Partitioning Method for Multiple Region Discovery Applied to Prostate Cancer MRI. Bayesian Analysis, 2023, -1, .	1.6	0
1915	Re: Jonas Hugosson, Marianne MÃ¥nsson, Jona WallstrÃ¶m, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126â€"37. European Urology Oncology, 2023, 6, 235.	2.6	2
1916	Biomarkers of Aggressive Prostate Cancer at Diagnosis. International Journal of Molecular Sciences, 2023, 24, 2185.	1.8	12
1919	Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer. Cancers, 2023, 15, 789.	1.7	1
1920	Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging. Molecular Pharmaceutics, 2023, 20, 1415-1425.	2.3	4
1921	Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points. Journal of the Korean Society of Radiology, 2023, 84, 75.	0.1	0
1922	Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study. PLoS ONE, 2023, 18, e0280262.	1.1	3

#	ARTICLE	IF	CITATIONS
1923	Evaluating the clinical application of PAMD score in the assessment of TRUS-biopsy positive outcomes in patients with PSA 4-10 ng/ml treated in Serbia. , 2023, 56, 15-20.		0
1924	Prostate cancer segmentation from MRI by a multistream fusion encoder. Medical Physics, 2023, 50, 5489-5504.	1.6	0
1925	Deep regression model with ordinal and triplet loss for the prediction of prostate cancer aggressiveness in multi-parametric MR images. , 2023, , .		0
1926	Multi-reader evaluation of different image quality scoring systems in prostate MRI. European Journal of Radiology, 2023, 161, 110733.	1.2	9
1927	A semi-automated software program to assess the impact of second reads in prostate MRI for equivocal lesions: results from a UK tertiary referral centre. European Journal of Radiology, 2023, 162, 110796.	1.2	0
1928	Test-retest repeatability of ADC in prostate using the multi b-Value VERDICT acquisition. European Journal of Radiology, 2023, 162, 110782.	1.2	0
1929	Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. European Urology Open Science, 2023, 51, 89-94.	0.2	1
1933	Multiparametric ultrasound of prostate: role in prostate cancer diagnosis. Therapeutic Advances in Urology, 2022, 14, .	0.9	11
1934	Diagnosis of prostate cancer in primary care: navigating updated clinical guidance. British Journal of General Practice, 2023, 73, 54-55.	0.7	1
1935	Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer. Current Oncology, 2023, 30, 1683-1691.	0.9	0
1936	Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene, 2023, 42, 926-937.	2.6	12
1937	A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide. Journal of Clinical Medicine, 2023, 12, 1186.	1.0	1
1938	Joint Cancer Segmentation and PI-RADS Classification on Multiparametric MRI Using MiniSegCaps Network. Diagnostics, 2023, 13, 615.	1.3	2
1939	Sub-differentiation of PI-RADS 3 lesions in TZ by advanced diffusion-weighted imaging to aid the biopsy decision process. Frontiers in Oncology, 0, 13, .	1.3	0
1940	Effectiveness and Accuracy of <scp>MRI</scp> â€Ultrasound Fusion Targeted Biopsy Based on <scp>PIâ€RADS</scp> v2.1 Category in Transition/Peripheral Zone of the Prostate. Journal of Magnetic Resonance Imaging, 0, , .	1.9	1
1941	Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. Cancer Medicine, 2023, 12, 9351-9362.	1.3	6
1942	Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillanceâ€"A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting. Bioengineering, 2023, 10, 247.	1.6	0
1943	Efficacy and safety evaluation of complete intrafascial prostatectomy in suspected prostate cancer patients with dysuria: a retrospective cohort study. Translational Andrology and Urology, 2023, 12, 300-307.	0.6	0

#	ARTICLE	IF	CITATIONS
1944	Prediction of Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging Lesions: A High-volume International Multicenter Study. European Urology Focus, 2023, 9, 606-613.	1.6	5
1945	Analysis of false positive PI-RADS 4 lesions: experience from a single nonacademic center using cognitive fusion. International Urology and Nephrology, 2023, 55, 1081-1085.	0.6	0
1946	Does including histological outcomes in a multiparametric MRI report improve prostate biopsy decision making?. British Journal of Radiology, 2023, 96, .	1.0	0
1947	Bridging the experience gap in prostate multiparametric magnetic resonance imaging using artificial intelligence: A prospective multi-reader comparison study on inter-reader agreement in PI-RADS v2.1, image quality and reporting time between novice and expert readers. European Journal of Radiology, 2023, 161, 110749.	1.2	3
1948	Feasibility and preliminary clinical tolerability of low‐field MRI‐guided prostate biopsy. Prostate, 2023, 83, 656-662.	1.2	2
1949	Joint estimation of relaxation and diffusion tissue parameters for prostate cancer with relaxation-VERDICT MRI. Scientific Reports, 2023, 13, .	1.6	5
1950	Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches. Urology, 2023, 175, 151-156.	0.5	3
1951	Prostate MRI and image Quality: It is time to take stock. European Journal of Radiology, 2023, 161, 110757.	1.2	9
1952	A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology. World Journal of Urology, 0, , .	1.2	0
1953	Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small, 0, , 2204956.	5.2	0
1954	Learning Curve of Transperineal MRI/US Fusion Prostate Biopsy: 4-Year Experience. Life, 2023, 13, 638.	1.1	1
1955	The Effect of Oral Laxatives on Rectal Distension and Image Quality in Magnetic Resonance Imaging of the Prostate. Cureus, 2023, , .	0.2	0
1956	3-D Transducer Mounted Shear Wave Absolute Vibro-Elastography: Proof of Concept. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2023, 70, 1026-1038.	1.7	0
1957	Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. BJU International, 2023, 132, 188-195.	1.3	3
1958	Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. European Urology, 2023, 84, 9-12.	0.9	1
1959	A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies. European Urology Open Science, 2023, 50, 91-105.	0.2	1
1960	DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men—study protocol for a randomized trial. Trials, 2023, 24, .	0.7	5
1961	Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI. World Journal of Surgical Oncology, 2023, 21, .	0.8	1

#	Article	IF	Citations
1962	Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer. Frontiers in Endocrinology, 0, 14, .	1.5	2
1963	Prostate cancer bone metastases biology and clinical management (Review). Oncology Letters, 2023, 25, .	0.8	4
1965	The role of multiparametric magnetic resonance in active surveillance of a low‑risk prostate cancer cohort from clinical practice. Prostate, 2023, 83, 765-772.	1.2	1
1966	Re: Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. European Urology, 2023, , .	0.9	0
1967	Patient‑reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy‑monitored study. Prostate, 2023, 83, 781-791.	1.2	0
1968	Magnetic Resonance Imaging of the Prostate in the PI-RADS Era. IDKD Springer Series, 2023, , 211-227.	0.8	0
1970	Detection of intermediate- and high-risk prostate cancer with biparametric magnetic resonance imaging: a systematic review and meta-analysis. Quantitative Imaging in Medicine and Surgery, 2023, .	1.1	0
1971	Current Role of Magnetic Resonance Imaging in the Screening, Diagnosis, and Treatment of Prostate Cancer. Acta Clinica Croatica, 2022, , .	0.1	0
1972	Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging. Frontiers in Oncology, 0, 13, .	1.3	0
1973	Does deep learning software improve the consistency and performance of radiologists with various levels of experience in assessing bi-parametric prostate MRI?. Insights Into Imaging, 2023, 14, .	1.6	2
1974	Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men. Prostate Cancer and Prostatic Diseases, 2023, 26, 588-595.	2.0	4
1975	Using "Age and Total-PSA" as the Main Indicators: The Results of Taizhou Integrated Prostate Screening (No 2). American Journal of Men's Health, 2023, 17, 155798832311612.	0.7	1
1977	Effect of constipation on acute urinary retention following transrectal prostate biopsy. Investigative and Clinical Urology, 0, 64, .	1.0	0
1978	Using 18F-DCFPyL Prostate-Specific Membrane Antigen‑Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy. Advances in Radiation Oncology, 2023, 8, 101241.	0.6	1
1979	Transperineal Prostate Biopsy Targeted by Magnetic Resonance Imaging Cognitive Fusion. Diagnostics, 2023, 13, 1373.	1.3	0
1980	Screening for Prostate Cancer. New England Journal of Medicine, 2023, 388, 1405-1414.	13.9	22
1981	PI‑RADS 3 score: A retrospective experience of clinically significant prostate cancer detection. BJUI Compass, 0, , .	0.7	0
1983	5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity. BMC Urology, 2023, 23, .	0.6	1

#	Article	IF	Citations
1984	Fusion‑targeted biopsy significantly improves prostate cancer detection in biopsy‑naïve men. International Journal of Urology, 2023, 30, 600-604.	0.5	3
1985	Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI/transrectal ultrasonography fusion biopsy. World Journal of Urology, 2023, 41, 3239-3247.	1.2	2
1986	Therapeutic management of hormone-dependent cancers in transgender patients. , 2023, , 399-416.		0
1989	Re: Thomas Bommelaere, Arnauld Villers, Philippe Puech, et al. Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. Eur Urol Open Sci 2022;41:24â€"34. European Urology Open Science, 2023, 52, 135-136.	0.2	0
2032	Re: Daniel D. Joyce, Matteo Soligo, Alessandro Morlacco, et al. Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy. Eur Urol Open Sci 2023;47:87â€"93. European Urology Open Science, 2023, 52, 153.	0.2	0
2097	Prostate Capsule Segmentation in Micro-Ultrasound Images Using Deep Neural Networks. , 2023, , .		0
2121	Diagnosis of Clinical Significant Prostate Cancer on Biparametric Mri Using Zone-Specific Radiomic Features. , 2023, , .		0
2141	MIC-CUSP: Multimodal Image Correlations forÂ Ultrasound-Based Prostate Cancer Detection. Lecture Notes in Computer Science, 2023, , 121-131.	1.0	0
2149	Diagnosis and Clinical Staging. , 2023, , 187-208.		0
2165	Focal therapy in intermediate- and high-risk prostate cancer. Memo - Magazine of European Medical Oncology, 2023, 16, 247-250.	0.3	1
2192	Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis. European Radiology, 0, , .	2.3	1
2199	From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. Health Information Science and Systems, 2024, 12, .	3.4	0
2200	Concerns regarding prostate cancer screening guidelines in minority populations. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	0
2225	LANDMARKS AND MODERN APPROACHES IN PROSTATE CANCER DIAGNOSIS. , 0, , .		0
2227	MRI/TRUS-Guided Auxiliary System for Transperineal Prostate Biopsy Based on Deep Learning. , 2023, , .		0